

BÁRBARA NERY ENES

**EFFECT OF CHIA (*Salvia hispanica* L.) ON GLUCOSE METABOLISM, AND
THEIR MOLECULAR MECHANISMS ON INSULIN RESISTANCE
CONDITIONS, IN VIVO AND IN VITRO**

Thesis submitted to the Universidade Federal de Viçosa, as part of the requirements of the Program in Nutrition Science to obtaining the title of Doctor Scientiae.

Adviser: Hércia Stampini Duarte Martino

Co-Advisers: Érica Aguiar Moraes
Helen Hermana M. Hermsdorff
Maria Eliza de Castro Moreira

VIÇOSA – MINAS GERAIS

2020

**Ficha catalográfica elaborada pela Biblioteca Central da Universidade
Federal de Viçosa - Campus Viçosa**

T

E56e
2020
Enes, Bárbara Nery, 1987-
Effect of chia (*Salvia hispanica* L.) on glucose metabolism,
and their molecular mechanisms on insulin resistance conditions,
in vivo and *in vitro* / Bárbara Nery Enes. – Viçosa, MG, 2020.
107 f. : il. (algumas color.) ; 29 cm.

Texto em inglês.

Inclui apêndice.

Orientador: Hércia Stampini Duarte Martino.

Tese (doutorado) - Universidade Federal de Viçosa.

Inclui bibliografia.

1. Óleo de chia. 2. Farinha de chia. 3. Proteínas quinases
ativadas por AMP. I. Universidade Federal de Viçosa.
Departamento de Nutrição e Saúde. Programa de Pós-Graduação
em Ciência da Nutrição. II. Título.

CDD 22. ed. 613.282

BÁRBARA NERY ENES

**EFFECT OF CHIA (*Salvia hispanica* L.) ON GLUCOSE METABOLISM, AND
THEIR MOLECULAR MECHANISMS ON INSULIN RESISTANCE
CONDITIONS, IN VIVO AND IN VITRO**

Thesis submitted to the Universidade Federal de Viçosa, as part of the requirements of the Program in Nutrition Science to obtaining the title of Doctor Scientiae.

APPROVED: February 28, 2020

Assent:

Bárbara Nery Enes
Author

Hércia Stampini Duarte Martino
Adviser

ACKNOWLEDGMENTS

To God for guiding me.

To my parents, Eliene and Gilberto, and my brother, Leonardo, for their love and support.

To my husband, Arnaldo, for being by my side during all these years, for his love and friendship, and all the support during our time abroad.

To Professor Hércia, my advisor, for welcoming again, as her student and for always believing in me.

To Professor Érica Aguiar Moraes for her friendship and all the contributions to this work, as my co-adviser.

To my co-advisers, Helen Hermana Miranda Hermsdorff and Maria Eliza de Castro Moreira for all the help and contributions to this work.

To Dra. Susanne Talcott, Dr. Steve Talcott and Dra. Giuliana Noratto, for all their empathy and support that allowed me to perform the in vitro experiment in their laboratory, in Texas A&M University, Texas, USA.

To Luiza that was always a good friend, and to Rodrigo, Oscar, Jaqueline, Andressa and Vinícius, that shared with me the hard work of conducting an in vivo experiment. Thank you for all support.

To all friends of the Laboratório de Nutrição Experimental, Mariana Juste, Mariana Grancieri, Bárbara Pereira, Marcella, Haira, Cíntia, Thaisa and Desirre.

To Mariana Juste and Daniel for their friendship and for receiving me in their home.

To Renata Celly for the support and help during the animal experiment, molecular biology analysis, and discussions about the results.

To the Professors, technicians and staff of the Nutrition and Health Department.

To the friends of Talcott's Laboratory in Texas A&M University, Ariela, Shirley, Helen, Mehdi, Maritza, Joselyn, Kevin, Marjorie, Vinícius, Elayna and Chuo.

To Ariela, for all the help and friendship in the USA.

To Patrícia, Breno (in memoriam) and Sofia, for being my family in Viçosa.

To the friends from Universidade Vale do Rio Doce for the support during these four years, especially to Eloísa and Enara, and to all my students that encouraged me for this accomplishment.

To the Professors of Programa de Pós-graduação em Ciência da Nutrição (PPGCN) for all their shared teaching, and to the Federal University of Viçosa, for the opportunity and contribution to my academic background.

To the funding agencies, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Comissão de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), for their financial support.

To the board members Professors Érica Aguiar Moraes, PhD (UFES); Natália E. Alves Galdino, PhD; Maria Eliza Moreira, PhD (Faculdade Dinâmica); and Bárbara Pereira da Silva, PhD (Faculdade Dinâmica); who kindly agreed to collaborate to this work.

All my gratitude to life!

ABSTRACT

ENES, Bárbara Nery, D.Sc., Universidade Federal de Viçosa, February, 2020. **Effect of chia (*Salvia hispanica* L.) on glucose metabolism, and their molecular mechanisms on insulin resistance conditions, in vivo and in vitro.** Adviser: Hércia Stampini Duarte Martino. Co-Advisers: Érica Aguiar Moraes, Helen Hermana Miranda Hermsdorff and Maria Eliza de Castro Moreira.

Chia (*Salvia hispanica* L.) is known for its high concentration of alpha linolenic acid omega 3, dietary fiber, proteins, vitamins, minerals and phytochemicals. These components are considered responsible for the improvement of biological markers related to non-communicable diseases. However, it is not clear whether there is an interaction between the compounds, or if a specific compound is responsible for the health benefits generated by the consumption of chia. In addition, the biochemical mechanisms and pathways involved in the chemoprevention of diseases caused by chia remain unknown. Therefore, the first investigations was, to compile evidence regarding the effects of chia seed (flour or oil) in studies with animals fed with unbalanced diets, and to understand the effects and molecular mechanisms in the modulation of metabolic biomarkers. Additional aims were to evaluate the influence of chia flour and oil on glucose metabolism in insulin-resistant Wistar rats, as well as to determine the effect of a phenolic extract from chia on glucose metabolism in insulin-resistant HepG2 cells. A systematic review was carried out on electronic databases, following the recommendations of PRISMA. The risk of bias and quality was assessed using the SYRILE toll and ARRIVE guidelines. The in vivo study was carried out with 40 male adults Wistar rats, initially divided into two groups: AIN-93M (n=10) and high fat and fructose content (HFHF) (n=30), during 8 weeks. Then, the HFHF group was divided into three groups (n=10): HFHF, HFHF with chia flour (14.7%) and HFHF with chia oil (4%). The parameters evaluated were: food consumption; adiposity; intraperitoneal tolerance to glucose and insulin; mRNA levels of enzymes and proteins involved on glucose metabolism (glycokinase, phosphofructokinase, pyruvate kinase, monophosphate-adenosine protein kinase, insulin receptor, protein transcription factor Forkhead box O1 and protein kinase B), as well as phosphorylated AKT (AKT1 [pS473]) protein level. The in vitro study was carried out with HepG2 cells, treated with glucose (25 mM) and palmitate (1mM) for 24 h, to induce insulin resistance. Insulin-resistant HepG2 cells were next, treated with hydrolyzed phenolics extract obtained from chia (20, 40 and 80 ppm). The hydrolyzed phenolics extract from chia were

obtained by ultrasound liquid-liquid extraction, followed by hydrolysis with HCl (1 M). The characterization and quantification of phenolics from the hydrolyzed extract were assessed by reverse phase HPLC. To check effects from chia's phenolics on insulin resistance, we analyzed the gene expression of AKT protein and enzymes involved in glycogenogenesis (phosphoenolpyruvate carboxykinase and glucose-6-phosphatase) and glycolysis (phosphofructokinase and pyruvate kinase). Throughout the 17 studies included in the systematic review, details on randomization and allocation concealment in studies were insufficient, as well as information on protocols. Among the studies, there was a lack of information about the sample size, the dose of chia used, and the number of animals evaluated for each parameter evaluated. However, summarizing the results, chia were associated with AMPK modulation, improvement on glucose and insulin tolerance, lipogenesis, antioxidant activity and inflammation. The original in vivo study demonstrated that chia (seed and oil) increased AKT1 [pS473]. Chia oil improved glucose and insulin tolerance, increased AMPK, insulin receptor, FOXO1, glycolysis enzymes and decreased gluconeogenesis enzymes. The in vitro experiment demonstrated that the phenolics of chia seeds decreased the expression of gluconeogenic enzymes without affecting the phosphorylation of AKT. Based on data from experimental studies, systematic review, chia presents bioactive potential and its daily consumption can reduce the risk of developing chronic diseases, mainly due to the antioxidant, antiinflammatory, hypoglycemic and hypolipidemic effects of the seed. The original in vivo study indicated the potential of chia to improve glucose tolerance and positively affect insulin, nevertheless, in vitro study showed that hydrolyzed phenolics from chia did not show effects. From the three fractions investigated in this research (flour, oil and hydrolyzed phenolics), the oil from chia demonstrated superior results regarding glucose metabolism in insulin resistance condition.

Keywords: Chia flour. Chia oil. Alpha-linolenic acid. Phenolic compounds. AMPK. AKT.

RESUMO

ENES, Bárbara Nery, D.Sc., Universidade Federal de Viçosa, fevereiro de 2020. **Efeito da chia (*Salvia hispanica* L.) no metabolismo de glicose, e mecanismos moleculares em condições de resistência à insulina, in vivo e in vitro.** Orientadora: Hércia Stampini Duarte Martino. Coorientadoras: Érica Aguiar Moraes, Helen Hermana Miranda Hermsdorff e Maria Eliza de Castro Moreira.

Chia (*Salvia hispanica* L.) é conhecida por sua alta concentração de ácido alfa linolênico ômega 3, fibra alimentar, proteínas, vitaminas, minerais e fitoquímicos. Esses componentes são considerados os responsáveis pela melhora de marcadores biológicos relacionados à doenças crônicas não transmissíveis. Embora ainda não esteja claro se há uma interação entre os compostos, ou se um composto específico é responsável pelos benefícios à saúde gerados pelo consumo da chia. Além disso, os mecanismos e vias bioquímicas envolvidos na quimioprevenção de doenças pela semente de chia permanecem desconhecidos. O objetivo deste trabalho foi, em primeiro lugar, compilar evidências referente aos efeitos da chia (farinha ou óleo) em estudos com animais alimentados com dietas desequilibradas, e entender os efeitos e mecanismos moleculares na modulação de biomarcadores metabólicos. Segundo, avaliar a influência da farinha e óleo de chia no metabolismo da glicose em ratos Wistar resistentes à insulina, e ainda o efeito de um extrato hidrolisado de fenólicos extraídos da chia, no metabolismo da glicose em células HepG2 resistentes à insulina. Uma revisão sistemática foi realizada em bancos de dados eletrônicos, seguindo as recomendações do PRISMA. O risco de viés e qualidade foi avaliado usando as diretrizes SYRILE toll e ARRIVE. O estudo in vivo foi conduzido por 8 semanas utilizando 40 ratos Wistar adultos, machos, divididos inicialmente em dois grupos: AIN-93M (n=10) e alto conteúdo de gordura e de frutose (HFHF) (n=30). Em seguida, o grupo HFHF foi dividido em três grupos (n=10): HFHF, HFHF com farinha de chia (14,7%) e HFHF com óleo de chia (4%). Foram analisados o consumo alimentar; adiposidade; tolerância intraperitoneal à glicose e insulina. No fígado, foram avaliados a expressão gênica de enzimas e proteínas envolvidas no metabolismo de glicose: glicoquinase, fosfofrutoquinase, piruvato quinase, monofosfato-adenosina proteína quinase (AMPK), receptor de insulina (INSR), fator de transcrição proteína Forkhead box 01 (FOX01) e proteína quinase B (AKT), e expressão proteica de AKT fosforilada (AKT1[pS473]). O estudo in vitro foi realizado com células HepG2, tratadas com glicose (25 mM) e palmitato (1 mM) durante 24 horas, para induzir resistênciã à insulina. As células,

foram em seguida, tratadas com fenólicos hidrolisados obtidos da semente de chia (20, 40 e 80 ppm). O extrato de fenólicos hidrolisados da chia foi obtido por meio de extração líquido-líquido com ultrassom, seguida de hidrólise com HCl (1 M). A caracterização e quantificação dos fenólicos contidos no extrato foi realizada utilizando HPLC de fase reversa. Para avaliar o efeito dos fenólicos da chia na resistência à insulina, foram analisados a expressão gênica de AKT, e das enzimas envolvidas na glicogenogênese (fosfoenolpiruvato carboxiquinase e glicose-6-fosfatase) e glicólise (fosfofrutoquinase e piruvato quinase). Dentre os 17 artigos incluídos na revisão sistemática, detalhes sobre a randomização e ocultação de alocação nos estudos foram considerados insuficientes, assim como informações sobre os protocolos utilizados. Entre os estudos, foram encontrados ausência de informações sobre o tamanho amostral, doses de chia e o número de animais utilizados para cada parâmetro avaliado. Entretanto, os principais efeitos da chia foram associados à modulação da AMPK, melhora da tolerância à glicose e insulina, lipogênese, atividade antioxidante e inflamação. O estudo original in vivo demonstrou que a chia (farinha e óleo) aumentou os níveis de AKT1[pS473]. O óleo de chia melhorou a tolerância à glicose e insulina, aumentou a AMPK, o receptor de insulina, FOXO1, as enzimas glicólise e diminuiu as enzimas gliconeogênese. O experimento in vitro demonstrou que os fenólicos das sementes de chia diminuíram a expressão das enzimas gliconeogênicas sem afetar a fosforilação do AKT. Com base em dados de estudos experimentais e da revisão sistemática, nota-se que a chia tem potencial bioativo e seu consumo diário pode reduzir o risco de desenvolvimento de doenças crônicas, principalmente devido aos efeitos antioxidantes, anti-inflamatórios, hipoglicêmicos e hipolipidêmicos da semente. O estudo original in vivo indicou potencial da chia em melhorar a tolerância à glicose, embora o estudo in vitro tenha demonstrado que os fenólicos da chia não apresentaram tais efeitos. Dentre as três frações investigadas no presente estudo (farinha, óleo e fenólicos hidrolisados), o óleo demonstrou resultados superiores, em relação ao metabolismo de glicose em condições de resistência á insulina.

Palavras-chave: Farinha de Chia. Óleo de chia. Ácido alfa-linolênico. Compostos fenólicos. AMPK. AKT.

LIST OF ABBREVIATIONS

ACC: acetyl-coA carboxylase
AKT: protein kinase B
ALA: alpha linolenic acid
ALP: alkaline phosphatase
ALT: alanine aminotransferase
AMPK: adenosine monophosphate-activated protein kinase
ARRIVE: animal research reporting of in vivo experiment
AST: aspartate aminotransferase
AT: adipose tissue
AUC: area under the curve
BSA: bovine serum albumin
CAT: catalase
CK: creatinine
CPT-1: carnitine-palmitoyl transferase-1
CRP: C-reactive protein
DBP: diastolic blood pressure
DG: diacylglyceride
DMEM: Dulbecco's modified Eagle's medium
FA: fatty acid
FAS: fatty acid synthase
FAT/DC36: Fatty acid translocase
FBS: fetal bovine serum
FFA: free fatty acid
Fox01: forkhead box protein O1
FRAP: ferric reducing ability of plasma
G6Pase: glucose-6-phosphate
G6PD: glucose-6-phosphate dehydrogenase
GAE: gallic acid equivalents
GAPDH: glyceraldehyde-3-phosphate dehydrogenase
GIR: glucose infusion rate
GK: glucokinase
GLUT-4: glucose transporter type 4

GPx: glutathione peroxidase
GR: glutathione reductase
GSH: reduced glutathione
GSK-3 β : glycogen synthase kinase 3 β
HDLc: high density lipoprotein
HFD: high fat diet
HFHF: high-fat and high-fructose
HOMA-IR: homeostasis model assessment: insulin resistance
HSP25: heat shock protein 25
HSP60: heat shock protein 60
HSP70: heat shock protein 70
iGTT: intraperitoneal glucose tolerance test
IL-10: interleukin 10
IL-6: interleukin 6
INSR: insulin receptor
IR: insulin resistance
IRS-1: insulin receptor substrate 1
IRS-2: insulin receptor substrate 2
ITT: insulin tolerance test
LCA-CoA: long-chain scyl-coA
LCMS: liquid chromatography–mass spectrometry
LDH: lactate dehydrogenase
LDLc: low density lipoprotein
LILACS: Latin American and Caribbean Center on Health Sciences Information
n3: omega 3
n6: omega 6
NEFA: nonesterified fatty acids
NF- κ B: factor nuclear kappa B
Nrf2: nuclear factor (erythroid-derived 2)-like 2
PA: palmitic acid
p-AKT: phospho-protein kinase B
pAMPK: phosphorylation of adenosine monophosphate-activated protein kinase
PBS: phosphate-buffered saline
PC: positive control

PEPCK: phosphoenolpyruvate carboxykinase
PDHa: pyruvate dehydrogenase E1 component subunit alpha
PFK: phosphofructokinase
PGC-1 α : peroxisome proliferator-activated receptor- γ coactivator
pIRS-1(Tyr)/IRS-1: phosphorylation on Tyr989 of IRS-1
PK: phosphokinase
PPAR: peroxisome proliferator-activated receptor
PRISMA: preferred reporting items for systematic reviews and meta-analysis
PPAR- α : peroxisome proliferator-activated receptor alpha
PPAR- γ : peroxisome proliferator-activated receptor gamma
PVDF: polyvinylidene difluoride
RA: rosmarinic acid
RD: reference diet
RD-RD: offspring from dams fed a reference diet (RD) and fed the RD after weaning
ROS: reactive oxygen species
RT-PCR: real-time polymerase chain reaction
SAMP8 HFD: senescence accelerated mouse - fed a high fat diet
SAMP8 LFD: Senescence Accelerated Mouse - fed a low fat diet
SAMR1 LFD: senescence-accelerated mouse - resistant 1 - fed a low fat diet
SBP: systolic blood pressure
SD: standard diet
SFA: saturated fatty acids
SOD: superoxide dismutase
SRD: sucrose rich diet
SRD-SRD: offspring from SRD-fed dams fed an SRD after weaning
SRD-SRDC: offspring from SRD-fed dams fed an SRD+chia after weaning
SREBP1: sterol regulator element-binding protein 1
SYRCLE: systematic review centre for laboratory animal experimentation
TAC: total antioxidant capacity
TBARS: thiobarbituric acid reactive substances
TBP: TATA box binding protein
TBS-T: tris-buffered saline twin
TC: total cholesterol
TE: total energy

TG: triacylglycerol

TNF- α : tumor necrosis factor alpha

VLDLc: very low density lipoprotein

w: weeks

XO: xanthine oxidase.

LIST OF FIGURES

Materials and Methods

Figure 1: In vivo study experimental design..	29
---	----

PAPER 1

Figure 1: Flowchart of the search and selection process for articles included in the systematic review, according to PRISMA recommendation.	47
Figure 2: Hypothesis of chia´s seeds mechanism of action based on unbalanced diet experimental studies.	56
Figure 3: Risk of bias summary: review authors' judgments about each risk of bias item for each included study.	64

PAPER 2

Figure 2: Hydrolyzed Phenolics from Chia Characterization.	88
Figure 3: Effect of chia flour and oil consumption on (A) food intake, (B) energy intake, (C) total weight gain, (D) % adiposity.	89
Figure 4: Chia oil decreased hyperglycemia and insulin resistance.	90
Figure 5: Chia oil modulated gene expression of biomarkers for IR.	91
Figure 6: Chia hydrolyzed phenolics extract decreased gluconeogenesis and glycolysis enzymes activity..	93
Figure 7: Proposed effect of Chia (<i>Salvia hispanica</i> L.) on glucose homeostasis by controlling AKT activation, gluconeogenesis and glycolysis pathways.	97
Figure S1: Chia hydrolyzed phenolics up to 80 ppm did not exert HepG2 cell toxicity...	104

LIST OF TABLES

MATERIALS AND METHODS

Table 1. Search strategy for different databases	26
Table 2. Nutritional composition of experimental diets.	30
Table 3. Sequencing primers used in the RT-qPCR analysis for in vivo study.....	32
Table 4. Sequencing primers used in the RT-qPCR analysis for in vitro study.	34

PAPER 1

Table 1: Characteristics of the animal studies	49
Table 2. Risk of bias from experimental studies	61
Table S1. Search strategy for different databases	73

PAPER 2

Table S1. Sequencing primers used in the RT-qPCR analysis for in vivo study	103
Table S2. Sequencing primers used in the RT-qPCR analysis for in vitro study.	103

SUMMARY

1. GENERAL INTRODUCTION.....	18
2. OBJECTIVES	21
2.1 General objective	21
2.2 Specifics objectives.....	21
3. HYPOTESIS	22
4. MATERIAL AND METHODS	23
4.1 Preparation of Chia Fractions and Characterization	23
4.1.1 Preparation of Chia Flour and Extration of Oil from Chia Seeds.....	23
4.1.2. Chemical Characterization of Chia Flour and Chia Oil.....	24
4.1.3 Extraction and Hydrolyses of Phenolics From Chia Flour	24
4.1.4 Chia Hydrolyzed Phenolics Extract Characterization	24
4.2 Systematic Review Study	25
4.2.1 Protocol and Registration.....	25
4.2.2 Literature Search.....	25
4.2.3 Study Selection and Data Collection Process	26
4.2.4 Quality Assessment.....	27
4.3 In Vivo Study	27
4.3.1 Study Design and Diets.....	28
4.3.2 Intraperitoneal Glucose Tolerance Test and Insulin Tolerance Test	31
4.3.3 Euthanasia and Tissue Collection	31
4.3.4 Gene Expression in Liver Tissue	31
4.3.5 Phospho-AKT Assessment	32
4.4 In Vitro Study.....	32
4.4.1 Cell line.....	33
4.4.2 Cell Viability.....	33
4.4.4 Gene Expression	34
4.4.5 Phospho-AKT Assessment	34
4.5 Statistical Analysis.....	35
5. REFERENCES	35
5. RESULTS	40
5.1 Paper 1	40
1. INTRODUCTION	43

2. METHODS	44
2.1. Protocol and registration.....	44
2.2. Literature Search.....	44
2.3. Study Selection and Data Collection Process	45
2.4. Quality assessment.....	45
3. RESULTS AND DISCUSSION.....	46
3.1 Included studies and characteristics.....	46
3.3 Impact of chia on metabolic and associated disorders.....	55
3.3.2 Lipid profile and lipolysis.....	56
3.3.3 Impact of chia on oxidative stress and inflammation	58
3.4. Impact of chia's bioactive compounds on metabolic and associated disorders.....	59
3.5. Reporting Quality and Risk of Bias	60
4. CONCLUSIONS	64
5.2 Paper 2	74
1. INTRODUCTION	78
2. MATERIALS AND METHODS.....	79
2.1 Chia flour prepare	79
2.2 Extraction of phenolics from chia flour.....	79
2.3 Oil extraction	80
2.4 Extract chemical analysis.....	80
2.5 Chia phenolics characterization and quantification	80
2.5 Animal Study	81
2.5.1 Study design and diets	81
2.5.2 Intraperitoneal glucose tolerance test and insulin tolerance test.....	84
2.5.3 Euthanasia and Tissue collection.....	84
2.5.4 Gene expression in liver tissue	84
2.5.5 Phospho-AKT assessment	85
2.6 In Vitro Study.....	85
2.6.1 Cell line.....	85
2.6.2 Cell Viability.....	85
2.6.3 Insulin resistance protocol	86
2.6.4 Gene Expression	86
2.6.5 Phospho-AKT assessment	86
2.7 Statistical Analysis.....	87

3. RESULTS	87
3.1 Chia phenolics, identification and quantification	87
3.2.1 Chia oil administration decreased body weight and body fat accumulation	88
3.2.2 Glucose and insulin tolerance tests	89
3.2.3 Gene expression and protein in liver tissue	90
3.3. In vitro study	92
3.3.1 Cell viability	92
3.3.2 Chia phenolics improved mRNA levels of gluconeogenic enzymes but did not modulate PI3K/AKT pathway in HepG2 cells	92
4. DISCUSSION	94
5. CONCLUSION	97
6. GENERAL CONCLUSIONS	105
7. FINAL CONSIDERATIONS	106
APPENDIX 1	107

1. GENERAL INTRODUCTION

Noncommunicable diseases, such as obesity, type 2 diabetes and cardiovascular diseases are responsible for three in five deaths in the world (GBD 2016 RISK FACTORS COLLABORATORS, 2017). These diseases are derived from high blood pressure, high cholesterol, and overweight (WORLD HEALTH ORGANIZATION, 2017). Epidemiological studies indicated strong correlation between obesity and high caloric diets (characterized by high amounts of sugar, fructose and saturated lipids). This dietary pattern is often termed as “western diet”, characterized by high intakes of fats, animal-source foods, refined carbohydrates and added sugar (POPKIN; ADAIR; NG, 2011; POPKIN; NIELSEN; BRAY, 2004).

The “western diet” is considered an unbalanced diet, since the macronutrients distribution is not adequate to human requirements (INSTITUTE OF MEDICINE, 2005). Sedentary lifestyle and unbalanced diets lead to overweight (WORLD HEALTH ORGANIZATION, 2017), which is associated with increased oxidative stress and chronic inflammation, and major biochemical and metabolic changes, which trigger a series of events associated with the development of comorbidities such as insulin resistance (IR) and type 2 diabetes mellitus (POZZA; ISIDORI, 2018). The disrupted glucose metabolism is considered key for other events such as atherosclerosis, cardiovascular diseases, high blood pressure, kidney injuries and nonalcoholic fatty liver disease (ISMAIEL; DUMITRAȘCU, 2019).

IR is known as the failed response to insulin by cells. It is a pathological condition, in which cells are unable to use insulin or the hormone production is impaired by pancreas, leading to high blood glucose (SCHENK; SABERI; OLEFSKY, 2008). Eventually, IR may cause hyperinsulinemia in attempt to maintain blood glucose at normal levels. These conditions also lead to increased gluconeogenesis activity and glucose output in liver. Additionally, a high caloric diet is related to the upregulation of FoxO1 transcriptional factor, which controls the transcription of gluconeogenesis enzymes. Under these conditions, the downregulation of PI3K/AKT pathway may occur leading to the insulin/AKT pathway disruption and impaired glucose receptor (GLUT) translocation to the plasmatic membrane. These changes in the homeostatic scenario are accompanied by decrease in AKT phosphorylation (CZECH, 2018).

In current context of increased obesity and comorbidities, plant food has been investigated as source of bioactive compounds that might act as a coadjuvant in decreasing risk of noncommunicable diseases (BOROWSKA; BRZÓSKA, 2016; GOMES et al.,

2019; MOREIRA et al., 2019; RIBEIRO et al., 2019). The search for mechanisms through which bioactive compounds would improve obese health and decrease comorbidities risk has increased the number of animal studies fed unbalanced diets, since it is a way to mitigate the human food intake pattern that contributes to overweight. Animal studies can be considered an important screening for testing new plant food and their different doses and fractions, attempting a deep investigation into molecular pathways using tissues, which is not possible to accomplish in research involving humans (CHALVON-DEMERSAY et al., 2017).

Research studies have demonstrated that food or bioactive compounds could attenuate or prevent the damage generated by obesity and IR (SKROVANKOVA et al., 2015). Among these plant foods and their bioactive, an alternative is chia seed (*Salvia hispanica* L.), which belongs to *Salvia* genus (ARCTOS SPECIMEN DATABASE, 2018), native to northern Guatemala and southern Mexico (BUENO et al., 2010), used by Pre-Colombian populations as nutritional food (AYERZA, 2009). Although chia is native from Central America, nowadays the seeds are cultivated all over the world. The largest exportations are from China (14.9%), followed by United States (8.9%) and Kazakhstan (7.6%) (TRIGDE SOURCING SOLUTIONS, 2019). The consumption of chia seed has been increasing over the years, due to its nutritional, physicochemical and sensory properties. The addition of chia seed in preparations, such as breads and cakes, improve their concentrations of proteins, unsaturated fatty acids, antioxidants, and dietary fiber. The gum content of chia flour increases its ability to hold water and oil, acting as an emulsifier and stabilizer. The absence of gluten also increases the demand for chia seed use (GRANCIERI; MARTINO; DE MEJIA, 2019).

This seed is also considered the highest botanical source of alpha-linolenic acid (ALA) omega 3 (n-3) and is a good source of dietary fiber, proteins, vitamins, minerals, and phytochemicals, such as phenolic compounds (MARINELI et al., 2014; SILVA et al., 2017). These components present in chia seed have been considered responsible for the improvement of biological markers related to diseases, presenting properties including: anti-inflammatory (HAMEDI et al., 2016), antioxidant (SCAPIN et al., 2016), hypotensive (TOSCANO et al., 2014), hypocholesterolemic (TAVARES TOSCANO et al., 2015) and hypoglycemic (FONTE-FARIA et al., 2019; MARINELI et al., 2015; VUKSAN et al., 2017). The doses used in animal studies vary from 3 to 41.3% for chia seed, and 0.15 to 10% for chia oil (ENES et al., 2020a). In clinical trials, the doses varied from 25g/day to 30g/1000 kcal (GRANCIERI; MARTINO; DE MEJIA, 2019).

The potential benefits of chia seed and oil on glucose metabolism control have been investigated in the last few years (FONTE-FARIA et al., 2019; MARINELI et al., 2015; SILVA et al., 2016) and some components of chia seed can be related. For example, rosmarinic acid (RA) is the major phenolic compound in chia seed (OLIVEIRA-ALVES et al., 2017) and it has been related to hypoglycemic effect (INUI et al., 2016). The high content of fiber and fat of chia seed could contribute to its potential in decreasing blood glucose. Rats fed high-fat and high-fructose diet (HFHF) added of chia seed (13.3%) or chia oil (4%) improved glucose tolerance and insulin resistance (MARINELI et al., 2015). Mice fed high-fat diet (HFD) had insulin cascade activated in skeletal muscle tissue after adding chia oil (0.15%) to the diet (FONTE-FARIA et al., 2019).

However, it remains unclear, if there is an interaction between chia's bioactive compounds, or if a specific compound is responsible for its health benefits. Regarding the hypoglycemic effect, remains unknown whether it is related only to skeletal muscle tissue or if other insulin dependent tissues may be affected. In addition remains unknown which fraction of chia seed (whole seed, oil or phenolic compounds) is responsible for the improvement on glucose metabolism. Since liver is the major site related to glucose metabolism control, our study aims to elucidate if chia and its fractions can modulate liver glucose control.

2. OBJECTIVES

2.1 General objective

Investigate the effect of different fractions (flour, oil and phenolic compounds) of chia (*Salvia hispanica* L.) on glucose metabolism, and their molecular mechanisms on insulin resistance conditions, in vivo and in vitro.

2.2 Specifics objectives

- Review the molecular mechanisms involved on chia effect on metabolic biomarker modulation, in animal studies;
- Identify and quantify the phenolic compounds in chia seed hydrolyzed extract;
- Evaluate the effect of chia flour and chia oil on food intake, weigh control and glucose metabolism in liver of rats fed HFHF diet;
- Evaluate the effect of chia seed hydrolyzed phenolics extract on glucose metabolism in insulin resistant hepatoma cells.

3. HYPOTESIS

Hypothesis 1. Chia flour and chia oil, improve glucose metabolism by modulating proteins involved on insulin cellular signaling, and glycolysis and gluconeogenesis enzymes, on liver of Wistar rats fed high-fat high-fructose diet.

Hypothesis 2. Hydrolyzed phenolic compounds from chia seed can attenuate insulin resistance, by regulating glycolysis and gluconeogenesis enzymes, on insulin resistant HepG2 cells.

4. MATERIAL AND METHODS

This study can be considered an umbrella trial, since the same experimental design will be investigated in different approaches, in attempt to find different effects of chia seed in Wistar rats fed HFHF diet. The first investigation was based on the potential of chia on health, focused on molecular mechanisms in animal studies, in a systematic review (ENES et al., 2020a). Based on these results, we were able to evaluate the lack of knowledge involving chia seed. Therefore, our research team conducted different investigations involving the same animal experiment. The first work was developed by Moreira (2019), focusing on chia's (flour and oil) effects on histomorphometry, inflammation and oxidative stress. The present study, therefore is the second work derived from the animal experiment, in which, we focused on chia flour and chia oil effects on liver glucose metabolism.

The content of this thesis include the review study (ENES et al., 2020a), and the original investigation about chia and its fraction (flour, oil and phenolics) effects on glucose metabolism, and their molecular mechanisms on insulin resistance conditions, in vivo and in vitro (ENES et al., 2020b).

4.1 Preparation of Chia Fractions and Characterization

4.1.1 Preparation of Chia Flour and Extration of Oil from Chia Seeds

The seeds used in the present study were cultivated in Rio Grande do Sul, Brazil, crop of 2017. Seeds were storage at -20 °C until use.

Chia seed was added to the diet as a flour that was obtained each 15 days in order to prepare experimental diets and to extract the oil from chia, also used to prepare one of the diets used in this protocol.

To obtain the flour, seeds were ground using a blender (PHILIPS WALITA®, model RI2035 500W), at level 4, room temperature, for 2 min. The flour was stored in black polypropylene bags, at -20 °C until diet preparation or oil extraction.

The oil was weekly obtained, by cold pressing chia flour throughout a hydraulic press (Carver Laboratory Press, ModelC 22400-36 - USA). During the oil extraction, precaution was taken to avoid light exposure. The oil extraction efficiency was 8%. The oil was collected, filtered using filter paper, centrifuged at 1050 x g, for 15 minutes at 7 °C, and stored in amber bottle glass at -20 °C until the moment of chemical characterization analyses, or its use for experimental diets preparation.

4.1.2. Chemical Characterization of Chia Flour and Chia Oil

The chemical composition of chia seed was determined according to analytical procedures recommended by the Association of Official Analytical Chemistry - AOAC (2012). The caloric density value was determined by the conversion factors 4 kcal. g⁻¹ for carbohydrates and proteins and 9 kcal. g⁻¹ for lipids.

The fatty acid profile of chia oil was determined by gas chromatography as proposed by Murrieta; Hess; Rule (2003), adapted for vegetable oil.

4.1.3 Extraction and Hydrolyses of Phenolics From Chia Flour

Phenolic extraction was performed using an ultrasound liquid–liquid extraction method proposed by Oliveira-Alves et al., (2017). Briefly, 2 g of chia flour and 10 mL of methanol: water (80:20, v/v) were vortexed for 10 s and placed in an ultrasound water bath (Model 3510R-MT, Branson Ultrasonic Corporation, Danbury, USA) operated at 42 kHz of ultrasound frequency, 100 W of power, for 60 min at 25 °C ± 3. This was followed by centrifugation at 1792g for 30 min. Collected supernatant was dried using a rotary evaporator, at 50 °C. The dried extracted phenolics were subjected to acid hydrolysis by dissolving in 2 mL of acidified water (formic acid 0.01%), then mixed with 1 M HCl (2 mL) and kept in water bath (100 °C) for 60 min. Hydrolyzed phenolics were purified using solid phase extraction (SPE). Solvent was evaporated to dryness at ± 50 °C under reduced pressure. Dried CHPE were stored at -20 °C with nitrogen gas for future analysis and cell culture experiments.

4.1.4 Chia Hydrolyzed Phenolics Extract Characterization

The total phenolic content of chia hydrolyzed phenolics extract (CHPE) was assessed according to Folin-Ciocalteu's (SWAIN; HILLIS, 2006), method with modifications (ABDERRAHIM et al., 2011). The results were quantified using a standard curve ranging 0 to 300 ppm of gallic acid and expressed in milligrams of gallic acid equivalents per milliliter of extract (mg GAE.mL⁻¹) ($y = 1.6229x - 0.0227$; R² = 0.9805). The content of total phenolics was used to establish the treatment doses in cell culture experiment.

The polyphenolic profile and quantification was assessed by reversed phase HPLC with a Waters 2695 Alliance system (Waters Corp.,Milford, MA). Identification and quantitation of polyphenolics were based on their spectral characteristics and retention time, as compared to authentic standards (Sigma Chemical Co., St. Louis, MO).

Compound identities were further confirmed by mass spectrometric analyses, performed on a Thermo Finnigan LCQ Deca XP Max MSn ion trap mass spectrometer equipped with an ESI ion source (Thermo Fisher, San Jose, CA). Separations were conducted using the Phenomenex (Torrance, CA) Synergi 4 μ Hydro-RP 80A (2 \times 150 mm; 4 μ m; S/N) 106273–106275) with a C18 guard column. Mobile phases consisted of 0.5% formic acid in water (phase A) and 0.5% formic acid in 50:50 methanol and acetonitrile (phase B) run at 0.25 mL/min. Polyphenolics were separated with a gradient elution program in which phase B changed from 5 to 30% in 5 min, from 30 to 65% in 70 min, and from 65 to 95% in 30 min and was held isocratic for 20 min. Ionization was conducted in the negative ion mode under the following conditions: sheath gas (N₂), 60 units/min; auxiliary gas (N₂), 5 units/min; spray voltage, 3.3 kV; capillary temperature, 250 °C; capillary voltage, 1.5 V; tube lens offset, 0 V.

4.2 Systematic Review Study

4.2.1 Protocol and Registration

The systematic review was carried out and reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (LIBERATI et al., 2009). The review has been registered at the PROSPERO (www.crd.york.ac.uk/prospero/): CRD42019119667.

4.2.2 Literature Search

Studies were identified by searching electronic databases: Latin American and Caribbean Center on Health Sciences Information (LILACS), PubMed/MEDLINE, Embase and Science Direct. The following terms were used to search in each database: (“Chia seed” OR “Chia seeds” OR “Salvia hispanica L.”) AND (Obesity OR Hyperglycemia OR Inflammation OR Dyslipidemias OR “Insulin Resistance” OR Diabetes OR “Cardiovascular Diseases” OR Hypertension OR “Metabolic syndrome” OR “Nonalcoholic fatty liver disease” OR “Nonalcoholic steatohepatitis”). Full search strategy employed in the electronic databases is presented in Table 1. Filters were used, if available, for animal studies. The reason of that choice was based on our purpose of investigating the mechanisms and pathways through which chia seed improves metabolic parameters. The results included original studies conducted with chia seeds and their fractions (oil, fiber, or both), regardless of study duration, dose or concentration used, or experimental design. To

be included in this review the study protocol should have an unbalanced diet group and a control group (standard diet). We excluded studies that used mixtures containing chia seeds, those involving other foods in the same treatment as chia, and those that used chia seed in a healthy diet context.

Table 1. Search strategy for different databases

A. PubMed

((“Chia seed” OR “Chia seeds” OR “Salvia hispanica L” OR “Chia seed” OR “Chia seed: OR “Salvia hispanica L”) AND (Obesity OR Hyperglycemia OR Inflammation O Dyslipidemias OR “Insulin Resistance” OR Diabetes OR “Cardiovascular Diseases” O Hypertension OR “Metabolic syndrome” OR “Nonalcoholic fatty liver disease” O “Nonalcoholic steatohepatitis”))

B. Embase

((“Chia seed” OR “Chia seeds” OR “Salvia hispanica L”) AND (Obesity O Hyperglycemia OR Inflammation OR Dyslipidemias OR “Insulin Resistance” O Diabetes OR “Cardiovascular Diseases” OR Hypertension OR “Metabolic syndrome” ((“Chia seed” OR “Chia seeds” OR “Salvia hispanica L”) AND (“Nonalcoholic fatty livi disease” OR “Nonalcoholic steatohepatitis”))

C. COCHRANE

((“Chia seed” OR “Chia seeds” OR “Salvia hispanica L”) AND (Obesity O Hyperglycemia OR Inflammation OR Dyslipidemias OR “Insulin Resistance” O Diabetes OR “Cardiovascular Diseases” OR Hypertension OR “Metabolic syndrome” O “Nonalcoholic fatty liver disease” OR “Nonalcoholic steatohepatitis”))

D. LILACS

(tw:(“Chia seed” OR “Chia seeds” OR “Salvia hispanica L”)) AND (tw:(Obesity)) O (tw:(Hyperglycemia)) OR (tw:(Inflammation)) OR (tw:(Dyslipidemias)) OR (tw:(“Insul: Resistance”)) OR (tw:(Diabetes)) OR (tw:(“Cardiovascular Diseases”)) O (tw:(Hypertension)) OR (tw:(“Metabolic syndrome”)) OR (tw:(“Nonalcoholic fatty livi disease”)) OR (tw:(“Nonalcoholic steatohepatitis”))

4.2.3 Study Selection and Data Collection Process

Following the recommendations of PRISMA (Liberati et al., 2009), two researchers independently assessed the eligibility of studies that evaluated the effect of chia consumption. Any discrepancies between reviewers were resolved through consensus. For

studies that fulfilled the inclusion criteria (as described in section 4.2.2), data extraction was performed by two independently working reviewers who were not blinded to author identity and study origin. Titles and abstracts were examined first, followed by full text screening. The reviewers extracted relevant information from each study: authors, publication date, animal model, chia fraction and dose, duration of the study, study protocol, pathway investigated, and main results. This information was summarized in a standardized model of data extraction.

4.2.4 Quality Assessment

The risk of bias was assessed using the Systematic Review Centre for Laboratory animal Experimentation Risk of Bias (SYRCLE RoB) tool (HOOIJMANS, CARLIJN R ROVERS et al., 2014), which is based on the Cochrane Collaboration. The SYRCLE RoB tool was developed to evaluate method quality and to measure the bias involving animal studies (HIGGINS et al., 2011). The SYRCLE RoB tool consider ten entries that are related to 6 types of bias: selection bias, performance bias, detection bias, attrition bias, reporting bias and others. For each included study the 6 bias types were classified as “high” (+, if one or more criteria were not attended), “low” (-, if all criteria were attended) or “unclear” (? , one or more criteria were partly attended).

To increase the strength of the present systematic review, the quality of the included studies was assessed using the Animal Research Reporting of in Vivo Experiment (ARRIVE) guidelines (KILKENNY et al., 2010). The ARRIVE guidelines are intended to standardize and improve the quality of reporting animal studies. It consists of 20 criteria which evaluate everything from the title to the conclusion of the report with special attention to the methods involved in the study and the discussion of results, as well as the relevance to human biology and the limitations of the study. Each of the included studies was evaluated and for each criteria, “0” or “1” was graded for “not reported” and “reported” information, respectively, and the frequency was calculated.

4.3 In Vivo Study

The in vivo study was conducted from June to October of 2018, in Experimental Nutrition Laboratory, of Universidade Federal de Viçosa, using chia flour and chia oil.

4.3.1 Study Design and Diets

This study was approved by the Ethics Commission on Animal Use (CEUA/UFV, protocol no. 31/2018, date of approval: April 26th, 2018) (Appendix 1) and followed university guidelines for animal use for experimental studies. Forty adults male Wistar rats (*Rattus norvegicus*), obtained from the Central Animal Facility of the Center for Biological Sciences and Health at Universidade Federal de Viçosa, Minas Gerais, Brazil. Rats remained in individual stainless-steel cages, with free access to water and diet, under controlled conditions ($22\text{ }^{\circ}\text{C} \pm 2$, 12h light/dark cycle). The animals were randomized by body weight and divided into 2 experimental groups, that received standard diet (AIN-93M) ($n= 10$; $156\text{ g} \pm 17$) and HFHF diet ($n=30$; $156.5\text{ g} \pm 17.9$), respectively, for 8 weeks, to induce insulin resistance (Phase I). In order to assess the effect of chia flour and chia oil on metabolic disorders (Phase II), animals fed HFHF ($\text{b.w.} = 358.04 \pm 33.00\text{ g}$, $n = 30$) were randomized into 3 experimental groups and fed HFHF ($\text{b.w.} = 366.8 \pm 35\text{ g}$, $n = 10$); chia flour HFHF ($\text{b.w.} = 362.4 \pm 35.4\text{ g}$, $n = 10$), or chia oil HFHF ($\text{b.w.} = 362.4 \pm 34.8\text{ g}$, $n = 10$) for 10 weeks. The lean control group ($\text{b.w.} = 350 \pm 29.1\text{ g}$, $n = 10$) fed AIN93M diet continued on same diet for 10 weeks. The experimental design is presented in Figure 1.




Figure 1 Figure 1. In vivo study experimental design. The experiment was divided into two phases. Phase I: Animals were divided in 2 groups: Control received a standard diet (AIN-93M); high-fat and highfructose group (HFHF) containing 4% (w/w) soybean oil, 31% (w/w) lard and 20% fructose (w/w) (Table 1) for 8 wk. Phase II: HFHF group was divided into 3 groups: HFHF; chia flour (HFHF with 14.7% of chia flour) and chia oil (HFHF with 4% of chia oil). Animals from control received AIN-93M diet on phase II. IR: insulin resistance.

Diets were based on the rodent standard AIN-93M diet (REEVES; NIELSEN; FAHEY GEORGE C., 1993), or high-fat and high-fructose diet (MARINELI et al., 2015). The control group (AIN-93M) received the standard diet from AIN-93M; the HFHF group received a diet containing 4% (w/w) of soybean oil, 31% (w/w) of lard, and 20% (w/w) of fructose; the chia flour group received the HFHF diet with 14.7% (w/w) of chia flour; the chia oil group received HFHF with 4% (w/w) of chia oil. For chia flour and chia oil groups the soybean oil was replaced by the fat content of chia (flour or oil). The content of protein and carbohydrate and dietary fiber of chia seed was taken into account to balance the chia seed diet. For dietary fiber adequacy, it was considered that the amount of chia flour to prepare 1000 g of chia flour diet (147 g/1000 g) offered 5.6% of dietary fiber. In order to standardize dietary fiber amount for all diets, based on chia flour diet amount, it was added cellulose for the other experimental diets (AIN-93M, HFHF and HFHF with chia oil) (Table 2). Diets were prepared every 15 days, packed in dark polyethylene bags and stored at -20 °C to minimize fatty acids oxidation. Diets and water were replaced every week. The food intake and weight gain of the animals were monitored weekly. Diets were prepared every 15 days, packed in dark polyethylene bags and stored at -20 °C to minimize fatty acid oxidation. Water and diet consumption were daily checked, and replaced every week,

with exception of chia oil diet, that was replaced every two days in attempt to avoid lipid oxidation. The food intake and animal weight gain were monitored weekly.

Table 2. Nutritional composition of experimental diets.

Ingredients (g/kg of diet)	Experimental Diets			
	AIN-93M	HFHF	Chia flour	Chia oil
Albumin*	136.4	136.4	101.8	136.4
Dextrinized starch	155	45.4	45.4	45.4
Corn starch	463.5	135	116.8	135
Sucrose	100	28.6	29.3	28.6
Fructose	-	200	200	200
Soybean oil	40	40	-	-
Chia flour	-	-	147.3	-
Chia oil	-	-	-	40
Lard	-	310	310	310
Microcrystalline Cellulose	55.8	55.8	0.00	55.8
Vitamin mix	10	10	10	10
Mineral mix	35	35	35	35
L-cystine	1.8	1.8	1.8	1.8
Choline bitartrate	2.5	2.5	2.5	2.5
Nutritional Composition				
Macronutrients				
Carbohydrates (%)	77.4	31.0	30.1	31.0
Protein (%)	12.9	9.1	9.2	9.1
Lipids (%)	9.7	59.8	60.4	59.8
Energetic density (kcal.g ⁻¹)	3.71	5.26	5.21	5.26
Fatty acids (g.kg⁻¹)**				
Linoleic (C18:2 n-6)	20.2	58.8	46.5	46.5
α -Linolenic (C18:3 n-3)	3.3	10.2	31.8	31.8
n-6/n-3 ratio	6.17:1	5.77:1	1.46:1	1.46:1

AIN-93M (Reeves, Nielsen e Fahey George C., 1993): standard diet group; HFHF (Marineli, et al., 2015): high fat and high-fructose group; Chia flour group: HFHF with 14.7% (w/w) chia flour; Chia oil group: HFHF with 4% (w/w) chia oil.

* Amount was calculated based on protein content equal to 88% to provide 12 g protein.100 g⁻¹ of diet (MOREIRA, 2019).

** Fatty acids expressed in g/kg diet and determined by gas chromatography (MOREIRA, 2019).

4.3.2 Intraperitoneal Glucose Tolerance Test and Insulin Tolerance Test

Intraperitoneal glucose tolerance test (iGTT) and insulin tolerance test (ITT) were performed after 9th and 10th weeks of chia flour or oil administration. Briefly, blood glucose levels were measured with a handheld glucometer (Accu-Chek®, Roche) using appropriate test strips. For the iGTT, D-glucose solution 50% (2 g.kg⁻¹ body weight) was injected into the peritoneal cavity. Blood glucose levels were measured after 30, 60, 90, and 120 min from the tail vein. The area under the curve (AUC) of glucose was calculated using GraphPad Prism 6 (GraphPad Software, San Diego, CA). ITT was accessed after intraperitoneal human insulin injection (0.75 U.kg⁻¹ body weight, Novolin®, Novo Nordisk) through glucose blood levels after 5, 10, 15, 20, 25, and 30 min of insulin injection. The formula $[0.693/(t_{1/2})]$ was used to calculate the constant rate of glucose disappearance. The glucose t_{1/2} was calculated from the slope of the least-squares analysis of the glucose concentrations during the linear phase (BONORA et al., 1987).

4.3.3 Euthanasia and Tissue Collection

The experiment was finished by euthanasia of animals at the end of 10 weeks of diets administration (no fast was performed). The animals were euthanized by cardiac puncture, after anesthetized with isoflurane (Isoforine, Cristália®). The liver was collected, weighted and immediately frozen with liquid nitrogen, prior storage at -80 °C for subsequent analysis. Adipose tissue was collected and weighted to calculate percentage of adiposity using the following formula: (visceral + retroperitoneal + epididymal adipose tissues)/total body weight × 100 (SILVA et al., 2018).

4.3.4 Gene Expression in Liver Tissue

Expression levels of genes involved on insulin and glucose metabolism in the liver were analyzed by RT-qPCR using the SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), according to the manufacture's protocol. Briefly, liver tissue (~100 mg) grinded in liquid nitrogen were homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) (1 mL) following manufacturer's protocol. Extracted mRNA was reverse transcribed into cDNA using the M-MLV reverse transcription kit (Invitrogen Corp., Grand Island, NY). The analyses were performed on the StepOne™ Real-TimePCR System (Thermo Fisher Scientific, Waltham, MA) by means of the measurement system involving SYBR-Green Fluorescence and Primer Express software (Applied Biosystems, Foster City, CA). Primers were purchase from Integrated DNA Technologies

(IDT DNA, Coralville, IA) to amplify AMPK, INSR, FOXO1, AKT, GK, PFK, PK and β -actin. β -actin was used as endogenous control to normalize the relative expression of mRNA. The primer sequences are presented in Table 4

Table 3. Sequencing primers used in the RT-qPCR analysis for in vivo study.

Genes	Oligonucleotide (5'-3')	
	Forward	Reverse
AMPK	TGAAGCCAGAGAACGTGTTG	ATAATTTGGCGATCCACAGC
INSR	TCATGGATGGAGGCTATCTGGA	TCCTTGAGCAGGTTGACGATTC
FOXO1	GATAAGGGCGACAGCAACAG	TGAGCATCCACCAAGAACTT
AKT	GGGCCACGGATACCATGAAC	AGCTGACATTGTGCCACTGA
GK	AGTATGAACCGGATGGTGGATGAA	CCAGCTTAAGCAGCACAAGTCGTA
PFK	CCACCTGGAGGCCATTGTAGA	GGGATGACGCACATGACGA
PK	ATCTGGGCAGATGATGTGGA	ATAGGGTGTAAGTGGTTCAGAATGG
β -actin	GTCGTACCACTGGCATTGTG	CTCTCAGCTGTGGTGGTAA

AMPK: AMP-activated protein kinase; INSR: Insulin receptor; FOXO1: Forkhead box protein 01; AKT: Protein kinase B; GK: Glucokinase; PFK: Phosphofructokinase, PK: Pyruvate kinase.

4.3.5 Phospho-AKT Assessment

Phospho-AKT protein levels were quantified using the AKT1[pS473] Ultrasensitive ELISA sandwich Kit (Invitrogen, ThermoFisher Scientific, MA, USA), according to the manufacture's protocol, on liver homogenate. Liver tissue was homogenized with phosphate buffer (1:10) 50 mM, at pH 7.4 containing 1 mM EDTA, and protease inhibitor (Protease Inhibitor Cocktail powder, Sigma Aldrich). The absorbance of samples was read at 450 nm (Multiskan Microplate Photometer, ThermoFisher Scientific, MA, USA).

4.4 In Vitro Study

The in vitro study was carried out in Laboratory of Nutritional Biochemistry, located in Texas A&M University, Texas, United States. The in vitro study was conducted in attempt to test the phenolics from chia, using an extract. The in vitro model was chosen to test phenolics from chia, since this was the first time that phenolics fraction of chia seed was used in order to check its effects in biological systems. Since no data were available

regarding its safety, we considered to use an in vitro model, once based on chia phenolics characterization studies, the seed presents high content of phenolics, and it could be harmful to animals. Otherwise, botanical extracts are usually chemically unstable. Using them in an in vivo model would be a risk since animal studies protocol's take at least weeks and extract changes would impair the study results and conclusions.

4.4.1 Cell line

The human hepatoma (HepG2) cell line were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dullbecco's modified Eagle's medium (DMEM) containing 5.5 mM Dglucose (GIBCO, Thermo Fisher, Waltham, MA), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C, 5% CO₂.

HepG2 cells were used since for the in vivo study we investigated the effects of chia flour and chia oil on liver glucose metabolism. The aim was to focus this research on the effects of different fractions of chia on liver glucose metabolism. Therefore, we choose hepatoma human cells to conduct the in vitro protocol.

4.4.2 Cell Viability

Cells were seeded at 80% confluence in a 96 well plate for 24 h to allow cell attachment. Followed by chia phenolics treatments (20 to 320 ppm) quantified as total phenolics (ABDERRAHIM et al., 2011) against a standard curve of gallic acid (0–300 ppm) and expressed in milligrams of gallic acid equivalents per milliliter of extract (mg GAE.mL⁻¹). After 48 h incubation, cell viability was determined using the in vitro toxicology assay kit resazurin following the manufacture's protocol (Sigma-Aldrich, San Luis, MO).

4.4.3 Insulin resistance protocol

HepG2 cells were maintained in DMEM medium at 37 °C, 5% CO₂ for 24 h. One day after plating, the medium was replaced for FBS free DMEM for 24 h. The cells were then treated with high glucose (25 mM) FBS free medium containing palmitic acid (PA) (1 mM) for 24 h (LEE; CHO; KWON, 2010; NAKAJIMA et al., 2000). After 24 h, insulin (100 μM) was added for 15 min. Cells cultured in 5.5 mM D-glucose DMEM, FBS free medium were used as negative controls (with and without insulin).

4.4.4 Gene Expression

A preliminary test was conducted with chia phenolics extract (20, 40, 80 ppm). Insulin resistance induced cells as described in 2.6.3 were treated with CHPE extract (80 ppm) for 24 h followed by insulin (100 μ M) was added for 15 min. Total RNA from HepG2 cells was extracted using Quick-RNA Mini Prep (Zymo Research, Irvine, CA), according to the manufacturer's protocol. cDNA was synthesized using iScript Reverse Transcription Supermix (BioRad, Hercules, CA). cDNA was subjected to quantitative Real-time polymerase chain reaction (RT-PCR) using the iTaq Universal SYBR Green Supermix Kit (BioRad, Hercules, CA) according to the manufacturer's protocol. RT-PCR data was analyzed with the delta CT method (Schmittgen and Livak, 2008) using TBP as the housekeeping gene. Primers were purchased from Sigma-Aldrich (San Luis, MO, USA) to amplify PFK, PK, PEPCK and G6Pase. Primers sequence are presented in Table 5.

Table 4. Sequencing primers used in the RT-qPCR analysis for in vitro study.

Genes	Oligonucleotide (5'-3')	
	Forward	Reverse
TBP	TGCACAGGAGCCAAGAGTGAA	CACATCACAGCTCCCCACCA
PFK	GGTAAGATCTCAGAGACTACAG	AGAAGTCGTTATCGATGGAG
PK	AAAATTGAGAACCACGAAGG	CAATCATCATCTTCTGAGCC
PEPCK	TGGAAGAATAAGGAGTGGAG	CTTCATAGACTAGAGGGACAC
G6Pase	ACTGTGCATACATGTTCATC	TGAATGTTTTGACCTAGTGC

TBP: TATA box binding protein; PFK: Phosphofructokinase; PK: Phosphokinase; PEPCK: Phosphoenolpyruvate carboxykinase; G6Pase: Glucose-6 phosphatase.

4.4.5 Phospho-AKT Assessment

Insulin resistance induced cells as described in 2.6.3 were treated with CHPE extract (20, 40 and 80 ppm) for 24 h followed by insulin (100 μ M) for 15 min. Negative controls were prepared as detailed in 2.7.3. Cells lysates were obtained adding X Tractor buffer (Takara Bio Company, CA, USA). Solid cellular debris was removed by centrifugation at 25,200g for 10 min at 4 °C. The supernatant was collected and stored at -80 °C. Protein content was determined using Bradford reagent (Bio-Rad, Hercules, CA, USA) following the manufacturer's protocol. Cell lysates (60 mg protein diluted with Laemmli's loading buffer and boiled for 5 min) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis at 100 V for 2 h. The proteins were transferred by wet

blotting onto a 0.2 mm PVDF membrane (Bio-Rad, Hercules, CA). The membranes were blocked using 5% non-fat milk in a 0.1% tween-phosphate buffer solution (T-PBS) for 30 min and incubated with the primary antibody (1:1000) in a 3% bovine serum albumin in T-PBS overnight at 4 °C with gentle shaking to assess the protein level of p-AKT(Ser473) (Cell Signalling, Danvers, MA) and β actin (Sigma-Aldrich, San Loius, MO). This was followed by incubation with the anti-rabbit IgG secondary antibody (1:2000) (Cell Signalling, Danvers, MA) in 5% milk T-PBS for 2 h. The reactive bands were visualized with a luminal reagent (Santa Cruz Biotechnology, Inc. Santa Cruz, CA) after 1 min of incubation, using an Omega Ultra Lum Molecular Imaging System (model Omega10gD) and band intensities were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, UDA; <https://imagej.nih.gov/ij/download.html>).

4.5 Statistical Analysis

Quantitative data were expressed as mean \pm standard error or standard deviation of the mean. Effect of treatments were analyzed using one-way analysis of variance (ANOVA) followed by NewmanKeuls post hoc test for parametric data and Kruskal-Wallis followed by Dun's for non-parametric. Tukey test was used to compare glucose blood levels means during different times on iGTT and ITT tests. The significance level was set at $p < 0.05$. GraphPad Prism 6 (GraphPad Software, San Diego, CA) was used to perform the analysis.

5. REFERENCES

ABDERRAHIM, F. et al. The Antioxidant Activity and Thermal Stability of Lemon Verbena (*Aloysia triphylla*) Infusion. **Journal of Medicinal Food**, v. 14, n. 5, p. 517–527, 24 mar. 2011.

AOAC - ASSOCIATION OF OFFICIAL ANALYTICAL CHEMISTRY. **Official methods of analysis of AOAC International: Agricultural chemicals, contaminants, drugs**. Gaithersburg: AOAC International, 2012. v. 16

ARCTOS SPECIMEN DATABASE. **Collaborative collection management solution**. Disponível em: <http://arctos.database.museum/name/Salvia_hispanica#_ArctosPlants>. Acesso em: 13 fev. 2019.

AYERZA, R. The Seed's Protein and Oil Content, Fatty Acid Composition, and Growing Cycle Length of a Single Genotype of Chia (*Salvia hispanica* L.) as Affected by Environmental Factors. **Journal of Oleo Science**, v. 58, n. 7, p. 347–354, 2009.

BONORA, E. et al. Relationships between insulin secretion, insulin metabolism and

insulin resistance in mild glucose intolerance. **Diabete Metabolism**, v. 13, n. 2, p. 116–121, 1987.

BOROWSKA, S.; BRZÓSKA, M. M. Chokeberries (*Aronia melanocarpa*) and Their Products as a Possible Means for the Prevention and Treatment of Noncommunicable Diseases and Unfavorable Health Effects Due to Exposure to Xenobiotics. **Comprehensive Reviews in Food Science and Food Safety**, v. 15, n. 6, p. 982–1017, 2016.

BUENO, M. et al. Análisis de la calidad de los frutos de *Salvia hispanica* L. (Lamiaceae) comercializados en la ciudad de Rosario (Santa Fe, Argentina). **Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas**, v. 9, p. 221–227, 2010.

CHALVON-DEMERSAY, T. et al. Animal Models for the Study of the Relationships between Diet and Obesity : A Focus on Dietary Protein and estrogen Deficiency. **Frontiers in Nutrition**, v. 4, n. March, p. 1–13, 2017.

CZECH, M. P. Insulin action and resistance in obesity and type 2 diabetes. **Nat Med**, v. 23, n. 7, p. 804–814, 2018.

ENES, B. N. et al. Chia seed (*Salvia hispanica* L.) effects and their molecular mechanisms on unbalanced diet experimental studies: A systematic review. **Journal of Food Science**, v. 85, n. 2, p. 226–239, 2020.

FONTE-FARIA, T. T. et al. Chia oil supplementation changes body composition and activates insulin signaling cascade in skeletal muscle tissue of obese animals. **Nutrition**, v. 58, p. 167–174, ago. 2019.

GBD 2016 RISK FACTORS COLLABORATORS. Global , regional , and national comparative risk assessment of 84 behavioural , environmental and occupational , and metabolic risks or clusters of risks , 1990 – 2016 : a systematic analysis for the Global Burden of Disease Study 2016. **The Lancet**, v. 390, p. 1345–422, 2017.

GOMES, J. V. P. et al. Antiobesity effects of anthocyanins on mitochondrial biogenesis, inflammation, and oxidative stress: A systematic review. **Nutrition**, v. 66, p. 192–202, 2019.

GRANCIERI, M.; MARTINO, H. S. D.; DE MEJIA, E. Chia Seed (*Salvia hispanica* L.) as a Source of Proteins and Bioactive Peptides with Health Benefits: A Review. **Comprehensive Reviews in Food Science and Food Safety**, v. 18, n. 2, p. 480–499, 2019.

HAMEDI, A. et al. *Salvia macrosiphon* seeds and seed oil : pharmacognostic , anti-inflammatory and analgesic properties. **International Research Journal of Pharmacy**, v. 3, n. 4, p. 27–37, 2016.

HIGGINS, J. P. T. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. **BMJ (Online)**, v. 343, n. 7829, p. 1–9, 2011.

HOOIJMANS, CARLIJN R ROVERS, M. M. et al. SYRCLE’s risk of bias tool for animal

studies. **Medical Research Methodology**, v. 14, n. 43, p. 2–9, 2014.

INSTITUTE OF MEDICINE. **Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids**. Washington, DC: The National Academies Press, 2005.

INUI, A. et al. Rosmarinic acid ameliorates hyperglycemia and insulin sensitivity in diabetic rats, potentially by modulating the expression of PEPCK and GLUT4. **Drug Design, Development and Therapy**, v. Volume 10, p. 2193–2202, 7 jul. 2016.

ISMAIEL, A.; DUMITRAȘCU, D. L. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review. **Frontiers in Medicine**, v. 6, p. 202, 2019.

KILKENNY, C. et al. The ARRIVE guidelines A nimal R esearch : R eporting I n V ivo E xperiments. **British Journal of Pharmacology**, v. 160, p. 1577–1579, 2010.

LEE, J.; CHO, H.-K.; KWON, Y. H. Palmitate induces insulin resistance without significant intracellular triglyceride accumulation in HepG2 cells. **Metabolism - Clinical and Experimental**, v. 59, n. 7, p. 927–934, 1 jul. 2010.

LIBERATI, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. **Journal of clinical epidemiology**, v. 62, n. 10, p. e1-34, 2009.

MARINELI, R. DA S. et al. Chemical characterization and antioxidant potential of Chilean chia seeds and oil (*Salvia hispanica* L.). **LWT - Food Science and Technology**, v. 59, n. 2P2, p. 1304–1310, 2014.

MARINELI, R. DA S. et al. Chia (*Salvia hispanica* L.) enhances HSP, PGC-1 α expressions and improves glucose tolerance in diet-induced obese rats. **Nutrition**, v. 31, n. 5, p. 740–748, 2015.

MOREIRA, L. DE P. D. et al. Potential of trace elements as supplements for the metabolic control of Type 2 Diabetes Mellitus: A systematic review. **Journal of Functional Foods**, v. 57, p. 317–327, 2019.

MOREIRA, L. DE P. D. **Efeito da Semente e do Óleo de Chia (*Salvia hispanica* L.) nas Alterações Metabólicas em ratos Alimentados com Dieta Rica em Gordura Saturada e Frutose**. [s.l.] Universidade Federal de Viçosa, 2019.

MURRIETA, C. M.; HESS, B. W.; RULE, D. C. Comparison of acidic and alkaline catalysts for preparation of fatty acid methyl esters from ovine muscle with emphasis on conjugated linoleic acid. **Meat science**, v. 65, n. 1, p. 523–529, set. 2003.

NAKAJIMA, K. et al. Selective attenuation of metabolic branch of insulin receptor down-signaling by high glucose in a hepatoma cell line, HepG2 cells. **The Journal of biological chemistry**, v. 275, n. 27, p. 20880–20886, jul. 2000.

OLIVEIRA-ALVES, S. C. et al. Characterization of phenolic compounds in chia (*Salvia hispanica* L.) seeds, fiber flour and oil. **Food Chemistry**, v. 232, p. 295–305, 2017.

POPKIN, B. M.; ADAIR, L. S.; NG, S. W. Global nutrition transition and the pandemic of obesity in developing countries. **Nutrition Reviews**, v. 70, n. 1, p. 3–21, 2011.

POPKIN, B. M.; NIELSEN, S. J.; BRAY, G. A. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. **The American Journal of Clinical Nutrition**, v. 79, n. 4, p. 537–543, 2004.

POZZA, C.; ISIDORI, A. . What's Behind the Obesity Epidemic. **Imaging in Bariatric Surgery**, p. 1–8, 2018.

REEVES, P. G.; NIELSEN, F. H.; FAHEY GEORGE C., J. AIN-93 Purified Diets for Laboratory Rodents: Final Report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of the AIN-76A Rodent Diet. **The Journal of Nutrition**, v. 123, n. 11, p. 1939–1951, 1 nov. 1993.

RIBEIRO, P. V. DE M. et al. Dietary non-nutrients in the prevention of non-communicable diseases: Potentially related mechanisms. **Nutrition**, v. 66, p. 22–28, 2019.

SCAPIN, G. et al. Phenolics compounds , flavonoids and antioxidant activity of chia seed extracts (*Salvia hispanica*) obtained by different extraction conditions. **Journal, International Food Research**, v. 23, n. 6, p. 2341–2346, 2016.

SCHENK, S.; SABERI, M.; OLEFSKY, J. M. Insulin sensitivity: modulation by nutrients and inflammation. **The Journal of Clinical Investigation**, v. 118, n. 9, p. 2992–3002, 2008.

SILVA, B. P. et al. Chia Seed Shows Good Protein Quality, Hypoglycemic Effect and Improves the Lipid Profile and Liver and Intestinal Morphology of Wistar Rats. **Plant Foods for Human Nutrition**, v. 71, n. 3, p. 225–230, 2016.

SILVA, B. P. et al. Chemical composition of Brazilian chia seeds grown in different places. **Food Chemistry**, v. 221, p. 1709–1716, 2017.

SILVA, B. P. et al. Effects of chia (*Salvia hispanica* L.) on calcium bioavailability and inflammation in Wistar rats. **Food Research International**, 2018.

SKROVANKOVA, S. et al. Bioactive Compounds and Antioxidant Activity in Different Types of Berries. **International Journal of Molecular Sciences**, v. 16, n. 10, p. 24673–24706, 16 out. 2015.

SWAIN, T.; HILLIS, W. E. The phenolic constituents of *Prunus domestica*. I.—The quantitative analysis of phenolic constituents. **Journal of the Science of Food and Agriculture**, v. 10, n. 1, p. 63–68, 2006.

TAVARES TOSCANO, L. L. et al. Chia induces clinically discrete weight loss and improves lipid profile only in altered previous values. **Nutricion hospitalaria**, v. 31, n. 3, p. 1176–1182, dez. 2015.

TOSCANO, L. T. et al. Chia Flour Supplementation Reduces Blood Pressure in Hypertensive Subjects. **Plant Foods for Human Nutrition**, v. 69, n. 4, p. 392–398, 2014.

TRIGDE SOURCING SOLUTIONS. **Top Exporting Countries of Chia Seed.**
Disponível em: <<https://www.tridge.com/intelligences/chia-seed/export>>.

VUKSAN, V. et al. Comparison of flax (*Linum usitatissimum*) and Salba-chia (*Salvia hispanica* L.) seeds on postprandial glycemia and satiety in healthy individuals: a randomized, controlled, crossover study. **European journal of clinical nutrition**, v. 71, n. 2, p. 234–238, fev. 2017.

WORLD HEALTH ORGANIZATION. **Noncumminicable Diseases Progress Monitor 2017.** [s.l: s.n.].

5. RESULTS

5.1 Paper 1

Published on Journal of Food Science, Impact factor (2018): 2.018

Original Research
 Hypothesis in Food Science

Chia seed (*Salvia hispanica* L.) effects and their molecular mechanisms on unbalanced diet experimental studies: A systematic review

Bárbara N. Enes , Luiza P. D. Moreira , Bárbara P. Silva , Mariana Grancieri , Haira G. Lúcio , Vinícius P. Venâncio , Susanne U. Mertens-Talcott , Carla O. B. Rosa , and Hércia S. D. Martino

Abstract: The aim of this review was to compile evidence and understand chia seed effects on unbalanced diet animal studies and the molecular mechanisms on metabolic biomarker modulation. A systematic review was conducted in electronic databases, following PRISMA recommendations. Risk of bias and quality was assessed using SYR-CLE toll and ARRIVE guidelines. Seventeen articles were included. Throughout the studies, chia's main effects are associated with AMPK modulation: improvement of glucose and insulin tolerance, lipogenesis, antioxidant activity, and inflammation. Details about randomization and allocation concealment were insufficient, as well as information about blind protocols. Sample size, chia dose, and number of animals evaluated for each parameter were found to be lacking information among the studies. Based on experimental study data, chia has bioactive potential, and its daily consumption may reduce the risk of chronic disease development, mainly due to the antioxidant, anti-inflammatory, hypoglycemic, and hypolipidemic effects of the seed.

Keywords: alpha linolenic acid, chia seed, dyslipidemia, glucose tolerance, *Salvia hispanica* L.

Practical Application: The consumption of chia seeds may improve lipid profile, insulin and glucose tolerance, and reduce risk of cardiovascular disease. Whole seed or its oil presents positive effect, but the effects of chia oil can act faster than the seed.

1. INTRODUCTION

Noncommunicable diseases, such as cardiovascular diseases, cancer, and diabetes, are responsible for three in five deaths in the world (Wang et al., 2016). These diseases are derived from high blood pressure, high cholesterol, and ultimately overweight and obesity (World Health Organization, 2017). Among various factors that may contribute to weight excess, epidemiological studies indicated strong correlation between the consumption of sugar, fructose, and saturated lipids—high content products with obesity. This pattern of food consumption is often termed as the “western diet,” characterized by high intakes of fats, animal-source foods, refined carbohydrates, and added sugar. (Popkin, Adair, & Ng, 2011; Popkin, Nielsen, & Bray, 2004).

The “western diet” is considered an unbalanced diet, since the macronutrients distribution is not adequate to human requirements (Institute of Medicine, 2005). Sedentary lifestyle and unbalanced diets lead to overweight (World Health Organization, 2017), which is associated with increased oxidative stress and chronic inflammation, and major biochemical and metabolic changes, which trigger a series of events associated with the development of comorbidities, such as insulin resistance (IR), type 2 diabetes mellitus, and cardiovascular diseases (Pozza & Isidori, 2018).

In the current context of increased obesity and comorbidities, plant food has been investigated as a source of bioactive compounds that might act as a coadjutant in the prevention and treatment of diseases (Borowska & Brzóska, 2016). The search for mechanisms through which bioactive compounds would improve obese health and decrease comorbidities risk has increased animal studies fed unbalanced diets, since it is a way to mitigate the human food intake pattern that contributes to overweight. Experimental studies involving Rodents are widely used in the nutrition research field since their physiology is similar to human's, including gastrointestinal (Hatton, Yadav, Basit, & Merchant, 2015). Animal studies can be considered an important screening for testing new plant food and their different doses and fractions, attempting a deep investigation into molecular pathways using tissues, which is not possible to accomplish in research involving humans (Chalvon-demersay, Blachier, Tomé, & Blais, 2017). Well-planned animal studies are considered a step before treatment application in clinical trials, which can be more successful when previous data are available to design efficient outcomes (Everitt, 2015).

A plant food alternative is chia seed (*Salvia hispanica* L.), which belongs to *Salvia* genus (Arctos Specimen Database, 2018), native to northern Guatemala and southern Mexico (Busiachi et al., 2013), used by Pre-Colombian populations as nutritional food (Ayerza, 2009). This seed is known for its high concentration of alpha linolenic acid (ALA) omega 3 (n-3), dietary fiber, proteins, vitamins, minerals, and phytochemicals, such as phenolic compounds (da Silva et al., 2017; Marmeli et al., 2014).

These components present in chia seed have been considered responsible for the improvement of biological markers related to diseases, presenting properties, including anti-inflammatory

JFDS-2019-0214 Submitted 1/30/2019, Accepted 11/22/2019. Authors Enes, Moreira, Silva, Grancieri, Lúcio, Rosa, and Martino are with Dept. of Nutrition and Health, Federal Univ. of Viçosa, Viçosa, MG 36570-900, Brazil. Authors Venâncio and Mertens-Talcott are with Dept. of Nutrition and Food Science, Texas A&M Univ., College Station, TX 77843, USA. Direct inquiries to author Martino (E-mail: hercia72@gmail.com).

Chia seed (*Salvia hispanica* L.) effects and their molecular mechanisms on unbalanced diet experimental studies: a systematic review

Bárbara N. Enes¹, Luiza P. D. Moreira¹, Bárbara P. Silva¹, Mariana Grancieri¹, Haira G. Lúcio¹, Vinícius P. Venâncio², Susanne U. Mertens-Talcott², Carla O.B. Rosa¹, Hércia S.D. Martino^{1*}

¹Department of Nutrition and Health, Federal University of Viçosa, Viçosa, MG, Brazil.

² Department of Nutrition and Food Science, Texas A&M University, College Station, Texas, United States

*Hércia Stampini Duarte Martino (corresponding author): Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, MG, Brazil. Tel. (+55 31) 3899-3742. Fax: (+55 31) 3899-2541. E-mail: hercia72@gmail.com

Word count: 8,007

Running Head: Chia seed effects on unbalanced diet

Abstract

The aim of this review was to compile evidence and understand chia seed effects on

unbalanced diet animal studies and the molecular mechanisms on metabolic biomarker modulation. A systematic review was conducted in electronic databases, following PRISMA recommendations. Risk of bias and quality was assessed using SYRCLE tool and ARRIVE guidelines. 17 articles were included. Throughout the studies, chia's main effects are associated to AMPK modulation: improvement of glucose and insulin tolerance, lipogenesis, antioxidant activity, and inflammation. Details about randomization and allocation concealment were insufficient, as well as information about blind protocols. Sample size, chia dose and number of animals evaluated for each parameter were found to be lacking information among the studies. Based on experimental study data, chia has bioactive potential, and its daily consumption may reduce the risk of chronic disease development, mainly due to the antioxidant, anti-inflammatory, hypoglycemic, and hypolipidemic effects of the seed.

Keywords: *Salvia hispanica* L., Chia seed, Glucose tolerance, Dyslipidemia, Alpha linolenic acid.

Practical Application: The consumption of chia seeds may improve lipid profile, insulin and glucose tolerance, and reduce risk of cardiovascular disease. Whole seed or its oil present positive effect, but the effects of chia oil can act faster than the seed.

1. INTRODUCTION

Noncommunicable diseases, such as cardiovascular diseases, cancer and diabetes are responsible for three in five deaths in the world (Wang et al., 2016). These diseases are derived from high blood pressure, high cholesterol, and ultimately overweight and obesity (World Health Organization, 2017). Among various factors that may contribute to weight excess, epidemiological studies indicated strong correlation between the consumption of sugar, fructose and saturated lipids-high content products with obesity. This pattern of food consumption is often termed as the “western diet”, characterized by high intakes of fats, animal-source foods, refined carbohydrates and added sugar (Popkin, Adair, & Ng, 2011; Popkin, Nielsen, & Bray, 2004).

The “western diet” is considered an unbalanced diet, since the macronutrients distribution is not adequate to human requirements (Institute of Medicine, 2005). Sedentary lifestyle and unbalanced diets lead to overweight (World Health Organization, 2017), which is associated with increased oxidative stress and chronic inflammation, and major biochemical and metabolic changes, which trigger a series of events associated with the development of comorbidities such as insulin resistance, type 2 diabetes mellitus, and cardiovascular diseases (Pozza & Isidori, 2018).

In current context of increased obesity and comorbidities, plant food has been investigated as source of bioactive compounds that might act as a coadjuvant in prevention and treatment of diseases (Borowska & Brzóska, 2016). The search for mechanisms through which bioactive compounds would improve obese health and decrease comorbidities risk has increased animal studies fed unbalanced diets, since it is a way to mitigate the human food intake pattern that contributes to overweight. Experimental studies involving rodents are widely used in the nutrition research field since their physiology is similar to human's, including gastrointestinal (Hatton, Yadav, Basit, & Merchant, 2015). Animal studies can be considered an important screening for testing new plant food and their different doses and fractions, attempting a deep investigation into molecular pathways using tissues, which is not possible to accomplish in research involving humans (Chalvon-demersay, Blachier, Tomé, & Blais, 2017). Well-planned animal studies are considered a step before treatment application in clinical trials, which can be more successful when previous data are available to design efficient outcomes (Carolina, 2015).

A plant food alternative is chia seed (*Salvia hispanica* L.) which belongs to *Salvia* genus (Arctos Specimen Database, 2018), native to northern Guatemala and southern

Mexico (Busilacchi et al., 2013), used by Pre-Colombian populations as nutritional food (Ayerza, 2009). This seed is known for its high concentration of alpha linolenic acid (ALA) omega 3 (n-3), dietary fiber, proteins, vitamins and minerals, and phytochemicals, such as phenolic compounds (da Silva et al., 2017; Marineli et al., 2014).

These components present in chia seed have been considered responsible for the improvement of biological markers related to diseases, presenting properties including: anti-inflammatory (Hamedi, Jamshidzadeh, Ahmadi, Sohrabpour, & Zarshenas, 2016), antioxidant (Scapin, Schmidt, Prestes, & Rosa, 2016), hypotensive (Toscano et al., 2014), hypoglycemic (Vuksan et al., 2017; Vuksan et al., 2010), and hypocholesterolemic (Toscano, Toscano, Tavares, & Oliveira Silva, 2015). Though it remains unclear if there is an interaction between them, acting in a synergic way or, if a specific compound is responsible for its health benefits. Besides that, the mechanisms and pathways involved in the chemoprevention of diseases by chia seeds remains unknown.

Thus, the aim of this review was to compile evidence of chia seed effects on unbalanced diet animal studies and to understand the effects and the molecular mechanisms on metabolic biomarker modulation.

2. METHODS

2.1. Protocol and registration

This systematic review was carried out and reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (Liberati et al., 2009). The review has been registered at the PROSPERO (www.crd.york.ac.uk/prospero/): CRD42019119667.

2.2. Literature Search

Studies were identified by searching electronic databases: Latin American and Caribbean Center on Health Sciences Information (LILACS), PubMed/MEDLINE, Embase and Science Direct. The following terms were used to search in each database: (“chia seed” OR “chia seeds” OR “salvia hispanica L.”) AND (obesity OR Hyperglycemia OR Inflammation OR Dyslipidemias OR “Insulin Resistance” OR diabetes OR “Cardiovascular Diseases” OR Hypertension OR “metabolic syndrome” OR “nonalcoholic fatty liver disease” OR “nonalcoholic steatohepatitis”). Full search strategy employed in the electronic databases is presented in **Table S1** in Supplementary Material. Filters were

used, if available, for animal studies. The reason of that choice was based on our purpose of investigating the mechanisms and pathways through which chia seed improves metabolic parameters. The results included original studies conducted with chia seeds and their fractions (oil, fiber, or both), regardless of study duration, dose or concentration used, or experimental design. To be included in this review the study protocol should have an unbalanced diet group and a control group (standard diet). We excluded studies that used mixtures containing chia seeds, those involving other foods in the same treatment as chia, and those that used chia seed in a healthy diet context.

2.3. Study Selection and Data Collection Process

Following the recommendations of PRISMA (Liberati et al., 2009), two researchers independently assessed the eligibility of studies that evaluated the effect of chia consumption. Any discrepancies between reviewers were resolved through consensus. For studies that fulfilled the inclusion criteria (as described in section 2.1), data extraction was performed by two independently working reviewers who were not blinded to author identity and study origin. Titles and abstracts were examined first, followed by full text screening. The reviewers extracted relevant information from each study: authors, publication date, animal model, chia fraction and dose, duration of the study, study protocol, pathway investigated, and main results. This information was summarized in a standardized model of data extraction.

2.4. Quality assessment

The risk of bias was assessed using the Systematic Review Centre for Laboratory animal Experimentation Risk of Bias (SYRCLE RoB) tool (Hooijmans et al., 2014) which is based on the Cochrane Collaboration. The SYRCLE RoB tool was developed to evaluate method quality and to measure the bias involving animal studies. (Higgins et al., 2011). The SYRCLE RoB toll consider ten entries that are related to 6 types of bias: selection bias, performance bias, detection bias, attrition bias, reporting bias and others. For each included study the 6 bias types were classified as “high” (+, if one or more criteria were not attended), “low” (-, if all criteria were attended) or “unclear” (? , one or more criteria were partly attended).

To increase the strength of the present systematic review, the quality of the included studies was assessed using the Animal Research Reporting of in Vivo Experiment (ARRIVE) guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010). The

ARRIVE guidelines are intended to standardize and improve the quality of reporting animal studies. It consists of 20 criteria which evaluate everything from the title to the conclusion of the report with special attention to the methods involved in the study and the discussion of results, as well as the relevance to human biology and the limitations of the study. Each of the included studies was evaluated and for each criteria, “0” or “1” was graded for “not reported” and “reported” information, respectively, and the frequency was calculated.

3. RESULTS AND DISCUSSION

3.1 Included studies and characteristics

The search yielded a total of 165 records from which 17 duplicates were removed. The selection of the remaining studies was made by reading their titles and abstracts and after this step, 19 studies that met the inclusion criteria were retrieved for full-text reading. From the full-text reading, 16 studies attended all the inclusion criteria and were included in this review. During the full-text reading, one study was identified by snowballing adding up to 17 studies included. Most records excluded were review publications, chemical characterization research, studies related to technological properties of chia, and absence of use of chia as study treatment (**Figure 1**). From 17 included records, only one was conducted with Flanders hybrid rabbits (Sierra, Roco, Alarcon, & Medina, 2015). The others were conducted with rodents: Wistar rats (da Silva et al., 2018; Fortino, Oliva, Rodriguez, Lombardo, & Chicco, 2017; Creus, Benmelej, Villafañe, & Lombardo, 2017; Creus et al., 2016; Marineli et al., 2015a; Marineli, Lenquiste, Moraes, & Maróstica, 2015b; Oliva, Ferreira, Chicco, & Lombardo, 2013; Poudyal, Panchal, Ward, & Brown, 2013; Poudyal, Panchal, Waanders, Ward, & Brown, 2012a; Poudyal, Panchal, Ward, Waanders, & Brown, 2012b; Chicco, D’Alessandro, Hein, Oliva, & Lombardo, 2009; Ayerza & Coates, 2007), C57BL/6 mice (Fonte-Faria et al., 2019), Swiss mice (de Miranda et al., 2019), and SAMR1/SAMP8 mice (Rui, Yang, Chen, Qin & Wan, 2018).




Figure 1: Flowchart of the search and selection process for articles included in the systematic review, according to PRISMA recommendation.

A total of 9 studies evaluated glucose metabolism, 10 studies evaluated the lipogenesis pathway, 5 studies analyzed the antioxidant effects, 3 studies analyzed the inflammation and 1 analyzed the atherosclerosis pathway. Regarding the used fractions, 11 studies used chia seed and the dose varied between 3 and 41.7%. The lowest dose, 3%, was able to increase the HDL-c of the animals (de Miranda et al., 2019), and the highest dose, 41.7%, was able to increase the antioxidant capacity, decrease the inflammatory markers (cytokines and NF- κ B expression), and decrease cholesterol (da Silva et al., 2018). The whole seed was offered to animals as flour since particle size acts directly on digestion and metabolic processes (Slavin, 2003). Furthermore, the whole seed flour has every component present in the grain, like endosperm, bran, germ and coat (Arvola et al., 2007) and the grinding allows bioaccessibility of bioactive antioxidant, such as phenolic acids to

cells which increase health benefits (Rosa, Dufour, Lullien-pellerin, & Micard, 2013).

Six studies used chia oil and the doses varied between 0.15% and 10%. The lowest concentration (0.15%) had effects that improved insulin resistance (IR), as increased glucose and insulin tolerance induced insulin receptor substrate (IRS) phosphorylation and GLUT-4 translocation to plasma membrane, and also reduced the serum fasting insulin levels (Fonte-Faria et al., 2019). Treatment duration varied between 3 and 24 weeks and all studies observed positive effects of chia seeds or oil. Chia seed has the highest known amount of n-3, ranged between 64.8% to 56.9% (Ayerza & Coates, 2011) which may explain the promising results found in animal studies. A summary of each publication is presented in **Table 1**.

Although there are published clinical trials with chia seeds, this review included only animal studies. Our choice was based on our purpose which was to investigate the mechanisms and pathways through which chia seed improves metabolic parameters. Most of the clinical trial results are limited to improvement on lipid profile (Vuksan et al., 2017; Toscano et al., 2015; Toscano et al., 2014; Nieman et al., 2012; Nieman et al., 2009), oxidative stress (Vuksan et al., 2017; Toscano et al., 2014; Vuksan et al., 2007), blood pressure (Toscano et al., 2014; Vuksan et al., 2007), and weight loss (Vuksan et al., 2017; Toscano et al., 2015), but all these parameters were not reproducible. This lack of major results may be due to feasible doses of chia used in these studies, which can be considered low when compared to doses offered to animals (20g/kg body weight) (Creus et al., 2017). The amount of chia seed (as food) expected to improve metabolic parameters may be too high for human consumption.

Table 1: Characteristics of the animal studies

References	Animal model	Study protocol	Fraction and Dose	Study duration	Pathway	Main Results
Fonte-Faria et al. (2019)	C57 BL/6 mice, male	- Control (n=8) - HFD (n=8) - HFD (n=8) followed by HFD + Chia oil	Chia oil 0.15%	19 weeks	Glucose metabolism Insulin signaling	<ul style="list-style-type: none"> ↑ Glucose and insulin tolerance ↓ Serum fasting insulin levels ↓ Serum leptin ↓ Serum TG ↑ HDLc ↓ Body fat mass and ↑ Body lean mass ↑ pIRS-1(Tyr)/IRS-1 ↑ GLUT-4 translocation to plasma membrane
da Silva et al. (2018)	Wistar rats, male	- Control + calcium carbonate (n=8) - Control + Chia seed (n=8) - HFD + calcium carbonate (n=8) - HFD + Chia seed (n=8)	Chia seed 41.3%	5 weeks	Antioxidant status Inflammation	<ul style="list-style-type: none"> ↓ Total, LDLc and VLDLc cholesterol ↑ SOD activity (liver) ↑ CAT (plasma) ↑ PPAR-α ↓ NFκB mRNA expression ↓ NFκB (liver) ↓ TNF and IL-10
de Miranda et al. (2018)	Swiss mice	- Control (n=6) - Control + Chia seed (n=6) - HFD (n=6) - HFD + Chia seed (n=6)	Chia seed 3%	16 weeks	Glucose metabolism Antioxidant status Lipogenesis Inflammation	<ul style="list-style-type: none"> - Did not modify glucose metabolism ↑ HDLc
Yehua Rui et al. (2018)	SAMR1 mice SAMP8 mice	- SAMR1 LFD (n=8) - SAMP8 LFD (n=8) - SAMP8 HFD (n=8) - SAMP8 HFD + Chia seed (n=8)	Chia seed 10%	18 weeks	Glucose metabolism	<ul style="list-style-type: none"> ↓ Insulin (plasma) ↓ HOMA-IR

Continuation Table 1: Characteristics of the animal studies

References	Animal model	Study protocol	Fraction and Dose	Study duration	Pathway	Main Results
Creus et al. (2017)	Wistar rats, male	- Control (n=24) - SRD (n=24) - SRD (n=24) followed by SRD + Chia seed	Chia seed 36.2%	24 weeks	AMPK Glucose metabolism	↓ pAMPK/AMPK ↓ TG, FFA, glucose (plasma) ↑ G-6-P, glycogen (heart muscle) ↑ Hexokinase and PDHa activities (heart muscle) ↑ GLUT-4, IRS-1 (Heart muscle) ↓ Collagen and hydroxyproline contents in left ventricle ↓ SBP
Fortino et al. (2017)	Wistar rats, male	Male offspring of RD-fed dams: - RD-RD (control) Male offspring of SRD - fed dams: - SRD-SRD (n=30) - SRD-SRD Chia seed (n=30)	Chia seed 20%	20 weeks	Glucose metabolism Lipogenesis	↓ TC, TG (plasma) ↓ n6:n3 ratio ↑ CPT-1 ↓ ACC ↓ Glucose (plasma) ↑ Glucose tolerance ↓ SBP and DBP
Ferreira et al. (2016)	Wistar rats, male	- Control (n=24, 24 w) - SRD (n= 24, 24 w) - SRD (n=24) followed by SRD + Chia seed	Chia seed 36.2%	12 weeks	Antioxidant status Lipogenesis Inflammation	↓ Epididymal fat and ↑ PPAR- γ (epididymal fat) ↓ TG, FFA, Uric acid, glucose, n3:n6 ratio (plasma) and ↑ GIR ↓ TNF, IL-6 (plasma) ↓ TBARS, protein carbonyl groups, XO activity and ROS ↑ GPx and SOD activity ↑ Nrf2 mRNA

Continuation Table 1: Characteristics of the animal studies

References	Animal model	Study protocol	Fraction and Dose	Study duration	Pathway	Main Results
Creus et al. (2016)	Wistar rats, male	- Control (n=20) - SRD (n=20) - SRD (n=20) followed by SRD + Chia seed	Chia seed 36.2%	24 weeks	Lipogenesis	↓Visceral Adiposity Index (%) ↑ GIR ↓TG, FFA, cholesterol, glucose (plasma) ↓ TG, LCA-CoA, DAG and ↑ PDHa (Intramyocardial lipid) ↑ CPT-1 ↑ FAT/CD36 ↓ Cardiac lipotoxicity ↑ Glucose oxidation ↓ SBP
Marineli et al. (2015)b	Wistar rats, male	- Control (n=6) - HFHF (n=6) - HFHF followed by HFHF + Chia seed (n=6) - HFHF followed by HFHF + Chia oil (n=6) - HFHF + Chia seed (n=6) - HFHF + Chia oil (n=6)	Chia seed 13.3% Chia Oil 4%	Short treatment: 6 weeks Long treatment: 12 weeks	Antioxidant status	↑TAC (plasma) ↑ GSH ↑ GR, GPx (liver and plasma) ↑ FRAP (liver and plasma) ↓ TBARS (plasma) ↓ 8-isoprostane
Marineli et al. (2015)a	Wistar rats, male	- Control (n=6) - HFHF (n=6) - HFHF followed by HFHF + Chia seed (n=6) - HFHF followed by HFHF + Chia oil (n=6) - HFHF + Chia seed (n=6) - HFHF + Chia oil (n=6)	Chia seed 13.3% Chia Oil 4%	Short treatment: 6 weeks Long treatment: 12 weeks	Antioxidant status Glucose metabolism Lipogenesis	↑ Glucose and insulin tolerance ↑ Expression of HSP70, HSP25 ↓ HSP60 (skeletal muscle) ↑ SOD and GPx ↑ TAC ↑ Expression of PGC-1 α ↓ NEFA ↓ ALT e AST

Continuation Table 1: Characteristics of the animal studies

References	Animal model	Study protocol	Fraction and Dose	Study duration	Pathway	Main Results
Sierra et al. (2015)	Flanders hybrids rabbits	- Control (n=8) - Chia oil (n=8) - Control + cholesterol 1% (n=8) - Chia oil + cholesterol 1% (n=8)	Chia oil 10%	6 weeks	Atherosclerosis	↓ TG (plasma) ↑ ALA (plasma) ↑ Endothelium relaxation ↓ Angiotensin II and noradrenaline
Oliva et al. (2013)	Wistar rats, male	- Control (n= 6) - SRD (n= 6) - SRD (n= 6) followed by SRD + Chia seed	Chia seed	24 weeks	Glucose metabolism	↓ TG, FFA, Glucose (plasma) ↑ GIR ↓ Epididymal AT ↓ TG (Adipocyte) ↓ FAS, G6PD, Malic enzyme ↑ Hexokinase, PDHa (gastrocnemius muscle) ↓ TG, Long-chain acyl CoA and DG (gastrocnemius muscle)
Poudyal et al. (2013)	Wistar rats, male	- Control (n=12) - Control followed by Control + Chia oil (n=12) - HFHF (n=12) - HFHF followed by HFHF + Chia oil (n=12)	Chia oil 3%	16 weeks	Lipogenesis	↓ Visceral adiposity (%), Abdominal circumference and Retroperitoneal adipose tissue ↓ Liver weight ↓ Lipid content in liver, heart and skeletal muscle ↓ TC, TG and NEFA (plasma) ↓ Insulin (plasma) ↑ Glucose and insulin tolerance ↑ n3:n6 (heart, liver, skeletal muscle, retroperitoneal adipose tissue) ↓ AST, LDH, ALP, CK ↑ SBP

Continuation Table 1: Characteristics of the animal studies

References	Animal model	Study protocol	Fraction and Dose	Study duration	Pathway	Main Results
Poudyal et al. (2012)a	Wistar rats, male	- Control (n=12) - Control + Chia (n=12) - HFHF (n=12) - HFHF + Chia seed (n=12)	Chia seed 5%	24 weeks	Lipogenesis Glucose metabolism	↓Visceral adiposity (%), retroperitoneal and omental adipose tissue ↓ Lipid content in liver and ↑ in heart ↑ TG and ↓ NEFA (plasma) ↑ n3:n6 (plasma and retroperitoneal AT) ↑ Glucose and insulin tolerance ↓ ALT and ↑ ALP ↓ Inflammatory cells in the left ventricle, collagen deposition, diastolic rigidity, fibrosis ↑ SBP
Poudyal et al. (2012)b	Wistar rats, male	- Control (n=12) - Control + Chia seed (n=12) - HFHF (n=12) - HFHF + Chia seed (n=12) 8w	Chia seed 5%	8 weeks	Lipogenesis Glucose metabolism	↓ Visceral adiposity (%), Body fat (%), abdominal circumference, retroperitoneal and omental adipose tissue and ↑ Total body lean mass ↓ Lipid content in skeletal muscle ↑ Lipid content in heart ↑ Glucose and insulin tolerance ↓ Uric acid, LDH, CRP, AST ↑ TG, ALP and n3:n6 ratio (plasma) ↓ Liver fibrosis ↑ SBP
Chicco et al. (2008)	Wistar rats, male	Experimental design 1: - Control (n=24) - SRD (n=24) - SRD + Chia seed (n=24) Experimental design 2: - Control (n=24) - SRD (n=72) divided into three subgroups: 1. immediately killed (n=24) 2. SRD (n=24) 3. SRD + Chia seed (n=24)	Chia seed 36.2%	Experimental design 1: 3 weeks Experimental design 2: 20 weeks	Lipogenesis	↓Epididymal and retroperitoneal AT ↓ TG, NEFA, TC (plasma) ↓ TG (liver) ↓ Glucose ↑ Glucose tolerance ↑ n3 total ↓ n6:n3 ratio (plasma)

Continuation Table 1: Characteristics of the animal studies

References	Animal model	Study protocol	Fraction and Dose	Study duration	Pathway	Main Results
Ayerza; Coates (2007)	Wistar rats, male	- Control (n=8, 4 w) - Whole chia seed (n=8) - Ground chia seed (n=8) - Chia oil (n=8)	Chia seed: 16% Chia oil: 5,34%	4 weeks	Lipogenesis	↓ TG, total SFA (plasma) ↑ HDLc and n3 (plasma)

↑: increase; ↓: decrease; ACC: acetyl-CoA Carboxylase; ALA: alpha linolenic acid; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AMPK: adenosine monophosphate-activated protein kinase; AST: aspartate aminotransferase; AT: adipose tissue; CAT: catalase; CK: creatinine; CPT-1: carnitine-palmitoyl transferase-1; CRP: C-reactive protein; DBP: diastolic blood pressure; DG: diacylglyceride; FAS: fatty acid synthase; FAT/DC36: Fatty acid translocase; FFA: free fatty acid; FRAP: ferric reducing ability of plasma; G-6-P: glucose-6-phosphate; G6PD: glucose-6-phosphate dehydrogenase; GIR: glucose infusion rate; GLUT-4: glucose transporter type 4; GPx: glutathione peroxidase; GR: glutathione reductase; GSH: reduced glutathione; HDLc: high density lipoprotein; HFD: high fat diet; HOMA-IR: homeostasis model assessment: insulin resistance; HSP25: heat shock protein 25; HSP60: heat shock protein 60; HSP70: heat shock protein 70; IL-10: interleukin 10; IL-6: interleukin 6; IRS-1: insulin receptor substrate 1; LCA-CoA: Long-chain Acyl-CoA; LDH: lactate dehydrogenase; LDLc: low density lipoprotein; n3: omega 3; n6: omega 6; NEFA: nonesterified fatty acids; NF-κB: factor nuclear kappa B; Nrf2: nuclear factor (erythroid-derived 2)-like 2; pAMPK: phosphorylation of adenosine monophosphate-activated protein kinase; PDHa: pyruvate dehydrogenase E1 component subunit alpha; PGC-1α: peroxisome proliferator-activated receptor-γ coactivator; pIRS-1(Tyr)/IRS-1: phosphorylation on Tyr989 of IRS-1; PPAR-α: peroxisome proliferator-activated receptor alpha; PPAR-γ: peroxisome proliferator-activated receptor gamma; RD: Reference diet; RD-RD: offspring from dams fed a reference diet (RD) and fed the RD after weaning; ROS: reactive oxygen species; SAMP8 HFD: Senescence Accelerated Mouse - fed a high fat diet; SAMP8 LFD: Senescence Accelerated Mouse - fed a low fat diet; SAMR1 LFD: senescence-accelerated mouse - resistant 1 - fed a low fat diet; SBP: systolic blood pressure; SD: standard diet; SFA: saturated Fatty acids; SOD: superoxide dismutase; SRD: sucrose rich diet; SRD-SRD: offspring from SRD-fed dams fed an SRD after weaning; SRD-SRDC: offspring from SRD-fed dams fed an SRD+Chia after weaning; TAC: total antioxidant capacity; TBARS: thiobarbituric acid reactive substances; TC: total cholesterol; TG: triacylglycerol; TNF-α: tumor necrosis factor alpha; VLDLc: very low density lipoprotein; w: weeks; XO: xanthine oxidase.

3.3 Impact of chia on metabolic and associated disorders

3.3.1 Glucose metabolism

The introduction of chia to rats fed with an unbalanced diet improved glucose tolerance and insulin sensitivity (Fonte-Faria et al., 2019; Rui et al., 2018; Fortino et al., 2017; Creus et al., 2017; Creus et al., 2016; Ferreira et al., 2016; Marineli et al., 2015a; Marineli et al., 2015b; Oliva et al., 2013; Poudyal et al., 2012a; Poudyal et al., 2012b; Chicco et al., 2009). These effects were confirmed by additional data of chia seed intake such as increased expression of heat shock proteins 25 (HSP25) and HSP70 in soleus muscle (Marineli et al., 2015a), increased insulin-stimulated phosphorylation on IRS-1 and GLUT-4 translocation on gastrocnemius (Fonte-Faria et al., 2019) and heart (Creus et al., 2017), increased AMP-activated protein kinase (AMPK) phosphorylation on gastrocnemius (Fonte-Faria et al., 2019), cardiac muscles (Creus et al., 2017), epididymal and subcutaneous adipose tissue (Rui et al., 2018).

AMPK is one of the most important proteins involved to the cellular energy balance and it works as sensor of energy-deprivation. Its decrease leads to noticeable effects on animal energy metabolism, among which are the oxidative pathways of glucose and lipids (Nelson & Cox, 2014). It is already well established that diets high in fat and sucrose (or both) reduce AMPK (Lindholm et al., 2013; Yang, Miyahara, Takeo, & Katayama, 2012), and HSP expression (Chung et al., 2008). Therefore, chia seed and its compounds present a promising role in energetic metabolism since animals fed unbalanced diets, when fed chia, had AMPK phosphorylation restored as control animals. Besides that, chia modulates other markers, including carnitine palmitoyltransferase 1 (CTP-1) (Creus et al., 2017; Fortino et al., 2017), peroxisome proliferator-activated receptor- γ coactivator 1- α (PGC-1 α) and HSP expression (Marineli et al., 2015a), signaling improvement in mitochondrial activity pattern, fatty acid oxidation, adipogenesis control and prevention of the overexpression of inflammatory mediators (da Silva et al., 2018; Creus et al., 2016; Musch, Kapil, & Chang, 2004).

From the included studies, we hypothesize that chia and its fractions mitigate obesity-induced insulin sensitivity by regulating AMPK and IRS-1 phosphorylation, which improve GLUT-4 translocation and increase hexokinase and glucose 6-phosphate enzymatic activity (Creus et al., 2017; Fortino et al., 2017; Ferreira et al., 2016; Marineli et al., 2015a; Oliva et al., 2013; Poudyal et al., 2012b; Chicco et al., 2009), which would restore glucose utilization as an energetic fuel. This hypothesis is supported by the increase

in CPT-1 activity (Creus et al., 2016), PGC-1 α expression and peritoneal glucose tolerance as a response to consumption of chia seed and oil (Marineli et al., 2015a) (**Figure 2**).




Figure 2. Hypothesis of chia's seeds mechanism of action based on unbalanced diet experimental studies. IRS1: Insulin receptor substrate 1; G6PD: Glucose 6 phosphate; AMPK: AMP-activated protein kinase; PPAR- γ : Peroxisome Proliferator-Activated Receptor Gamma; PGC1- α : Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; CTP-1: Carnitine palmitoyl transferase I; SOD: Superoxide dismutase; GPx: Gluthatione peroxidase; ROS: Reative reative oxygen species; CTA: Tricarboxylic acid.

3.3.2 Lipid profile and lipolysis

The consumption of chia improved the lipid profile in animals fed nutritionally inadequate diets (high in simple carbohydrates like sucrose and fructose, high in saturate fat, or both). These results are related to improving plasma cholesterol profile (Fonte-Faria et al., 2019; da Silva et al., 2018; de Miranda et al., 2019; Creus et al., 2016; Sierra et al., 2015; Poudyal et al., 2013) and decreasing plasma triglycerides (Fonte-Faria et al., 2019; Creus et al., 2017; Fortino et al., 2017; Creus et al., 2016; Sierra et al., 2015; Oliva et al., 2013; Poudyal et al., 2013; Poudyal et al., 2012a; Chicco et al., 2009; Ayerza & Coates, 2007). Additionally, chia seed increased the plasmatic levels of n-3 and α -linoleic (n-6) fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), n-3/saturated fatty acids and n-3/n-6 ratio (Creus et al., 2017; Fortino et al., 2017; Sierra et al., 2015;

Oliva et al., 2013; Poudyal et al., 2012a; Chicco et al., 2009; Ayerza & Coates, 2007).

Among plant foods chia seed is the major source of n-3 (da Silva et al., 2017; Ayerza, 2009; Ayerza & Coates, 2005) and despite being the primary fatty acid of the n-3 pathway, its conversion to EPA and DHA has been widely held as inefficient (Ratnayake & Galli, 2009). Studies with chia seed as a source of ALA have been demonstrating that its physiological effects are different than that produced by EPA and DHA in rats with metabolic syndrome. They also showed that although ALA was not efficient in reducing total body fat (Poudyal et al., 2013; Poudyal et al., 2012a), it has induced fat redistribution away from the abdominal area (Fonte-Faria et al., 2019; Oliva et al., 2013; Poudyal et al., 2013; Poudyal et al., 2012a; Poudyal et al., 2012b), decreasing risk of cardiovascular diseases.

Moreover, the modulation of glucose metabolism markers by chia seed had impact on lipogenesis, evidenced by the increase of peroxisome proliferator-activated receptor (PPAR) (da Silva et al., 2018; Creus et al., 2016), improvement in serum lipid profile, reduction of visceral adiposity, and decrease of epididymal adipose tissue weight (Fortino et al., 2017; Creus et al., 2017; Creus et al., 2016; Ferreira et al., 2016; Oliva et al., 2013; Sierra et al., 2015; Chicco et al., 2009; Ayerza & Coates, 2007) (**Figure 2**).

Regarding lipogenesis, rats fed a high-fat-diet (HFD) had impaired recruitment of FAT/CD36 by insulin as well as CTP-1 activity (Creus et al., 2016) and PPAR- α protein mass (da Silva et al., 2018; Creus et al., 2016). These findings are related to chronic high exposure to fatty acids provided by HFD, disrupting the balance between lipid oxidation-storage. The recruitment of FAT/CD36 by insulin is a key mechanism for beta-oxidation and for restoring mitochondrial activity. Chia seed was able to revert this condition by recruiting FAT/CD36 to the sarcolemma through insulin signaling (Creus et al., 2016), increasing PPAR- α (da Silva et al., 2018), increasing PGC1- α expression (Marineli et al., 2015a) and decreasing visceral adiposity (Creus et al., 2016; Ferreira et al., 2016; Poudyal et al., 2013; Poudyal et al., 2012b)

Our review allowed us to develop a hypothesis about how chia seed can improve lipid biomarkers. Unbalanced diets induce insulin intolerance and this is a key event for lipogenesis. Chia seed reversed abnormal glucose homeostasis and peripheral insulin insensitivity (Fonte-Faria et al., 2019; Rui et al., 2018; Fortino et al., 2017; Creus et al., 2017; Creus et al., 2016; Ferreira et al., 2016; Marineli et al., 2015a; Marineli et al., 2015b; Oliva et al., 2013; Poudyal et al., 2012a; Poudyal et al., 2012b; Chicco et al., 2009) and insulin induced the translocation of FAT/CD36 (Creus et al., 2016) to the plasmatic

membrane. Our hypothesis is that the normalization of insulin response is one of the most important events involved in chia seed improvement on lipogenesis, recovering beta-oxidation and balancing fuel utilization. Thus, the normalization of insulin response by chia seed may reverse triggers for lipogenesis.

3.3.3 Impact of chia on oxidative stress and inflammation

Several authors described chia's effects on decreasing oxidative stress by increasing total antioxidant capacity, restoring antioxidant enzymes (da Silva et al., 2018; Marineli et al., 2015a; Marineli et al., 2015b), and decreasing reactive oxygen species (ROS) and lipid peroxidation (Ferreira et al., 2016; Marineli et al., 2015b). The decrease of the plasma lipid peroxidation may be connected to hypoglycemic effect of chia that is associated to decrease of LDL oxidation, probably due to a reduction on its plasmatic levels (Marineli et al., 2015b). With exception of de Miranda et al. (2019), all the studies included in this review that evaluated glucose metabolism, plasma lipids, or its peroxidation and ROS production found simultaneously glycaemia decrease and plasmatic lipid level improvement (Fonte-Faria et al., 2019; Fortino et al., 2017; Creus et al., 2017; Creus et al., 2016; Ferreira et al., 2016; Oliva et al., 2013; Poudyal et al., 2013; Poudyal et al., 2012a). Three other papers showed decrease in peroxidation markers (Ferreira et al., 2016; Marineli et al., 2015a; Marineli et al., 2015b).

Compounds in chia, such as phenolic acids (rosmarinic acid, caffeic acid, danshensu, chlorogenic acid, quercetin, myricetin and kaempferol) and lipophilic compounds (carotenoids, tocopherols, phospholipids and ALA) were associated with antioxidant effects (da Silva et al., 2017; Oliveira-Alves et al., 2017; Ixtaina et al., 2010; Reyes-Caudillo, Tecante & Valdivia-López, 2008). Although antioxidant activity and phenolic compounds quantities between chia seeds and oil are different (Oliveira-Alves et al., 2017), studies have highlighted similar effects of both seed and oil in the modulation of oxidative stress (Marineli et al., 2015b). The beneficial effect demonstrated for both fractions may be due to interactions between the chemical components in the seed, and synergistic activity between the lipophilic compounds in chia oil. The variability observed between the studies may be due to the distinct composition of chia from different locations and cultivation conditions (da Silva et al., 2017).

Regarding the effect of chia seed on inflammation, some studies showed reduction on inflammation biomarkers (da Silva et al., 2018; Creus et al., 2017; Creus et al., 2016; Poudyal et al., 2012a; Poudyal et al., 2012b) or on associated ones, such as glutamic-

oxalacetic transaminase, alanine aminotransferase (Marineli et al., 2015a; Poudyal et al., 2013; Poudyal et al., 2012a; Poudyal et al., 2012b), liver fibrosis (Poudyal et al., 2012a) and HSP72 upregulation, which is associated to preventing the overexpression of inflammatory mediators (Moura, Lollo, Morato & Amaya-Farfan, 2018). All of them interestingly, were associated to other improvements such as glucose and insulin tolerance and lipogenesis control. This finding strengthens our previous hypothesis about insulin activity normalization and positive effects of chia seed on health.

3.4. Impact of chia's bioactive compounds on metabolic and associated disorders

All studies included in this review mentioned the bioactive compounds of chia seed as potential in improving metabolic disorders developed by unbalanced diets. However, none of them are able to point out a compound as responsible for a specific action. Previous studies using other food sources or isolated bioactive compounds evidenced that phenolic compounds (e.g. quercetin, chlorogenic acid, caffeic acid, rosmarinic acid), dietary fiber, fatty acid (e.g. ALA), and others, play a role in repairing health conditions triggered by unbalanced diets (Sadeghi, Seyyed Ebrahimi, Golestani & Meshkani, 2017; Gonzalez-Manan et al., 2012; Pal & Ghosh, 2012;). Nevertheless, regarding chia seed, it is hard to link the effect on metabolism to one specific compound. Even the studies that used fractions like oil or fiber cannot discern which "compound" is associated to that action.

The fractions of the seed have different components that result in distinct actions. Apparently hydrolyzed extracts of chia as well as extracts from the seed and its fiber present higher antioxidants (Oliveira-Alves et al., 2017), and flavonoid bioaccessibility may be impaired by the seed's fat (Pellegrini et al., 2018). Nevertheless, studies conducted with chia oil presented improvement in inflammation (Poudyal et al., 2012a) and restored the antioxidant system (Marineli et al., 2015b). Studies that compared chia's fraction during different times showed that chia oil presents a faster action than chia seed (Marineli et al., 2015a; Marineli et al., 2015b), but more studies must be conducted to confirm it. Although chia oil seems to be superior to the seed, the extraction methods should be observed in order to avoid losses regarding antioxidant compounds. Özcan et al (2019a) showed that chia oil obtained from roasted seeds presents lower content of α -Tocopherol, β + γ -Tocopherol, δ -Tocopherol, β -Tocotrienol and γ -Tocotrienol compared with non-roasted seeds, regardless of the method used to obtain the oil: cold press or Soxhlet extraction. Recent data showed that heat acts negatively on physical-chemical and

bioactive properties of chia oil, where the content of fatty acids and phenolic compounds was decreased by microwave roasting (Özcan et al., 2019b).

Therefore, it still remains unclear if there is a specific bioactive compound or the synergism of them are implicated in the improvement of biomarkers evidenced by the studies. None of them make a direct association to a certain compound with the results obtained. However, most of the studies mentioned that the major action of chia on health conditions is due to the improvement of glucose uptake, its oxidation and restored tissue sensibility to insulin and its regulation of gene expression (PPAR α , CTP-1, PGC1- α) related to lipogenesis and mitochondrial activity.

Based on the few studies that evaluated the effects of chia on metabolic pathways, we hypothesized that chia compounds increase AMPK expression which increases the PGC1- α and CTP-1, increasing expression of PPAR α , reducing the lipogenesis, increasing mitochondrial activity and consequently fatty acid oxidation. Therefore, the AMPK together with IRS, stimulates the translocation of GLUT-4 to plasmatic membrane and allows the entrance of glucose inside the cells, reducing the IR. Moreover, AMPK allows the translocation of FAT/CD36 to the sarcolemma in muscle cells, facilitating the FA oxidation by mitochondria. Chia's effects on restoring antioxidant defense may come from the improvement on glucose tolerance, from the reduction of oxidative stress or the improvement on mitochondrial dysfunction, but it is unknown how chia seed is able to increase these anti-oxidative enzymes (**Figure 2**).

3.5. Reporting Quality and Risk of Bias

Among the 17 studies evaluated, 1 study did not show the dose of chia administered to the animals (Chicco et al., 2009). None of them discussed potential adverse effects of the doses and/or compounds used in the intervention, as well as insufficient information on the limitations of the study, especially concerning extrapolation of data to humans (Creus et al., 2017; Fortino et al., 2017; Sierra et al., 2015; Oliva et al., 2013; Poudyal et al., 2013; Poudyal, et al., 2012a; Poudyal, et al., 2012b) (**Table 2**). Our findings are consistent to Kilkeny et al. (2009) who claims that there is a lack of important information regarding experimental and statistics methods applied in research regarding animals and in publications.

Table 2. Risk of bias from experimental studies

References	Marineli et. al., 2015a	Marineli et. al., 2015 b	Oliva et. al., 2013	Poudyal et.al., 2012 a	Creus et. al., 2017	Creus et. al., 2016	Chicco et. al., 2008	Sierra et. al., 2015	Ayerza; Coates, 2007	Fortino et. al., 2017	Poudyal et. al., 2012b	Ferreira et. al., 2016	Poudyal et. al., 2013	Yehua et al. 2018	de Miranda et al. 2018	da Silva et al. 2018	Fonte-Faria et al. 2019	Percentage (%)
(1) Title	1	1	1	0	1	1	1	1	1	1	1	1	1	1	1	1	1	94.1
(2) Abstract Introduction	1	1	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1	88.2
(3) Background information	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(4) Primary and secondary objectives	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	94.1
Methods																		
(5) Ethical statement	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(6) Study design, allocation concealment, blinding and randomization	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(7) Experimental procedure	1	1	1	1	1	1	1	1	1	1	1	1	0	1	1	1	1	94.1
(8) Experiment animals details including species, gender, age, weight and source	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(9) Housing and husbandry conditions	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(10) Sample size	1	1	0	1	1	1	1	1	1	1	1	1	1	1	0	1	1	88.2
(11) Allocation of animals to experimental groups	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(12) Experiment outcomes	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(13) Statistical analysis	1	1	1	1	1	1	1	1	0	1	1	1	1	1	1	1	1	94.1
Results																		
(14) Baseline data	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(15) Number of animals analyzed	1	1	0	0	0	0	0	1	1	1	0	1	1	0	1	0	1	52.9

(16) Outcomes and estimation, results for each animal	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(17) Adverse events (details of all important adverse)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Discussion																			
(18) Interpretation, scientific implications, study limitations	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	100
(19) Generalizability and translation, relevance to human biology	1	1	0	1	0	1	0	0	1	0	0	1	1	1	1	1	1	1	64.7
(20) Funding	1	1	0	1	0	1	0	1	1	0	1	0	0	1	1	1	1	1	64.7

Moreover, about the risk of bias (**Figure 3**), none of the studies reported about blinding the investigators involved in the research. Only one study (da Silva et al., 2018) reported details about the animal's randomization to groups. 16 studies failed to report information about allocation concealment strategies. The lack of information reported in studies may reveal significant short-comings on designing animal studies, which in turn may impair the scientific community to obtain reliable data from previous studies, generating a negative effect on laboratory research. Our data about lack of blinding is consent with findings demonstrating little blinding in experimental research (Holman, Head, Lanfear & Jennions, 2015). Selection and measurement bias can be solved with randomization and blinded assessment of outcome (Macleod et al., 2015), since they are related to the randomness of outcomes. We suggest researchers involved in animal studies to follow the ARRIVE guidelines to avoid misinformation in their reports.

	Sequence generation (Selection bias)	Baseline characteristics (Selection bias)	Allocation concealment (selection bias)	Random housing(Performance bias)	Blinding (Performance bias)	Random outcome assessment (Detection bias)	Blinding (Detection bias)	Incomplete outcome data (Attrition bias)	Selective outcome reporting (Reporting bias)	Other bias
Ayerza; Coates 2007	?	+	?	?	-	+	-	+	+	+
Chicco et. al. 2008	?	+	?	?	-	?	-	+	+	+
Creus et. al. 2017	?	+	?	?	-	?	-	+	+	+
Creus et al. 2016	?	+	?	-	-	?	-	+	+	-
da Silva et al. 2018	?	+	+	+	-	+	-	+	+	+
de Miranda et al. 2018	?	+	-	-	-	-	-	+	-	+
Ferreira et. al. 2016	?	+	?	?	-	?	-	+	+	+
Fonte-Faria et al. 2019	?	+	?	?	-	?	-	+	+	+
Fortino et. al. 2017	?	+	+	+	-	+	-	+	+	+
Marineli et. al. 2015a	?	+	?	?	-	?	-	+	+	+
Marineli et. al. 2015b	?	+	?	?	-	?	-	+	+	+
Oliva et. al. 2013	?	+	?	?	-	?	-	+	+	+
Poudyal et.al., 2012b	?	+	?	?	-	?	-	+	+	+
Poudyal et.al., 2013	?	+	?	?	-	?	-	+	+	+
Poudyal et al. 2012a	?	+	?	?	-	?	-	+	+	+
Sierra et. al. 2015	?	+	?	?	-	?	-	+	+	+
Yehua et al. 2018	?	+	?	-	-	?	-	+	+	+

Figure 3. Risk of bias summary: review authors' judgments about each risk of bias item for each included study.

4. CONCLUSIONS

This review supports the prospective use of chia in the prevention and treatment of comorbidities associated to unbalanced diets. Despite the limitations in extrapolating the results to humans, we consider chia seed a potential bioactive food, as the realistic consumption of chia seeds and oil could be able to prevent and attenuate metabolic changes. We highlight the lack of data about which compound would be responsible to stimulate or down regulate the pathways discussed in this review as well as the dose that would present an efficient and secure effect on human health. We reinforce the need of future clinical studies that consider the dose of chia seed consumed daily and the seed fraction that best impacts health. Thus, the biological effects of the seed and its components can be clinically confirmed and may represent a dietary strategy to prevent

and treat chronic health problems. The use of tools for quality assessment identified methodological gaps that suggest operational improvements on running experimental research for future high quality controlled trials.

Acknowledgments

We thank Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for the financial support.

Conflict of interest

The authors state they have no conflict of interest.

Author Contribution

Bárbara N. Enes researched prior studies, evaluated each study, compiled data, interpreted the results and drafted the manuscript.

Luiza P. D. Moreira researched prior studies, evaluated each study, interpreted the results and drafted the manuscript.

Bárbara P. Silva compiled data and drafted the manuscript.

Mariana Grancieri drafted the manuscript and reviewed the manuscript.

Haira G. Lúcio researched prior studies and compiled data.

Vinícius P. Venâncio drafted and reviewed critically the manuscript.

Susanne U. Mertens-Talcott reviewed critically the manuscript.

Carla O.B. Rosa reviewed critically the manuscript.

Hércia S.D. Martino reviewed critically the manuscript and approved the final and revised version.

All authors have read and approved the final manuscript.

5. REFERENCES

Arctos Specimen Database. (2018). Collaborative collection management solution. Retrieved from <http://arctos.database.museum/name/Salvia%20hispanica#> ArctosPlants Accessed: February, 13, 2019.

Ayerza, R. (2009). The seed's protein and oil content, fatty acid composition, and growing cycle length of a single genotype of chia (*Salvia hispanica* L.) as affected by environmental factors. *Journal of Oleo Science*, 58(7), 347-354. <https://doi.org/10.5650/jos.58.347>

Ayerza, R., & Coates, W. (2005). Ground chia seed and chia oil effects on plasma lipids and fatty acids in the rat. *Nutrition Research*, 25(11), 995–1003. <https://doi.org/https://doi.org/10.1016/j.nutres.2005.09.013>

Ayerza, R. J., & Coates, W. (2007). Effect of dietary alpha-linolenic fatty acid derived from chia when fed as ground seed, whole seed and oil on lipid content and fatty acid composition of rat plasma. *Annals of Nutrition & Metabolism*, 51(1), 27–34. <https://doi.org/10.1159/000100818>

Borowska, S., & Brzówska, M. M. (2016). Chokeberries (*Aronia melanocarpa*) and their products as a possible means for the prevention and treatment of noncommunicable diseases and unfavorable health effects due to exposure to xenobiotics. *Comprehensive Reviews in Food Science and Food Safety*, 15(6), 982–1017. <https://doi.org/10.1111/1541-4337.12221>

Busilacchi, H., Quiroga, M., Bueno, M., Di Sapio, O., Flores, V., & Severin, C. (2013). Evaluación de *Salvia hispanica* L. cultivada en el sur de santa fe (Republica Argentina). *Cultivos Tropicales*, 34(4), 55–59. Retrieved from <http://scielo.sld.cu/pdf/ctr/v34n4/ctr09413.pdf>

Chalvon-demersay, T., Blachier, F., Tomé, D., & Blais, A. (2017). Animal models for the study of the relationships between diet and obesity : a focus on dietary protein and estrogen deficiency. *Frontiers in Nutrition*, 4, 1–13. <https://doi.org/10.3389/fnut.2017.00005>

Chicco, A. G., D'Alessandro, M. E., Hein, G. J., Oliva, M. E., & Lombardo, Y. B. (2009). Dietary chia seed (*Salvia hispanica* L.) rich in alpha-linolenic acid improves adiposity and normalises hypertriacylglycerolaemia and insulin resistance in dyslipaemic rats. *The British Journal of Nutrition*, 101(1), 41–50. <https://doi.org/10.1017/S000711450899053X>

Chung, J., Nguyen, A., Henstridge, D. C., Holmes, A. G., Chan, M. H. S., Mesa, J. L., ... Febbraio, M. A. (2008). HSP72 protects against obesity-induced insulin resistance. *PhysiologyBiochemistry & Molecular Biology*, 105(5), 1739–1744.

Creus, A., Benmelej, A., Villafañe, N., & Lombardo, Y. B. (2017). Dietary salba (*Salvia hispanica* L.) improves the altered metabolic fate of glucose and reduces increased collagen deposition in the heart of insulin-resistant rats. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 121, 30–39. <https://doi.org/10.1016/j.plefa.2017.06.002>

Creus, A., Ferreira, M. R., Oliva, M. E., & Lombardo, Y. B. (2016). Mechanisms involved in the improvement of lipotoxicity and impaired lipid metabolism by dietary alpha-linolenic acid rich *Salvia hispanica* L. (salba) seed in the heart of dyslipemic insulin-resistant rats. *Journal of Clinical Medicine*, 5(2). <https://doi.org/10.3390/jcm5020018>

da Silva, B. P., Anunciação, P. C., Matyelka, J. C. da S., Della Lucia, C. M., Martino, H. S. D., & Pinheiro-Sant'Ana, H. M. (2017). Chemical composition of Brazilian chia seeds grown in different places. *Food Chemistry*, 221, 1709–1716. <https://doi.org/10.1016/j.foodchem.2016.10.115>

da Silva, B. P., Toledo, R. C. L., Grancieri, M., Moreira, M. E. de C., Medina, N. R., Silva, R. R., ... Martino, H. S. D. (2018). Effects of chia (*Salvia hispanica* L.) on calcium

bioavailability and inflammation in Wistar rats. *Food Research International*. In Press. <https://doi.org/https://doi.org/10.1016/j.foodres.2018.08.078>

da Silva Stefani, F., de Campo, C., Paese, K., Stanisçuaski Guterres, S., Haas Costa, T. M., & Hickmann Flôres, S. (2019). Nanoencapsulation of linseed oil with chia mucilage as structuring material: characterization, stability and enrichment of orange juice. *Food Research International*. <https://doi.org/10.1016/j.foodres.2018.11.052>

de Miranda, D. A., da Silva, F. P., Carnier, M., Mennitti, L. V., Figuerêdo, R. G., Hachul, A. C. L., ... Oyama, L. M. (2019). Chia flour (*Salvia hispanica* L.) did not improve the deleterious aspects of hyperlipidic diet ingestion on glucose metabolism, but worsened glycaemia in mice. *Food Research International*. <https://doi.org/10.1016/j.foodres.2018.12.033>

Everitt, J.I. (2015). The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions. *Toxicologic Pathology*, 43, 70-77. <https://journals.sagepub.com/doi/pdf/10.1177/0192623314555162>

Ferreira, M. S., Alvarez, M. R., Illesca M, S., Giménez, P., & Lombardo, Y. B. (2016). Dietary salba (*Salvia hispanica* L.) ameliorates the adipose tissue dysfunction of dyslipemic insulin - resistant rats through mechanisms involving oxidative stress, inflammatory cytokines and peroxisome proliferator - activated receptor γ . *European Journal of Nutrition*, 57(1), 83-94. <https://doi.org/10.1007/s00394-016-1299-5>

Fonte-Faria, T., Citelli, M., Atella, G. C., Raposo, H. F., Zago, L., de Souza, T., ... Barja-Fidalgo, C. (2019). Chia oil supplementation changes body composition and activates insulin signaling cascade in skeletal muscle tissue of obese animals. *Nutrition*, 58, 167-174. <https://doi.org/https://doi.org/10.1016/j.nut.2018.08.011>

Fortino, M. A., Oliva, M. E., Rodriguez, S., Lombardo, Y. B., & Chicco, A. (2017). Could post-weaning dietary chia seed mitigate the development of dyslipidemia, liver steatosis and altered glucose homeostasis in offspring exposed to a sucrose-rich diet from utero to adulthood? *Prostaglandins Leukotrienes and Essential Fatty Acids*, 116, 19-26. <https://doi.org/10.1016/j.plefa.2016.11.003>

Gonzalez-Manan, D., Tapia, G., Gormaz, J. G., D'Espessailles, A., Espinosa, A., Masson, L., ... Valenzuela, R. (2012). Bioconversion of [small alpha]-linolenic acid to n-3 LCPUFA and expression of PPAR-alpha, acyl coenzyme A oxidase 1 and carnitine acyl transferase I are incremented after feeding rats with [small alpha]-linolenic acid-rich oils. *Food & Function*, 3(7), 765-772. <https://doi.org/10.1039/C2FO30012E>

Hamedi, A., Jamshidzadeh, A., Ahmadi, S., Sohrabpour, M., & Zarshenas, M. M. (2016). *Salvia macrosiphon* seeds and seed oil : pharmacognostic, anti-inflammatory and analgesic properties. *International Research Journal of Pharmacy*, 3(4), 27-37.

Hatton, G. B., Yadav, V., Basit, A. W., & Merchant, H. A. (2015). Animal farm : considerations in animal gastrointestinal physiology and relevance to drug delivery in humans. *Journal of Pharmaceutical Sciences*, 104(9), 2747-2776. <https://doi.org/10.1002/jps.24365>

- Higgins, J. P. T., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., ... Sterne, J. A. C. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ (Online)*, 343(7829), 1–9. <https://doi.org/10.1136/bmj.d5928>
- Holman, L., Head, M. L., Lanfear, R., & Jennions, M. D. (2015). Evidence of experimental bias in the life sciences: why we need blind data recording. *PLoS Biology*, 13(7), 1–12. <https://doi.org/10.1371/journal.pbio.1002190>
- Hooijmans, Carlijn R Rovers, M. M., Vries, R. B. de, Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014). SYRCLE's risk of bias tool for animal studies. *Medical Research Methodology*, 14(43), 2–9. <https://doi.org/10.7507/1672-2531.20140206>
- Institute of Medicine. (2005). *Dietary reference intakes for energy, carbohydrates, fiber, fat, fatty acids, cholesterol, protein and amino acids*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/10490>
- Ixtaina, V. Y., Vega, A., Nolasco, S. M., Tomás, M. C., Gimeno, M., Bárzana, E., & Tecante, A. (2010). Supercritical carbon dioxide extraction of oil from Mexican chia seed (*Salvia hispanica* L.): characterization and process optimization. *J Supercrit Fluids*, 55 (1), 192-199. <https://doi.org/10.1016/j.supflu.2010.06.003>
- Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010). The ARRIVE guidelines animal research : reporting in vivo experiments. *British Journal OfPharmacology*, 160, 1577–1579.
- Kilkenny, C., Parsons, N., Kadyszewski, E., Festing, M. F. W., Cuthill, I. C., Fry, D., ... Altman, D. G. (2009). Survey of the quality of experimental design, statistical analysis and reporting of research using animals. *PLoS ONE*, 4(11). e7824. <https://doi.org/10.1371/journal.pone.0007824>
- Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., ... Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Journal of Clinical Epidemiology*, 62(10), e1-34. <https://doi.org/10.1016/j.jclinepi.2009.06.006>
- Lindholm, C. R., Ertel, R. L., Bauwens, J. D., Schmuck, E. G., Mulligan, J. D., & Saupe, K. W. (2013). A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats. *Journal of Physiology and Biochemistry*, 69(2), 165–175. <https://doi.org/10.1007/s13105-012-0199-2>
- Macleod, M. R., Lawson McLean, A., Kyriakopoulou, A., Serghiou, S., de Wilde, A., Sherratt, N., ... Sena, E. S. (2015). Risk of bias in reports of in vivo research: a focus for improvement. *PLoS Biology*, 13(10), 1–12. <https://doi.org/10.1371/journal.pbio.1002273>
- Marineli, R. S., Moura, C. S., Moraes, E. A., Lenquiste, S. A., Lollo, P. C. B., Morato, P. N., ... Marostica, M. R. J. (2015a). Chia (*Salvia hispanica* L.) enhances HSP, PGC-1 α expressions and improves glucose tolerance in diet-induced obese rats. *Nutrition*, 31(5), 740–748. <https://doi.org/10.1016/j.nut.2014.11.009>

- Marineli, R. da S., Lenquiste, S. A., Moraes, É. A., & Maróstica, M. R. (2015b). Antioxidant potential of dietary chia seed and oil (*Salvia hispanica* L.) in diet-induced obese rats. *Food Research International*, 76, 666–674. <https://doi.org/10.1016/j.foodres.2015.07.039>
- Marineli, R. da S., Moraes, É. A., Lenquiste, S. A., Godoy, A. T., Eberlin, M. N., & Maróstica, M. R. (2014). Chemical characterization and antioxidant potential of Chilean chia seeds and oil (*Salvia hispanica* L.). *LWT - Food Science and Technology*, 59(2), 1304–1310. <https://doi.org/10.1016/j.lwt.2014.04.014>
- Moura, C. S., Lollo, P. C. B., Morato, P. N., & Amaya-Farfan, J. (2018). Dietary nutrients and bioactive substances modulate heat shock protein (HSP) expression: a review. *Nutrients*, 10(6), 1–13. <https://doi.org/10.3390/nu10060683>
- Musch, M. W., Kapil, A., & Chang, E. B. (2004). Heat shock protein 72 binds and protects dihydrofolate reductase against oxidative injury. *Biochemical and Biophysical Research Communications*, 313(1), 185–192. <https://doi.org/10.1016/j.bbrc.2003.11.096>
- Nelson, D. L., & Cox, M. M. (2014). *Princípios de bioquímica de Lehninger* (6th edition). Porto Alegre: Artmed Editora.
- Nieman, D. C., Cayea, E. J., Austin, M. D., Henson, D. A., McAnulty, S. R., & Jin, F. (2009). Chia seed does not promote weight loss or alter disease risk factors in overweight adults. *Nutrition Research*, 29(6), 414–418. <https://doi.org/https://doi.org/10.1016/j.nutres.2009.05.011>
- Nieman, D. C., Gillitt, N., Jin, F., Henson, D. A., Kennerly, K., Shanely, R. A., ... Schwartz, S. (2012). Chia seed supplementation and disease risk factors in overweight women: a metabolomics investigation. *Journal of Alternative and Complementary Medicine*, 18(7), 700–708. <https://doi.org/10.1089/acm.2011.0443>
- Oliva, M. E., Ferreira, M. R., Chicco, A., & Lombardo, Y. B. (2013). Dietary salba (*Salvia hispanica* L.) seed rich in alpha-linolenic acid improves adipose tissue dysfunction and the altered skeletal muscle glucose and lipid metabolism in dyslipidemic insulin-resistant rats. *Prostaglandins, Leukotrienes, and Essential Fatty Acids*, 89(5), 279–289. <https://doi.org/10.1016/j.plefa.2013.09.010>
- Oliveira-Alves, S. C., Vendramini-Costa, D. B., Betim Cazarin, C. B., Maróstica Júnior, M. R., Borges Ferreira, J. P., Silva, A. B., ... Bronze, M. R. (2017). Characterization of phenolic compounds in chia (*Salvia hispanica* L.) seeds, fiber flour and oil. *Food Chemistry*, 232, 295–305. <https://doi.org/10.1016/j.foodchem.2017.04.002>
- Özcan, M. M., Al-Juhaimi, F. Y., Ahmed I. A. M., Osman, M. A., Gassem, M. A (2019). Effect of different microwave power setting on quality of Chia seed oil obtained in a cold press. *Food Chemistry*, 278, 190-196. <https://doi.org/10.1016/j.foodchem.2018.11.048>
- Özcan, M. M., Al-Juhaimi, F. Y., Ahmed I. A. M., Osman, M. A., Gassem, M. A (2019). Effect of soxhlet and cold press extractions on the physico-chemical characteristics of roasted and non-roasted chia seed oils. *Journal of Food Measurement and*

Characterization, 13, 648-655. <https://doi.org/10.1007/s11694-018-9977>

Pal, M., & Ghosh, M. (2012). Prophylactic effect of α -linolenic acid and α -eleostearic acid against MeHg induced oxidative stress, DNA damage and structural changes in RBC membrane. *Food and Chemical Toxicology*, 50(8), 2811–2818. <https://doi.org/10.1016/j.fct.2012.05.038>

Pellegrini, M., Lucas-Gonzalez, R., Sayas-Barberá, E., Fernández-López, J., Pérez-Álvarez, J. A., & Viuda-Martos, M. (2018). Bioaccessibility of phenolic compounds and antioxidant capacity of chia (*Salvia hispanica* L.) seeds. *Plant Foods for Human Nutrition*, 73(1), 47–53. <https://doi.org/10.1007/s11130-017-0649-7>

Popkin, B. M., Adair, L. S., & Ng, S. W. (2011). Global nutrition transition and the pandemic of obesity in developing countries. *Nutrition Reviews*, 70(1), 3–21. <https://doi.org/10.1111/j.1753-4887.2011.00456.x>

Popkin, B. M., Nielsen, S. J., & Bray, G. A. (2004). Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. *The American Journal of Clinical Nutrition*, 79(4), 537–543. <https://doi.org/10.1093/ajcn/79.4.537>

Poudyal, H., Panchal, S. K., Ward, L. C., & Brown, L. (2013). Effects of ALA, EPA and DHA in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. *The Journal of Nutritional Biochemistry*, 24(6), 1041–1052. <https://doi.org/https://doi.org/10.1016/j.jnutbio.2012.07.014>

Poudyal, H., Panchal, S. K., Waanders, J., Ward, L., & Brown, L. (2012a). Lipid redistribution by alpha-linolenic acid-rich chia seed inhibits stearoyl-CoA desaturase-1 and induces cardiac and hepatic protection in diet-induced obese rats. *The Journal of Nutritional Biochemistry*, 23(2), 153–162. <https://doi.org/10.1016/j.jnutbio.2010.11.011>

Poudyal, H., Panchal, S. K., Ward, L. C., Waanders, J., & Brown, L. (2012b). Chronic high-carbohydrate, high-fat feeding in rats induces reversible metabolic, cardiovascular, and liver changes. *American Journal of Physiology. Endocrinology and Metabolism*, 302(12), E1472-82. <https://doi.org/10.1152/ajpendo.00102.2012>

Pozza, C., & Isidori, A. . (2018). What's behind the obesity epidemic. *Imaging in Bariatric Surgery*, Springer, Cham, 1-8.

Ratnayake, W. M. N., & Galli, C. (2009). Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. *Annals of Nutrition and Metabolism*, 55(1–3), 8–43. <https://doi.org/10.1159/000228994>

Reyes-Caudillo, E., Tecante, A., & Valdivia-López, M. A. (2008). Dietary fibre content and antioxidant activity of phenolic compounds present in Mexican chia (*Salvia hispanica* L.) seeds. *Food Chemistry*, 107(2), 656–663. <https://doi.org/10.1016/j.foodchem.2007.08.062>

Rincón-cervera, M. Á., Valenzuela, R., & Hernandez-rodas, M. C. (2017). The effects of ω -6 and ω -3 fatty-acids on early stages of mice DMBA submandibular glands tumorigenesis. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 125, 48–55.

<https://doi.org/10.1016/j.plefa.2016.02.002>

Rosa, N. N., Dufour, C., Lullien-pellerin, V., & Micard, V. (2013). Exposure or release of ferulic acid from wheat aleurone : Impact on its antioxidant capacity. *Food Chemistry*, 141(3), 2355–2362. <https://doi.org/10.1016/j.foodchem.2013.04.132>

Rui, Y., Yang, S., Chen, L.-H., Qin, L.-Q., & Wan, Z. (2018). Chia seed supplementation reduces senescence markers in epididymal adipose tissue of High-Fat Diet-Fed SAMP8 mice. *Journal of Medicinal Food*, 21(8), 755–760. <https://doi.org/10.1089/jmf.2017.4129>

Sadeghi, A., Seyyed Ebrahimi, S. S., Golestani, A., & Meshkani, R. (2017). Resveratrol ameliorates palmitate-induced inflammation in skeletal muscle cells by attenuating oxidative stress and JNK/NF- κ B Pathway in a SIRT1-independent mechanism. *Journal of Cellular Biochemistry*, 118(9), 2654–2663. <https://doi.org/10.1002/jcb.25868>

Scapin, G., Schmidt, M. M., Prestes, R. C., & Rosa, C. S. (2016). Phenolics compounds, flavonoids and antioxidant activity of chia seed extracts (*Salvia hispanica*) obtained by different extraction conditions. *Journal, International Food Research*, 23(6), 2341–2346.

Sierra, L., Roco, J., Alarcon, G., & Medina, M. (2015). Dietary intervention with *Salvia hispanica* (Chia) oil improves vascular function in rabbits under hypercholesterolaemic conditions. *Journal of Functional Foods*, 14, 641–649. <https://doi.org/10.1016/j.jff.2015.02.042>

Slavin, J. (2003). Why whole grains are protective : biological mechanisms. *Proceedings of the Nutrition Society*, 62, 129–134. <https://doi.org/10.1079/PNS2002221>

Tavares Toscano, L., Tavares Toscano, L., Leite Tavares, R., da Oliveira Silva, C. S., & Silva, A. S. (2014). Chia induces clinically discrete weight loss and improves lipid profile only in altered previous values. *Nutricion Hospitalaria*, 31(3), 1176–1182. <https://doi.org/10.3305/nh.2015.31.3.8242>

Toscano, L. T., da Silva, C. S. O., Toscano, L. T., de Almeida, A. E. M., Santos, A. da C., & Silva, A. S. (2014). Chia flour supplementation reduces blood pressure in hypertensive subjects. *Plant Foods for Human Nutrition (Dordrecht, Netherlands)*, 69(4), 392–398. <https://doi.org/10.1007/s11130-014-0452-7>

Toscano, L. T., Toscano, L. T., Tavares, R. L., Oliveira, C. S., & Silva, A. S. (2015). Chia induces clinically discrete weight loss and improves lipid profile only in altered previous values. *Nutricion hospitalaria*, 31(3), 1176–1182. <https://doi.org/10.3305/nh.2015.31.3.8242>

Vuksan, V., Choleva, L., Jovanovski, E., Jenkins, A. L., Au-Yeung, F., Dias, A. G., ... Duvnjak, L. (2017). Comparison of flax (*Linum usitatissimum*) and Salba-chia (*Salvia hispanica* L.) seeds on postprandial glycemia and satiety in healthy individuals: a randomized, controlled, crossover study. *European Journal of Clinical Nutrition*, 71(2), 234–238. <https://doi.org/10.1038/ejcn.2016.148>

Vuksan, V., Jenkins, A. L., Dias, A. G., Lee, A. S., Jovanovski, E., Rogovik, A. L., & Hanna, A. (2010). Reduction in postprandial glucose excursion and prolongation of satiety:

possible explanation of the long-term effects of whole grain Salba (*Salvia hispanica* L.). *European Journal of Clinical Nutrition*, 64(4), 436–438. <https://doi.org/10.1038/ejcn.2009.159>

Vuksan, V., Whitham, D., Sievenpiper, J. L., Jenkins, A. L., Rogovik, A. L., Bazinet, R. P., ... Hanna, A. (2007). Supplementation of conventional therapy with the novel grain Salba (*Salvia hispanica* L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial. *Diabetes Care*, 30(11), 2804–2810. <https://doi.org/10.2337/dc07-1144>

Wang, H., Naghavi, M., Allen, C., Barber, R. M., Carter, A., Casey, D. C., ... Zuhlke, L. J. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet*, 388(10053), 1459–1544. [https://doi.org/10.1016/S0140-6736\(16\)31012-1](https://doi.org/10.1016/S0140-6736(16)31012-1)

World Health Organization. (2017). Noncommunicable diseases progress monitor 2017. World Health Organization 2017. <https://doi.org/10.2766/120051>

Yang, Z. H., Miyahara, H., Takeo, J., & Katayama, M. (2012). Diet high in fat and sucrose induces rapid onset of obesity-related metabolic syndrome partly through rapid response of genes involved in lipogenesis, insulin signalling and inflammation in mice. *Diabetology and Metabolic Syndrome*, 4(1), 1–10. <https://doi.org/10.1186/1475-925X-13-S2>

Supplemental material

Table S1. Search strategy for different databases

<p>A. PubMed</p> <p>((“chia seed” OR “chia seeds” OR “salvia hispanica L” OR chia seed OR chia seeds OR salvia hispanica L) AND (obesity OR Hyperglycemia OR Inflammation OR Dyslipidemias OR “Insulin Resistance” OR diabetes OR “Cardiovascular Diseases” OR Hypertension OR “metabolic syndrome” OR “nonalcoholic fatty liver disease” OR “nonalcoholic steatohepatitis”))</p>
<p>B. Embase</p> <p>((“chia seed” OR “chia seeds” OR “salvia hispanica L”) AND (obesity OR Hyperglycemia OR Inflammation OR Dyslipidemias OR “Insulin Resistance” OR diabetes OR “Cardiovascular Diseases” OR Hypertension OR “metabolic syndrome”)) ((“chia seed” OR “chia seeds” OR “salvia hispanica L”) AND (“nonalcoholic fatty liver disease” OR “nonalcoholic steatohepatitis”))</p>
<p>C. COCHRANE</p> <p>((“chia seed” OR “chia seeds” OR “salvia hispanica L”) AND (obesity OR Hyperglycemia OR Inflammation OR Dyslipidemias OR “Insulin Resistance” OR diabetes OR “Cardiovascular Diseases” OR Hypertension OR “metabolic syndrome” OR “nonalcoholic fatty liver disease” OR “nonalcoholic steatohepatitis”))</p>
<p>D. LILACS</p> <p>(tw:(“chia seed” OR “chia seeds” OR “salvia hispanica L”)) AND (tw:(obesity)) OR (tw:(Hyperglycemia)) OR (tw:(Inflammation)) OR (tw:(Dyslipidemias)) OR (tw:(“Insulin Resistance”)) OR (tw:(diabetes)) OR (tw:(“Cardiovascular Diseases”)) OR (tw:(Hypertension)) OR (tw:(“metabolic syndrome”)) OR (tw:(“nonalcoholic fatty liver disease”)) OR (tw:(“nonalcoholic steatohepatitis”))</p>

5.2 Paper 2

Published on Journal of Functional Foods, Impact factor (2019): 3.197

Journal of Functional Foods 71 (2020) 104026



Contents lists available at ScienceDirect

Journal of Functional Foods

journal homepage: www.elsevier.com/locate/jff

Effect of different fractions of chia (*Salvia hispanica* L.) on glucose metabolism, *in vivo* and *in vitro*



Barbara Nery Enes^a, Luiza de Paula Dias Moreira^a, Renata Celi Lopes Toledo^a,
Érica Aguiar Moraes^b, Maria Eliza de Castro Moreira^c, Helen Hermans Miranda Hermsdorff^a,
Giuliana Noratto^d, Susanne Ursula Mertens-Talcott^d, Stephen Talcott^d,
Hércia Stampini Duarte Martino^{a,*}

^a Department of Nutrition and Health, Federal University of Viçosa, Viçosa, MG, Brazil

^b Department of Integrated Health Education, Federal University of Espírito Santo, Vitória, ES, Brazil

^c Dinâmica Faculty, Fome Nova, MG, Brazil

^d Department of Nutrition and Food Science, Texas A&M University, College Station, TX, United States

ARTICLE INFO

Keywords:
Glucose tolerance
AKT
AMPK
Chia oil
Chia phenolics

ABSTRACT

The influence of chia (*Salvia hispanica* L.) flour and oil on glucose metabolism (GM) in insulin resistant (IR) Wistar rats and the effect of chia hydrolyzed phenolics extract (CHPE) on GM in IR HepG2 cells were evaluated. *In vivo* study: animals were divided into four groups: AIN-93M, high-fat and high-fructose (HFHF), HFHF with chia flour (14.7%) or chia oil (4%). *In vitro* study: IR HepG2 cells were treated with CHPE (80 ppm). *In vivo*, chia flour and oil reduced adiposity and increased AMPK mRNA. Chia oil improved glucose tolerance, increased AKT1 [pS473] protein level, mRNA of insulin receptor, FOXO1 and glycolysis enzymes. *In vitro*, CHPE decreased gluconeogenesis enzymes mRNA. Chia flour and oil decreased adiposity, but only chia oil was able to improve glucose tolerance and restore energy fuel system in liver of rats fed HFHF diet. CHPE decreased mRNA levels of gluconeogenesis enzymes.

1. Introduction

Three in five deaths in the world are related to chronic diseases like obesity, type 2 diabetes and cardiovascular diseases (GBD 2016 Risk Factors Collaborators, 2017). These outcomes are derived from hypertension, high cholesterol and overweight (World Health Organization, 2017). Moreover, obesity leads to an impaired glucose metabolism caused by insulin resistance (IR) and type 2 diabetes (Samuel, 2011). The disrupted glucose metabolism is considered key for other events such as atherosclerosis, cardiovascular diseases, high blood pressure, kidney injuries and nonalcoholic fatty liver disease (Imaiei & Dumitraşcu, 2019).

In this context, IR is known as the failed response to insulin by cells. It is a physiological condition, in which cells are unable to use insulin or the hormone production is impaired by pancreas, leading to high blood glucose (Schenk, Saberi, & Olefsky, 2008). Eventually, IR may cause hyperinsulinemia in attempt to maintain blood glucose at normal levels. These conditions also lead to increased gluconeogenesis activity and glucose output in liver. Epidemiological studies indicate a strong correlation between obesity and high caloric diets (high in sugar, fructose, and saturated fat) (Popkin, Adair, & Ng, 2011; Popkin, Nielsen, & Bray, 2004). Additionally, a high caloric diet is related to the upregulation of FOXO1 transcriptional factor, which controls the transcription of gluconeogenesis enzymes. Under these conditions, the

Abbreviation: AKT, protein kinase B; p-AKT, phospho-protein kinase B; ALA, alpha linolenic acid; AMPK, AMP-activated protein kinase; AUC, area under the curve; BSA, bovine serum albumin; BW, body weight; CHPE, chia hydrolyzed phenolics extract; DMEM, Dulbecco's modified Eagle's medium; FAT/CD36, Fatty acid translocase; FBS, fetal bovine serum; FoxO1, forkhead box protein O1; G6Pase, glucose-6 phosphatase; GAE, gallic acid equivalents; GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase; GK, glucokinase; GSK-3 β , glycogen synthase kinase 3 β ; HFHF, high-fat and high-fructose; HFD, high-fat diet; iGTT, intraperitoneal glucose tolerance test; INSR, insulin receptor; IR, insulin resistance; IRS2, insulin receptor substrate 2; ITT, insulin tolerance test; LCMS, liquid chromatography-mass spectrometry; PA, palmitic acid; PBS, phosphate-buffered saline; PEPCK, phosphoenolpyruvate carboxylase; PFK, phosphofructokinase; PK, phosphokinase; PPAR, peroxisome proliferator-activated receptor; PVDF, polyvinylidene difluoride; RA, rosmarinic acid; RT-PCR, real-time polymerase chain reaction; SREBP1, sterol regulator element-binding protein 1; TBP, TATA box binding protein; TBS-T, tris-buffered saline twin

* Corresponding author at: Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, MG, Brazil.

E-mail address: hercia@ufv.br (H.S.D. Martino).

<https://doi.org/10.1016/j.jff.2020.104026>

Received 31 December 2019; Received in revised form 17 May 2020; Accepted 19 May 2020

Available online 25 May 2020

1756-4646/ © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Effect of different fractions of chia (*Salvia hispanica* L.) on glucose metabolism, in vivo and in vitro

Bárbara Nery Enes¹, Luiza de Paula Dias Moreira¹, Renata Celi Lopes Toledo¹, Érica Aguiar Moraes², Maria Eliza de Castro Moreira³, Helen Hermana Miranda Hermsdorff¹, Giuliana Noratto⁴, Susanne Ursula Mertens-Talcott⁴, Stephen Talcott⁴, Hércia Stampini Duarte Martino^{1*}

¹Department of Nutrition and Health, Federal University of Viçosa, Viçosa, MG, Brazil.

²Department of Integrated Health Education, Federal University of Espírito Santo, Vitoria, ES, Brazil.

³Dinâmica Faculty, Ponte Nova, MG, Brazil.

⁴Department of Nutrition and Food Science, Texas A&M University, College Station, Texas, United States.

*Hércia Stampini Duarte Martino (corresponding author): Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, MG, Brazil. Tel. (+55 31) 3612-5207. Fax: (+55 31) 3612-5181. E-mail: hercia@ufv.br

ABSTRACT

The influence of chia (*Salvia hispanica* L.) flour and oil on glucose metabolism (GM) in insulin resistant (IR) Wistar rats and the effect of chia hydrolyzed phenolics extract (CHPE) on GM in IR HepG2 cells were evaluated. In vivo study: animals were divided into four groups: AIN-93M, high-fat and high-fructose (HFHF), HFHF with chia flour (14.7%) or chia oil (4%). In vitro study: IR HepG2 cells were treated with CHPE (80 ppm). In vivo, chia flour and oil reduced adiposity and increased AMPK mRNA. Chia oil improved glucose tolerance, increased AKT1[pS473] protein level, mRNA of insulin receptor, FOXO1 and glycolysis enzymes. In vitro, CHPE decreased gluconeogenesis enzymes mRNA. Chia flour and oil decreased adiposity, but only chia oil was able to improve glucose tolerance and restore energy fuel system in liver of rats fed HFHF diet. CHPE decreased mRNA levels of gluconeogenesis enzymes.

Keywords: Glucose tolerance, AKT, AMPK, Chia oil, Chia phenolics.

ABBREVIATION

AKT: protein kinase B; p-AKT: phospho-protein kinase B; ALA: alpha linolenic acid; AMPK: AMP-activated protein kinase; AUC: area under the curve; BSA: bovine serum albumin; BW: body weight; CHPE: chia hydrolyzed phenolics extract; DMEM: Dulbecco's modified Eagle's medium; FAT/CD36: Fatty acid translocase; FBS: fetal bovine serum; FoxO1: forkhead box protein O1; G6Pase: glucose-6 phosphatase; GAE: gallic acid equivalents; GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase; GK: glucokinase; GSK-3 β : glycogen synthase kinase 3 β ; HFHF: high-fat and high-fructose; HFD: high-fat diet; iGTT: intraperitoneal glucose tolerance test; INSR: insulin receptor; IR: insulin resistance; IRS2: insulin receptor substrate 2; ITT: insulin tolerance test; LCMS: Liquid chromatography–mass spectrometry; PA: palmitic acid; PBS: phosphate-buffered saline; PEPCK: phosphoenolpyruvate carboxykinase; PFK: phosphofructokinase; PK: phosphokinase; PPAR: peroxisome proliferator-activated receptor; PVDF: polyvinylidene difluoride; RA: rosmarinic acid; RT-PCR: real-time polymerase chain reaction; SREBP1: sterol regulator element-binding protein 1; TBP: TATA box binding protein; TBS-T: tris-buffered saline twin.

1. INTRODUCTION

Three in five deaths in the world are related to chronic diseases like obesity, type 2 diabetes and cardiovascular diseases (GBD 2016 Risk Factors Collaborators, 2017). These outcomes are derived from hypertension, high cholesterol and overweight (World Health Organization, 2017). Moreover, obesity leads to an impaired glucose metabolism caused by insulin resistance (IR) and type 2 diabetes (Samuel, 2011). The disrupted glucose metabolism is considered key for other events such as atherosclerosis, cardiovascular diseases, high blood pressure, kidney injuries and nonalcoholic fatty liver disease (Ismaiel & Dumitraşcu, 2019).

In this context, IR is known as the failed response to insulin by cells. It is a physiological condition, in which cells are unable to use insulin or the hormone production is impaired by pancreas, leading to high blood glucose (Schenk, Saberi, & Olefsky, 2008). Eventually, IR may cause hyperinsulinemia in attempt to maintain blood glucose at normal levels. These conditions also lead to increased gluconeogenesis activity and glucose output in liver. Epidemiological studies indicate a strong correlation between obesity and high caloric diets (high in sugar, fructose, and saturated fat) (Popkin, Adair, & Ng, 2011; Popkin, Nielsen, & Bray, 2004). Additionally, a high caloric diet is related to the upregulation of FOXO1 transcriptional factor, which controls the transcription of gluconeogenesis enzymes. Under these conditions, the downregulation of PI3K/AKT pathway may occur leading to the insulin/AKT pathway disruption and impaired glucose receptor (GLUT) translocation to the plasmatic membrane. These changes in the homeostatic system are accompanied by the decrease in AKT phosphorylation (Czech, 2018).

Research studies have demonstrated that food or bioactive compounds could attenuate or prevent the damage generated by obesity and IR (Skrovankova et al., 2015). Chia seed (*Salvia hispanica* L.) is considered the highest botanical source of alpha linolenic acid (ALA) omega 3 (n-3). In addition, chia seeds are good source of dietary fiber, proteins, vitamins, minerals, and phytochemicals, such as phenolic compounds (Silva et al., 2017; Marineli et al., 2014). Chia seed and oil have been investigated in the last few years for their potential benefits on glucose metabolism control (Marineli et al., 2015; Fonte-Faria et al., 2019). For example, rosmarinic acid (RA), is the major phenolic compound in chia seed (Oliveira-Alves et al., 2017), has been related to hypoglycemic effect (Runtuwene et al., 2016). Rats fed high-fat and high-fructose diet (HFHF) improved glucose tolerance and insulin resistance after chia seed (13.3%) and chia oil (4%) intake

(Marineli et al., 2015). Mice fed high-fat diet (HFD) supplemented with chia oil (0.15%) for 90 to 135 days, showed activation of the insulin cascade in skeletal muscle (Fonte-Faria et al., 2019).

However, it remains unknown if the hypoglycemic effect of chia oil targets only skeletal muscle, and which fraction of chia (flour, oil or phenolic compounds) are responsible for glucose metabolism improvement on liver. This study aims to investigate the effects of chia flour and chia oil on liver glucose metabolism of rats fed a high-fat and high-fructose diet and the *in vitro* influence of chia hydrolyzed phenolics extract (CHPE) on glucose metabolism of HepG2 cells.

2. MATERIALS AND METHODS

The chia seeds were cultivated in Rio Grande do Sul, Brazil, crop of 2017. Seeds were storage at -20 °C until use.

2.1 Chia flour prepare

Chia seeds were used for diet preparation in the form of flour (seeds were ground in a blender for approximately 2 min). Chia flour diet was prepared every 15 days with freshly ground chia seeds and stored at -20 °C to prevent lipid oxidation.

2.2 Extraction of phenolics from chia flour

Phenolic extraction was performed using an ultrasound liquid-liquid extraction method Oliveira-Alves et al. (2017). Briefly, 2 g of chia flour and 10 mL of methanol: water (80:20, v/v) were vortexed for 10 s and placed in an ultrasound water bath (Model 3510R-MT, Branson Ultrasonic Corporation, Danbury, USA) operated at 42 kHz of ultrasound frequency, 100 W of power, for 60 min at 25 °C ± 3. This was followed by centrifugation at 1792 g for 30 min. Collected supernatant was dried using a rotary evaporator, at 50 °C. The dried extracted phenolics were subjected to acid hydrolysis by dissolving in 2 mL of acidified water (formic acid 0.01%), then mixed with 1 M HCl (2 mL) and kept in water bath (100 °C) for 60 min. Hydrolyzed phenolics were purified using solid phase extraction (SPE). Solvent was evaporated to dryness at ± 50 °C under reduced pressure. Dried CHPE were stored at -20 °C with nitrogen gas for future analysis and cell culture experiments.

2.3 Oil extraction

Chia seeds were ground and cold pressed throughout a hydraulic press (Carver Laboratory Press, Model C 22400-36 - USA) to obtain the oil. During the oil extraction, precaution was taken to avoid light exposure. Extracted oil was stored at -20 °C until use in diet preparation to prevent lipid oxidation.

2.4 Extract chemical analysis

The total phenolic content of CHPE was assessed according to Folin-Ciocalteu's (Swain & Hillis, 2006), method with modifications (Abderrahim et al., 2011). The results were quantified using a standard curve ranging 0 to 300 ppm of gallic acid and expressed in milligrams of gallic acid equivalents per milliliter of extract (mg GAE.mL⁻¹) ($y = 1,6229x - 0,0227$; $R^2 = 0.9805$). The content of total phenolics was used to establish the treatment doses in the HepG2 cells experiment.

2.5 Chia phenolics characterization and quantification

The polyphenolic profile and quantification was assessed by reversed phase HPLC with a Waters 2695 Alliance system (Waters Corp., Milford, MA). Identification and quantitation of polyphenolics were based on their spectral characteristics and retention time, as compared to authentic standards (Sigma Chemical Co., St. Louis, MO). Compound identities were further confirmed by mass spectrometric analyses, performed on a Thermo Finnigan LCQ Deca XP Max MSn ion trap mass spectrometer equipped with an ESI ion source (Thermo Fisher, San Jose, CA). Separations were conducted using the Phenomenex (Torrance, CA) Synergi 4 μ Hydro-RP 80A (2 \times 150 mm; 4 μ m; S/N) 106273-106275) with a C18 guard column. Mobile phases consisted of 0.5% formic acid in water (phase A) and 0.5% formic acid in 50:50 methanol and acetonitrile (phase B) run at 0.25 mL/min. Polyphenolics were separated with a gradient elution program in which phase B changed from 5 to 30% in 5 min, from 30 to 65% in 70 min, and from 65 to 95% in 30 min and was held isocratic for 20 min. Ionization was conducted in the negative ion mode under the following conditions: sheath gas (N₂), 60 units/min; auxiliary gas (N₂), 5 units/min; spray voltage, 3.3 kV; capillary temperature, 250 °C; capillary voltage, 1.5 V; tube lens offset, 0 V.

2.5 Animal Study

2.5.1 Study design and diets

This study was approved by the Ethics Commission on Animal Use (CEUA/UFV, protocol no. 31/2018, date of approval: April 26th, 2018) and followed university guidelines for animal use for experimental studies. Forty male Wistar rats (*Rattus norvegicus*), 45-50 days old, were obtained from the Central Animal Facility of the Center for Biological Sciences and Health at Federal University of Viçosa, Minas Gerais, Brazil. The animals remained in individual stainless-steel cages, with free access to water and diet, under controlled conditions ($22\text{ °C} \pm 2$, 12h light/dark cycle). Animals were randomized according to body weight and fed with standard diet (AIN-93M) (b.w.= 156 ± 17.0 g, n=10) or HFHF diet (b.w.= 156.5 ± 17.9 g, n=30) for 8 wk to induce insulin resistance (Phase I). In order to assess the effect of chia flour and chia oil on metabolic disorders (Phase II), animals fed HFHF (b.w.= 358.04 ± 33.00 g, n=30) were randomized into 3 experimental groups and fed HFHF (b.w.= 366.8 ± 35 g, n=10); chia flour HFHF (b.w.= 362.4 ± 35.4 g, n=10), or chia oil HFHF (b.w.= 362.4 ± 34.8 g, n=10) for 10 weeks. The lean control group (b.w.= 350 ± 29.1 g, n=10) fed AIN93M diet continued on same diet for 10 wk. The experimental design is presented in Figure 1. Diet composition and ingredients are presented in Table 1. Chia flour and oil composition were taken into account in order to prepare diets. Diets were prepared every 15 days, packed in dark polyethylene bags and stored at -20 °C to minimize fatty acid oxidation. Water and diet consumption were daily checked, and replaced every week, with exception of chia oil diet, that was replaced every two days in attempt to avoid lipid oxidation. The food intake and animal weight gain were monitored weekly.




Figure 1. Experimental design. The experiment was divided into two phases. Phase I: Animals were divided in 2 groups: Control received a standard diet (AIN-93M) ; high-fat and high-fructose group (HFHF) containing 4% (w/w) soybean oil, 31% (w/w) lard and 20% fructose (w/w) (Table 1) for 8 wk. Phase II: HFHF group was divided into 3 groups: HFHF; chia flour (HFHF with 14.7% of chia flour) and chia oil (HFHF with 4% of chia oil). Animals from control received AIN-93M diet on phase II. IR: insulin resistance.

Table 1. Nutritional composition of experimental diets.

Ingredients (g/kg diet)	Experimental Diets			
	AIN-93M	HFHF	Chia seed	Chia oil
Albumin*	136.4	136.4	101.8	136.4
Dextrinized starch	155	45	45.4	4
Corn starch	463.5	135	116.8	135
Sucrose	100	28.6	29.3	28.6
Fructose	-	200	200	200
Soybean oil	40	40	-	-
Chia seed	-	-	147.3	-
Chia oil	-	-	-	40
Lard	-	310	310	310
Microcrystalline Cellulose	55.8	55.8	55.8	55.8
Vitamin mix	10	10	10	10
Mineral mix	35	35	35	35
L-cystine	1.8	1.8	1.8	1.8
Choline bitartrate	2.5	2.5	2.5	2.5
Nutritional Composition				
Macronutrients				
Carbohydrates (%)	77.4	31.0	30.1	31.0
Protein (%)	12.9	9.1	9.2	9.1
Lipids (%)	9.7	59.8	60.4	59.8
Energetic density (kcal.g ⁻¹)	3.71	5.26	5.21	5.26
Fatty acids (g.kg ⁻¹)**				
Linoleic (C18:2 n-6)	20.2	58.8	46.5	46.5
α -Linolenic (C18:3 n-3)	3.3	10.2	31.8	31.8
n-6/n-3 ratio	6.17:1	5.77:1	1.46:1	1.46:1

AIN-93M (Reeves, Nielsen, Fahey George, 1993): standard diet group; HFHF (MARINELI et al., 2015): high fat and high-fructose group; Chia flour group: HFHF with 14.7% (w/w) chia flour; Chia oil group: HFHF with 4% (w/w) chia oil.

* Amount was calculated based on protein content equal to 88% to provide 12 g protein.100 g-1 of diet.

** Fatty acids expressed in g/kg diet and determined by gas chromatography (MOREIRA, L.P.D., 2019)

2.5.2 Intraperitoneal glucose tolerance test and insulin tolerance test

Intraperitoneal glucose tolerance test (iGTT) and insulin tolerance test (ITT) were performed on 9th and 10th week of chia flour (n=10) or chia oil (n=10) administration, respectively. Briefly, blood glucose levels were measured with a handheld glucometer (Accu-Chek®, Roche) using appropriate test strips. For the iGTT, D-glucose solution 50% (2 g.kg⁻¹ body weight) was injected into the peritoneal cavity after 12 h fasting. Blood glucose levels were measured at baseline (time 0) and after 30, 60, 90, and 120 min from the tail vein. The area under the curve (AUC) of glucose was calculated using GraphPad Prism 6 (GraphPad Software, San Diego, CA). ITT was accessed on animals fasted for 12 h, after intraperitoneal human insulin injection (0.75 U.kg⁻¹ body weight, Novolin®, Novo Nordisk). Glucose blood levels were measured on baseline (time 0) and after 5, 10, 15, 20, 25, and 30 min of insulin injection. The formula $[0.693/(t_{1/2})]$ was used to calculate the constant rate of glucose disappearance. The glucose t_{1/2} was calculated from the slope of the least-squares analysis of the glucose concentrations during the linear phase (Bonora, Manicardi, Zavaroni, Coscelli, & Butturini, 1987). The euthanasia was performed 7 days after the ITT test.

2.5.3 Euthanasia and Tissue collection

The experiment was finished by euthanasia of animals at the end of 10 weeks of diets administration (no fast was performed). The animals were euthanized by cardiac puncture, after anesthetized with isoflurane (Isoforine, Cristália®). The liver was collected, weighted and immediately frozen with liquid nitrogen, prior storage at -80 °C for subsequent analysis. Adipose tissue was collected and weighted to calculate percentage of adiposity using the following formula: (visceral + retroperitoneal + epididymal adipose tissues)/total body weight × 100.

2.5.4 Gene expression in liver tissue

Expression levels of genes involved on insulin and glucose metabolism in the liver were analyzed by RT-qPCR using the SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), according to the manufacture's protocol. Briefly, liver tissue (~100 mg) grinded in liquid nitrogen were homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) (1 mL) following manufacturer's protocol. Extracted mRNA was reverse transcribed into cDNA using the M-MLV reverse transcription kit (Invitrogen Corp., Grand Island, NY). The analyses were performed on the StepOne™ Real-

TimePCR System (Thermo Fisher Scientific, Waltham, MA) by means of the measurement system involving SYBR-Green Fluorescence and Primer Express software (Applied Biosystems, Foster City, CA). Primers were purchase from Integrated DNA Technologies (IDT DNA, Coralville, IA) to amplify AMPK, INSR, FOXO1, AKT, GK, PK, PFK PEPCCK, G6Pase and β -actin (Supplementary materials Table S1). β -actin was used as endogenous control to normalize the relative expression of mRNA. The primer sequences are presented in supplementary material (Table S1).

2.5.5 Phospho-AKT assessment

Phospho-AKT protein levels were quantified using the AKT1[pS473] Ultrasensitive ELISA sandwich Kit (Invitrogen, ThermoFisher Scientific, MA, USA), according to the manufacture's protocol, on liver homogenate. Liver tissue was homogenized with phosphate buffer (1:10) 50 mM, at pH 7.4 containing 1 mM EDTA, and protease inhibitor (Protease Inhibitor Cocktail powder, Sigma Aldrich). The absorbance of samples was read at 450 nm (Multiskan Microplate Photometer, ThermoFisher Scientific, MA, USA).

2.6 In Vitro Study

2.6.1 Cell line

The human hepatoma (HepG2) cell line were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 5.5 mM D-glucose (GIBCO, Thermo Fisher, Waltham, MA), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37 °C, 5% CO₂.

2.6.2 Cell Viability

Cells were seeded at 80% confluence in a 96 well plate for 24 h to allow cell attachment. Followed by chia phenolics treatments (20 to 320 ppm) quantified as total phenolics (Abderrahim et al., 2011) against a standard curve of gallic acid (0-300 ppm) and expressed in milligrams of gallic acid equivalents per milliliter of extract (mg GAE.mL⁻¹). After 48h incubation, cell viability was determined using the in vitro toxicology assay kit resazurin following the manufacture's protocol (Sigma-Aldrich, San Luis, MO).

2.6.3 Insulin resistance protocol

HepG2 cells were maintained in DMEM medium at 37 °C, 5% CO₂ for 24 h. One day after plating, the medium was replaced for FBS free DMEM for 24 h. The cells were then treated with high glucose (25 mM) FBS free medium containing palmitic acid (PA) (1 mM) for 24 h (Nakajima, K. et al., 2000; Lee, J., Cho, H., Kwon, Y., 2010). After 24 h, insulin (100 µM) was added for 15 min. Cells cultured in 5.5 mM D-glucose DMEM, FBS free medium were used as negative controls (with and without insulin).

2.6.4 Gene Expression

A preliminary test was conducted with chia phenolics extract (20, 40, 80 ppm). Insulin resistance induced cells as described in 2.6.3 were treated with CHPE extract (80 ppm) for 24 h followed by insulin (100 µM) was added for 15 min. Total RNA from HepG2 cells was extracted using Quick-RNA Mini Prep (Zymo Research, Irvine, CA), according to the manufacturer's protocol. cDNA was synthesized using iScript Reverse Transcription Supermix (BioRad, Hercules, CA). cDNA was subjected to quantitative Real-time polymerase chain reaction (RT-PCR) using the iTaq Universal SYBR Green Supermix Kit (BioRad, Hercules, CA) according to the manufacturer's protocol. RT-PCR data was analyzed with the delta CT method (Schmittgen and Livak, 2009) using TBP as the housekeeping gene. Primers were purchased from Sigma-Aldrich (San Luis, MO, USA) to amplify PFK, PK, PEPCK and G6Pase. Primers sequence are presented in supplementary material (Table S2).

2.6.5 Phospho-AKT assessment

Insulin resistance induced cells as described in 2.6.3 were treated with CHPE extract (20, 40 and 80 ppm) for 24 h followed by insulin (100 µM) for 15 min. Negative controls were prepared as detailed in 2.6.3. Cells lysates were obtained adding X Tractor buffer (Takara Bio Company, CA, USA). Solid cellular debris was removed by centrifugation at 25,200 g for 10 min at 4 °C. The supernatant was collected and stored at -80 °C. Protein content was determined using Bradford reagent (Bio-Rad, Hercules, CA, USA) following the manufacturer's protocol. Cell lysates (60 mg protein diluted with Laemmli's loading buffer and boiled for 5 min) were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis at 100 V for 2 h. The proteins were transferred by wet blotting onto a 0.2 mm PVDF membrane (Bio-Rad, Hercules, CA). The membranes were blocked using 5% non-fat milk in a 0.1% tween-phosphate buffer solution (T-PBS) for 30

min and incubated with the primary antibody (1:1000) in a 3% bovine serum albumin in T-PBS overnight at 4 °C with gentle shaking to assess the protein level of p-AKT(Ser473) (Cell Signalling, Danvers, MA) and β -actin (Sigma-Aldrich, San Loius, MO). This was followed by incubation with the anti-rabbit IgG secondary antibody (1:2000) (Cell Signalling, Danvers, MA) in 5% milk T-PBS for 2 h. The reactive bands were visualized with a luminal reagent (Santa Cruz Biotechnology, Inc. Santa Cruz, CA) after 1 min of incubation, using an Omega Ultra Lum Molecular Imaging System (model Omega10gD) and band intensities were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, UDA; <https://imagej.nih.gov/ij/download.html>).

2.7 Statistical Analysis

Quantitative data were expressed as mean \pm standard error or standard deviation of the mean. Effect of treatments were analyzed using one-way analysis of variance (ANOVA) followed by Newman-Keuls post hoc test for parametric data and Kruskal-Wallis followed by Dun's for non-parametric. Tukey test was used to compare glucose blood levels means during different times on iGTT and ITT tests. The significance level was set at $p < 0.05$. GraphPad Prism 6 (GraphPad Software, San Diego, CA) was used to perform the analysis.

3. RESULTS

3.1 Chia phenolics, identification and quantification

The chromatogram of CHPE and the content of phenolic compounds are presented in Figure 2. CHPE presented 28,000 mg GAE. mL⁻¹ of total phenolic. The main phenolic compounds on the extract were rosmarinic acid, danshensu glycoside, ferulic acid and caffeic acid.




Figure 2. Hydrolyzed Phenolics from Chia Characterization. (A). Chromatographic profile at 280 nm of the chia hydrolyzed phenolics extract from chia flour used in the *in vitro* study. (B). Quantification of phenolic compounds by LCMS from chia hydrolyzed phenolics extract.

3.2.1 Chia oil administration decreased body weight and body fat accumulation

Results from food and energy intake showed higher food intake in control group (AIN-93M), but energy intake was similar among all experimental groups (Figure 3A and B). Body weight gain in animals fed chia oil was lower compared to HFHF, while chia flour group was similar to AIN-93M (Figure 3C). Furthermore, adiposity in chia oil and chia flour groups were 5.1% and 6.9%, respectively, lower than HFHF (7.8%) control, and similar to AIN-93M group (4.2%) ($p < 0.05$) (Figure 3D).




Figure 3. Effect of chia flour and oil consumption on (A) food intake, (B) energy intake, (C) total weight gain, (D) % adiposity. Data are expressed as mean \pm standard deviation. Different letters represent significant differences ($p < 0.05$) by Newman-Keuls test. HFHF: high-fat and high-fructose, chia flour (HFHF with 14.7% of chia flour) and chia oil (HFHF with 4% of chia oil).

3.2.2 Glucose and insulin tolerance tests

Results showed that chia oil decreased significantly the blood glucose levels and the AUC to levels that were similar to those on AIN-93M group. Blood glucose of chia oil group was lower than HFHF and chia flour groups, and similar to control group at times 30, 60 and 90 min (Figure 4A and B). Consistently, kITT showed a similar pattern, with chia oil administration presenting faster glucose disappearing as well as AIN-93M group (Figure 4C). Blood glucose levels were similar to AIN-93M group at 20 min (Figure 4D).




Figure 4. Chia oil decreased hyperglycemia and insulin resistance. Glucose and insulin tolerance were assessed through intraperitoneal glucose tolerance test (iGTT) and insulin tolerance test (ITT). (A) glucose area under the curve during iGTT, (B) mean blood glucose levels after intraperitoneal infusion of glucose solution, (C) kITT during ITT, (D) mean blood glucose levels after insulin intraperitoneal infusion. Data are expressed as mean and standard deviation. Different letters represent significant differences ($p < 0.05$) by Tukey's test. HFHF: high-fat and high-fructose, chia flour (HFHF with 14.7% of chia flour) and chia oil (HFHF with 4% of chia oil). kITT: constant rate of glucose disappearance in ITT test.

3.2.3 Gene expression and protein in liver tissue

Results showed that chia oil and chia flour at lesser extent modulated the expression of biomarkers that play an important role in liver IR. Among the assessed biomarkers (AMPK, INSR, AKT, FOXO1, GK, PFK and PK), chia oil upregulated the mRNA levels of all of them ($p < 0.05$) (7.3, 5.3, 1.9, 4.7, 10.5, 5.18 and 1.9-fold of HFHF control, respectively); while chia flour upregulated only AMPK and AKT (3.8 and 2.0-fold of HFHF control, respectively) mRNA levels (Figure 5). Moreover, chia oil prevented HFHF-induced downregulation of AMPK, INSR, and FOXO1 mRNA maintaining those levels similar to AIN-93M group (Figure 5A, 5B, 5C) upregulated the mRNA levels. These results suggest that chia seed may help to ameliorate or delay the onset of IR, while chia oil is the active compound in chia seeds with potential to reverse or prevent this condition.

AKT1[pS473] protein level was increased for chia oil group. For HFHF and lean control groups, the AKT1 [pS473] protein levels were similar (Figure 5H) and consistent with mRNA levels (Figure 5D).




Figure 5. Chia oil modulated gene expression of biomarkers for IR. Chia (flour and oil) increased p-AKT. (A) AMPK, (B) INSR, (C) FOXO1, (D) AKT, (E) GK, (F) PFK, (G) PK, and (H) AKT[pS473]. Gene expression of key proteins related to glucose metabolism and glycolysis enzymes. mRNA was extracted from Wistar rats liver and analyzed by qRT-PCR. Protein levels of AKT1[pS473] were quantified in Wistar rats liver homogenates by ELISA. Data are mean \pm standard error of the mean (SEM). Different letters represent significant differences ($p < 0.05$) by Newman-Keuls test. AMPK adenosine monophosphate-activated protein; INSR insulin receptor; FOXO1 Forhead box protein 01; AKT: protein kinase B; GK glucokinase; PFK phosphofructo kinase; PK pyruvate kinase. HFHF: high-fat and high-fructose, chia flour (HFHF with 14.7% of chia flour) and chia oil (HFHF with 4% of chia oil).

3.3. In vitro study

3.3.1 Cell viability

HepG2 cell viability was not inhibited by CHPE at dose range 10-80 ppm (Figure S1). Therefore, this dose range was used for future in vitro experiments.

3.3.2 Chia phenolics improved mRNA levels of gluconeogenic enzymes but did not modulate PI3K/AKT pathway in HepG2 cells

Results showed that mRNA levels of gluconeogenic and glycolysis enzymes were modulated by CHPE (Figure 6). The mRNA levels of glycolytic and gluconeogenic enzymes indicate if these pathways are involved on CHEP glucose modulation. In general, enzyme mRNA levels were upregulated in positive control (PC) upon insulin resistance induction by palmitate and high glucose indicating a cell homeostatic response, and chia phenolics decreased this cell response. This indicates that chia phenolics lessened the cell insults and the cell response needed to maintain homeostasis. Protein levels of p-AKT were decreased as expected under conditions resembling insulin resistance induced by palmitic acid (1 mM) associated to high glucose media (25 mM) as shown in PC. However, chia phenolics failed to reverse this condition (Figure 6E).




Figure 6. Chia hydrolyzed phenolics extract decreased gluconeogenesis and glycolysis enzymes activity. Chia hydrolyzed phenolics extract did not increase pAKT protein levels. (A) PFK, (B) PK, (C) PEPCK, (D) G6Pase, (E) p-AKT(Ser473). Gene expression of gluconeogenesis enzymes. mRNA was extracted from HepG2 cells and analysed by qRT-PCR. Negative control: HepG2 cells treated with low glucose media. Positive Control: HepG2 cells treated with high glucose media (25 mM) and Palmitate (1mM) for 24 h followed by hydrolyzed chia extract for 12 h and insulin for 15 min. Chia 80 ppm: dose of chia hydrolyzed phenolics extract (based on total phenolics content). Protein expression was extracted from HepG2 cells and analyzed by western blot (β -actin as control). Negative control: HepG2 cells treated with low glucose media. Positive Control (PC): HepG2 cells treated with high glucose media (25 mM) and Palmitate (1mM) for 24 h followed by hydrolyzed chia extract for 12 h and insulin for 15 min. 20, 40, 80: doses of chia hydrolyzed phenolics extract (based on total phenolics content). Data are mean \pm standard error of the mean (SEM). Different letters represent significant differences ($p < 0.05$) by Newman-Keuls test. PFK Phosphofruktokinase; PK: pyruvate kinase; PEPCK Phosphoenolpyruvate carboxykinase; G6Pase: Glucose-6 phosphatase.

4. DISCUSSION

This study brought new insights into the chia seeds health properties regarding different fractions (flour, oil or phenolics) on insulin pathway activation and blood glucose control in nutritional unbalanced status.

Regarding the *in vivo* study, food intake in HFHF groups was lower than in AIN-93M group, however, energy intake was similar (Figure 3A and B). This outcome could be explained due to the higher energy density of HFHF diet. These results were consistent with the study reported by Marineli et al. (2015).

Besides the same energy consumption among experimental groups, chia oil group showed the lowest body weight gain compared with chia flour and HFHF groups (Figure 3C). However, adiposity was lower in chia flour and oil groups compared to HFHF group and similar to AIN93M group (Figure 3D). These results are consistent with previous reports (Fonte-Faria et al., 2019; Creus et al., 2017; Poudyal et al., Brown, 2012; Poudyal, Panchal, Ward, & Brown, 2013; Poudyal, Panchal, Ward, et al., 2012). The reduced body adiposity may be associated with ALA intake, since the consumption of chia has been associated to a lipid redistribution with FAT/CD36 recruitment to plasmatic membrane, mitochondrial activity and beta-oxidation (Creus et al., 2016; Marineli et al., 2015; Poudyal, Panchal, Waander, Ward & Brown, 2012). The lipid redistribution could also contribute to glucose tolerance improvement (Adeva-andany, Noemi, & Fern, 2016).

Glucose and insulin tolerance intraperitoneal tests showed that only chia oil was able to repair glucose metabolism. This finding is supported by Fonte-Faria et al. (2019), which found that chia oil restored glucose and insulin tolerance in mice fed HFD diet. Nevertheless, Marineli et al., (2015) found that both, chia oil and flour, improved glucose and insulin tolerance in rats fed HFHF diet. In contrast, Miranda et al. (2018) did not find improvement on glucose tolerance by chia flour administration in mice fed HFD. Although the high content of dietary fiber in chia seeds (37.9%, data not showed) was expected to contribute to glucose and insulin tolerance reestablishment, results indicate that ALA in chia oil could be the bioactive compound that contributed to improve glucose and insulin resistance. However, its content may be influenced by chia seed variety, and growing conditions (temperature, climate and soil) (Silva et al., 2017). In our study, ALA content in animals' diet was 31.8 g.kg⁻¹. It was higher than reported by Marineli et al. (2015), Miranda et al. (2018), Fonte-Faria et al. (2019) (25.87 g.kg⁻¹, 4.93 g.kg⁻¹, and 1.7 g.kg⁻¹, respectively). It should be highlighted that the chia seeds were grown in different locations.

Besides the GTT and ITT tests outcomes, chia flour and oil increased liver AMPK gene expression. AMPK, considered an energy-deprivation sensor, is downregulated during the onset of obesity and metabolic syndrome, and under unbalanced diet conditions, as HFHF, disrupting energy balance. However, exercise, caloric restriction and anti-diabetic compounds activate this pathway (Kim et al., 2016). Our results showed that liver AMPK gene expression increased after chia flour and oil intake (3.8- and 7.3-fold of HFHF, respectively). Chia oil group showed increment even higher than in AIN93M group (5-fold). It suggests ALA as AMPK activator as reported by Wang et al. (2018). This outcome should be highlighted because AMPK activation could decrease blood glucose levels by AS160 protein phosphorylation. This protein plays a role on trafficking glucose transporter, increasing glucose uptake in an insulin-independent pathway (Bradley, et al., 2015). Therefore, both, chia flour and oil, seem to modulate AMPK expression as insulin-independent mechanism to improve glucose metabolism, although only the oil have impacted on GTT and ITT. To our knowledge, this is the first study which chia flour and oil intake induced upregulation of AMPK gene expression in liver.

In addition, chia flour and oil were effective on increasing AKT and PFK mRNA levels. While chia oil also upregulated gene expression of INSR, FOXO1, GK and PK. These results imply the enhanced activity of chia oil on glucose metabolism modulation in dependent and independent insulin pathways. The upregulation of INSR and AKT mRNA, followed by phospho-AKT protein level for chia oil group may indicate increasing in glucose uptake and oxidation, glycolysis (according to the increment of GK, PK and PFK mRNA expression), and decreasing gluconeogenesis (indicated by FOXO1 upregulation). These data and chia oil effect on glucose metabolism are reinforced by ITT test (Figure 4C).

Even though the oil content of chia flour and oil diets were similar, the availability of oil compounds may be impaired by other components of chia, such as dietary fiber, protein and calcium, which could bound compounds, like fatty acids, decreasing its availability to digestive enzymes and absorption (SILVA et al., 2017, 2018). These findings draw attention to chia oil and to its effect on glycolysis modulation, which are associated with AKT and AMPK activation, and may represent an important outcome on glucose metabolism.

The in vitro results showed that CHPE, simultaneously, downregulated mRNA of enzymes involved on gluconeogenesis and glycolysis, PEPCK and G6Pase, and PFK and PK, respectively. Opposite to the in vivo results, the in vitro studies showed CHPE do not

contribute to activate the AKT signaling cascade in HepG2 cells. These results suggest that chia phenolics may reduce obesity-related metabolic disorders linked to the impaired gluconeogenesis pathway. As an example, mice treated with ferulic acid (25 mg.kg^{-1}) had improved insulin resistance associated with decreased protein expression of PEPCK and G6Pase enzymes, which are involved on gluconeogenesis (Naowaboot, Piyabhan, Munkong, & Parklak, 2016). Moreover, Rosmarinic acid, has been associated with glucose improvement related to AMPK phosphorylation, with no involvement of PI3K – AKT signaling cascade (Vlavcheski, Naimi, Murphy, Hudlicky, & Tsiani, 2017). Also, caffeic acid from propolis, improved glucose uptake in HepG2 cells and decreased G6Pase expression in insulin resistant HepG2 cells (Nie et al., 2017). In this research, the evaluation of chia phenolics effects on HepG2 IR cells were limited to p-AKT protein levels and mRNA of enzymes involved on gluconeogenesis and glycolysis. We reinforce the need for further investigations regarding enzymes activity as wells as the crosstalk pathways.

Considering the *in vitro* and *in vivo* research models used in this study, the proposed underlying mechanisms modulated by chia in insulin resistance are illustrated in Figure 7. Among the different components of chia, the oil showed a major impact on glucose and insulin tolerance. This may be related to its lipid profile highlighted by ALA. Some of the underlying mechanisms modulated by chia oil were the mRNA upregulation of INSR. This is linked to improvement of insulin affinity for its receptor on hepatocyte membrane, activating AKT phosphorylation, contributing to glucose uptake and glucose oxidation as major energy fuel (indicated by GK, PFK and PK glycolysis enzymes mRNA expression). Both, chia flour and oil, upregulated AMPK gene expression, which may implicate in an insulin-independent mechanism on glucose metabolism control. Chia phenolics may contribute to glucose control by decreasing gluconeogenesis activity, linked to PEPCK and G6Pase mRNA levels downregulation (Figure 7).




Figure 7. Proposed effect of Chia (*Salvia hispanica* L.) on glucose homeostasis by controlling AKT activation, gluconeogenesis and glycolysis pathways. Chia oil increased insulin receptor expression, contributing to insulin bind to its, signaling to phosphorylate AKT. P-AKT blocks FOX01 to migrate to nucleus and to initiate transcription of gluconeogenesis enzymes, controlling glucose synthetase. Chia hydrolyzed phenolics contributes to decrease gluconeogenic pathway. Chia flour and chia oil increased AMPK expression, which increases glucose uptake and oxidation, as well as glycolysis enzymes, resulting in glucose tolerance improvement.

5. CONCLUSION

Chia flour and oil decreased adiposity and may modulate glucose metabolism throughout insulin independent mechanism (AMPK) in rats fed HFHF diet. However, only chia oil improved glucose and insulin tolerance and restored energy fuel system on hepatocytes, increasing AKT phosphorylation and improving glycolysis. Chia hydrolyzed phenolics extract was associated with gene expression modulation of gluconeogenic and glycolytic enzymes on HepG2 insulin resistant cells. The present study provides information with the positive effects of chia components on glucose metabolism in the liver under insulin resistance conditions.

Acknowledgments

The authors would like to thank the National Counsel of Technological and Scientific Development (CNPq, Brazil) for Research Support (MCTIC/CNPq N° 28/2018 - Universal -

406517/2018-5); the Coordination for the Improvement of Higher Education Personnel (CAPES, Brazil) for Scholarship Research support (88881.190055/2018-01); and Foundation for Research Support of Minas Gerais (FAPEMIG, Brazil).

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

6. REFERENCES

- Abderrahim, F., Estrella, S., Susín, C., Arribas, S. M., González, M. C., & Condezo-Hoyos, L. (2011). The Antioxidant Activity and Thermal Stability of Lemon Verbena (*Aloysia triphylla*) Infusion. *Journal of Medicinal Food*, 14(5), 517–527. <https://doi.org/10.1089/jmf.2010.0102>
- Adeva-andany, M., Noemi, P., & Fern, C. (2016). Liver glucose metabolism in humans, 0, 1–15. <https://doi.org/10.1042/BSR20160385>
- Bradley, H., Shaw, C. S., Bendtsen, C., Worthington, P. L., Wilson, O. J., Strauss, J. A., Wallis, G. A., Turner, A. M., Wagenmakers, A. J. M. (2015). Visualization and quantitation of GLUT4 translocation in human skeletal muscle following glucose ingestion and exercise. *Physiol Rep*, 3 (5), 2015, e12375. doi: 10.14814/phy2.12375
- Bonora, E., Manicardi, V., Zavaroni, I., Coscelli, C., & Butturini, U. (1987). Relationships between insulin secretion, insulin metabolism and insulin resistance in mild glucose intolerance. *Diabete Metabolism*, 13(2), 116–121.
- Creus, A., Benmelej, A., Villafañe, N., Lombardo, Y. B., Villafane, N., Lombardo, Y. B., ... Lombardo, Y. B. (2017). Dietary Salba (*Salvia hispanica* L.) improves the altered metabolic fate of glucose and reduces increased collagen deposition in the heart of insulin-resistant rats. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 121(March), 30–39. <https://doi.org/10.1016/j.plefa.2017.06.002>
- Creus, A., Ferreira, M. R., Oliva, M. E., & Lombardo, Y. B. (2016). Mechanisms Involved in the Improvement of Lipotoxicity and Impaired Lipid Metabolism by Dietary alpha-Linolenic Acid Rich *Salvia hispanica* L. (Salba) Seed in the Heart of Dyslipemic Insulin-Resistant Rats. *Journal of Clinical Medicine*, 5(2). <https://doi.org/10.3390/jcm5020018>
- Czech, M. P. (2018). Insulin action and resistance in obesity and type 2 diabetes. *Nat Med*, 23(7), 804–814. <https://doi.org/10.1038/nm.4350>. Insulin
- Fonte-Faria, T. T., Citelli, M., Atella, G. C., Raposo, H. F., Zago, L., de Souza, T., ... Barja-Fidalgo, C. (2019). Chia oil supplementation changes body composition and activates insulin signaling cascade in skeletal muscle tissue of obese animals. *Nutrition*, 58, 167–174. <https://doi.org/https://doi.org/10.1016/j.nut.2018.08.011>
- GBD 2016 Risk Factors Collaborators. (2017). Global , regional , and national comparative risk assessment of 84 behavioural , environmental and occupational , and metabolic

- risks or clusters of risks , 1990 – 2016 : a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*, 390, 1345–422. [https://doi.org/10.1016/S0140-6736\(17\)32366-8](https://doi.org/10.1016/S0140-6736(17)32366-8)
- Guo, X.-X., Zeng, Z., Qian, Y.-Z., Qiu, J., Wang, K., Wang, Y., ... Zhou, F. (2019). Wheat Flour, Enriched with γ -Oryzanol, Phytosterol, and Ferulic Acid, Alleviates Lipid and Glucose Metabolism in High-Fat-Fructose-Fed Rats. *Nutrients*, 11(7), 1697. <https://doi.org/10.3390/nu11071697>
- Han, S., Jiao, J., Zhang, W., Xu, J., Wan, Z., & Zhang, W. (2015). Dietary fiber prevents obesity-related liver lipotoxicity by modulating sterol-regulatory element binding protein pathway in C57BL / 6J mice fed a high-fat / cholesterol diet. *Nature Publishing Group*, (October), 1–10. <https://doi.org/10.1038/srep15256>
- Ismaiel, A., & Dumitraşcu, D. L. (2019). Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review. *Frontiers in Medicine*, 6, 202. <https://doi.org/10.3389/fmed.2019.00202>
- Kim, J., Yang, G., Kim, Y., Kim, J., & Ha, J. (2016). AMPK activators: mechanisms of action and physiological activities. *Experimental & molecular medicine*, 48(4), e224. <https://doi.org/10.1038/emm.2016.16>
- Lee, J., Cho, H., Kwon, Y. (2010) Palmitate induces insulin resistance without significant intracellular triglyceride accumulation in HepG2 cells. *Metabolism*, 59(7), 927-934. <https://doi.org/10.1016/j.metabol.2009.10.012>.
- Lindholm, C. R., Ertel, R. L., Bauwens, J. D., Schmuck, E. G., Mulligan, J. D., & Saupe, K. W. (2013). A high-fat diet decreases AMPK activity in multiple tissues in the absence of hyperglycemia or systemic inflammation in rats. *Journal of Physiology and Biochemistry*, 69(2), 165–175. <https://doi.org/10.1007/s13105-012-0199-2>
- Marineli, R. da S., Lenquist, S. A., Moraes, É. A., & Maróstica, M. R. (2015). Antioxidant potential of dietary chia seed and oil (*Salvia hispanica* L.) in diet-induced obese rats. *Food Research International*, 76, 666–674. <https://doi.org/https://doi.org/10.1016/j.foodres.2015.07.039>
- Marineli, R. da S., Moraes, É. A., Lenquist, S. A., Godoy, A. T., Eberlin, M. N., & Maróstica, M. R. (2014). Chemical characterization and antioxidant potential of Chilean chia seeds and oil (*Salvia hispanica* L.). *LWT - Food Science and Technology*, 59(2P2), 1304–1310. <https://doi.org/10.1016/j.lwt.2014.04.014>
- Marineli, R., Moura, C. S., Moraes, É. A., Lenquist, S. A., Lollo, P. C. B., Morato, P. N., ... Maróstica, M. R. (2015). Chia (*Salvia hispanica* L.) enhances HSP, PGC-1 α expressions and improves glucose tolerance in diet-induced obese rats. *Nutrition*, 31(5), 740–748. <https://doi.org/https://doi.org/10.1016/j.nut.2014.11.009>
- Mohd Ali, N., Yeap, S. K., Ho, W. Y., Beh, B. K., Tan, S. G. S. W., Tan, S. G. S. W., ... Tan, S. G. S. W. (2012). The Promising Future of Chia, *Salvia hispanica* L. *Journal of Biomedicine and Biotechnology*, 2012, 171956. <https://doi.org/10.1155/2012/171956>
- Moreira, L.P.D. (2019). Efeito da semente e do óleo de chia (*Salvia hispanica* L.) nas

- alterações metabólicas em ratos alimentados com dieta rica em gordura saturada e frutose. (Master thesis). Universidade Federal de Viçosa, Viçosa, MG, Brasil.
- Nakajima, K. et al. (2000). Selective Attenuation of Metabolic Branch of Insulin Receptor Down-signaling by High Glucose in a Hepatoma Cell Line, HepG2 Cells. *The Journal of Biology Chemistry*, 275(27), 20880-20886. <https://doi.org/10.1074/jbc.M905410199>.
- Naowaboot, J., Piyabhan, P., Munkong, N., & Parklak, W. (2016). Ferulic acid improves lipid and glucose homeostasis in high-fat diet-induced obese mice, 242–250. <https://doi.org/10.1111/1440-1681.12514>
- Nie, J., Chang, Y., Li, Y., Zhou, Y., Qin, J., Sun, Z., & Li, H. (2017). Caffeic Acid Phenethyl Ester (Propolis Extract) Ameliorates Insulin Resistance by Inhibiting JNK and NF- κ B Inflammatory Pathways in Diabetic Mice and HepG2 Cell Models. *Journal of Agricultural and Food Chemistry*, 65(41), 9041–9053. <https://doi.org/10.1021/acs.jafc.7b02880>
- Oliveira-Alves, S. C., Vendramini-Costa, D. B., Betim Cazarin, C. B., Maróstica Júnior, M. R., Borges Ferreira, J. P., Silva, A. B., ... Bronze, M. R. (2017). Characterization of phenolic compounds in chia (*Salvia hispanica* L.) seeds, fiber flour and oil. *Food Chemistry*, 232, 295–305. <https://doi.org/10.1016/j.foodchem.2017.04.002>
- Popkin, B. M., Adair, L. S., & Ng, S. W. (2011). Global nutrition transition and the pandemic of obesity in developing countries. *Nutrition Reviews*, 70(1), 3–21. <https://doi.org/10.1111/j.1753-4887.2011.00456.x>
- Popkin, B. M., Nielsen, S. J., & Bray, G. A. (2004). Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. *The American Journal of Clinical Nutrition*, 79(4), 537–543. <https://doi.org/10.1093/ajcn/79.4.537>
- Poudyal, H., Panchal, S. K., Waanders, J., Ward, L., & Brown, L. (2012). Lipid redistribution by alpha-linolenic acid-rich chia seed inhibits stearyl-CoA desaturase-1 and induces cardiac and hepatic protection in diet-induced obese rats. *The Journal of Nutritional Biochemistry*, 23(2), 153–162. <https://doi.org/10.1016/j.jnutbio.2010.11.011>
- Poudyal, H., Panchal, S. K., Ward, L. C., & Brown, L. (2013). Effects of ALA, EPA and DHA in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. *The Journal of Nutritional Biochemistry*, 24(6), 1041–1052. <https://doi.org/https://doi.org/10.1016/j.jnutbio.2012.07.014>
- Poudyal, H., Panchal, S. K., Ward, L. C., Waanders, J., & Brown, L. (2012). Chronic high-carbohydrate, high-fat feeding in rats induces reversible metabolic, cardiovascular, and liver changes. *American Journal of Physiology. Endocrinology and Metabolism*, 302(12), E1472-82. <https://doi.org/10.1152/ajpendo.00102.2012>
- Reeves, P. G., Nielsen, F. H., & Fahey George C., J. (1993). AIN-93 Purified Diets for Laboratory Rodents: Final Report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of the AIN-76A Rodent Diet. *The Journal of Nutrition*, 123(11), 1939–1951. <http://dx.doi.org/10.1093/jn/123.11.1939>

- Runtuwene, J., Cheng, K.-C., Asakawa, A., Amitani, H., Amitani, M., Morinaga, A., ... Inui, A. (2016). Rosmarinic acid ameliorates hyperglycemia and insulin sensitivity in diabetic rats, potentially by modulating the expression of PEPCK and GLUT4, 2193–2202.
- Samuel, V. T. (2011). Fructose induced lipogenesis : from sugar to fat to insulin resistance. *Trends in Endocrinology & Metabolism*, 22(2), 60–65.
<https://doi.org/10.1016/j.tem.2010.10.003>
- Samuel, V. T., Shulman, G. I., Samuel, V. T., & Shulman, G. I. (2016). The pathogenesis of insulin resistance : integrating signaling pathways and substrate flux Find the latest version : The pathogenesis of insulin resistance : integrating signaling pathways and substrate flux, 126(1), 12–22. <https://doi.org/10.1172/JCI77812.thesis>
- Schenk, S., Saberi, M., & Olefsky, J. M. (2008). Insulin sensitivity: modulation by nutrients and inflammation. *The Journal of Clinical Investigation*, 118(9), 2992–3002.
<https://doi.org/10.1172/JCI34260>
- Silva, B. P., Anunciação, P. C., Matyelka, J. C. da S., Della Lucia, C. M., Martino, H. S. D., & Pinheiro-Sant'Ana, H. M. (2017). Chemical composition of Brazilian chia seeds grown in different places. *Food Chemistry*, 221, 1709–1716.
<https://doi.org/10.1016/j.foodchem.2016.10.115>
- Silva, B. P., Dias, D. M., de Castro Moreira, M. E., Toledo, R. C. L., da Matta, S. L. P., Lucia, C. M. Della, ... Pinheiro-Sant'Ana, H. M. (2016). Chia Seed Shows Good Protein Quality, Hypoglycemic Effect and Improves the Lipid Profile and Liver and Intestinal Morphology of Wistar Rats. *Plant Foods for Human Nutrition*, 71(3), 225–230. <https://doi.org/10.1007/s11130-016-0543-8>
- Silva, B. P., Toledo, R. C. L., Grancieri, M., Moreira, M. E. de C., Medina, N. R., Silva, R. R., ... Martino, H. S. D. (2018). Effects of chia (*Salvia hispanica* L.) on calcium bioavailability and inflammation in Wistar rats. *Food Research International*.
<https://doi.org/https://doi.org/10.1016/j.foodres.2018.08.078>
- Skrovankova, S., Sumczynski, D., Mlcek, J., Jurikova, T., Sochor, J. (2015). Bioactive Compounds and Antioxidant Activity in Different Types of Berries. *International Journal of Molecular Sciences*, 16(10), 24673–24706.
<https://doi.org/10.3390/ijms161024673>
- Smith, G. C., & Turner, N. (2017). FOXO1 Is the Headline Akt Regulating Hepatic Glucose Metabolism. *Endocrinology*, 158(8), 2436–2438.
<https://doi.org/10.1210/en.2017-00525>
- Swain, T., & Hillis, W. E. (2006). The phenolic constituents of *Prunus domestica*. I.—The quantitative analysis of phenolic constituents. *Journal of the Science of Food and Agriculture*, 10(1), 63–68. <https://doi.org/doi:10.1002/jsfa.2740100110>
- Vlavcheski, F., Naimi, M., Murphy, B., Hudlicky, T., & Tsiani, E. (2017). Rosmarinic Acid, a Rosemary Extract Polyphenol, Increases Skeletal Muscle Cell Glucose Uptake and Activates AMPK. *Molecules*, (22). <https://doi.org/10.3390/molecules22101669>

Wang, M., Ma, L., Yang, Y., Xiao, Z., Wan, J., Wang, M., ... Wan, J. (2018). n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease : A critical review n-3 Polyunsaturated fatty acids for the management of alcoholic liver. *Critical Reviews in Food Science and Nutrition*, 0(0), 1–14. <https://doi.org/10.1080/10408398.2018.1544542>

World Health Organization. (2017). *Noncommunicable Diseases Progress Monitor 2017*. World Health Organization 2017. <https://doi.org/10.2766/120051>

Supplementary material

Table S1. Sequencing primers used in the RT-qPCR analysis for in vivo study

Genes	Oligonucleotide (5'-3')	
	Forward	Reverse
AMPK	TGAAGCCAGAGAACGTGTTG	ATAATTTGGCGATCCACAGC
INSR	TCATGGATGGAGGCTATCTGGA	TCCTTGAGCAGGTTGACGATTTC
FOXO1	GATAAGGGCGACAGCAACAG	TGAGCATCCACCAAGAACTT
AKT	GGGCCACGGATACCATGAAC	AGCTGACATTGTGCCACTGA
GK	AGTATGAACCGGATGGTGGATGAA	CCAGCTTAAGCAGCACAAGTCGTA
PK	ATCTGGGCAGATGATGTGGA	ATAGGGTGTAAGTGGGTCAGAATGG
PFK	CCACCTGGAGGCCATTGTAGA	GGGATGACGCACATGACGA
β -actin	GTCGTACCACTGGCATTGTG	CTCTCAGCTGTGGTGGTAA

AMPK: AMP-activated protein kinase; INSR: Insulin receptor; FOXO1: Forkhead box protein O1; AKT: Protein kinase B; GK: Glucokinase; PK: Pyruvate kinase; PFK: Phosphofructokinase.

Table S2. Sequencing primers used in the RT-qPCR analysis for in vitro study.

Genes	Oligonucleotide (5'-3')	
	Forward	Reverse
TBP	TGCACAGGAGCCAAGAGTGAA	CACATCACAGCTCCCCACCA
PFK	GGTAAGATCTCAGAGACTACAG	AGAAGTCGTTATCGATGGAG
PK	AAAATTGAGAACCACGAAGG	CAATCATCATCTTCTGAGCC
PEPCK	TGGAAGAATAAGGAGTGGAG	CTTCATAGACTAGAGGGACAC
G6Pase	ACTGTGCATACATGTTTCATC	TGAATGTTTTGACCTAGTGC

TBP: TATA box binding protein; PFK: Phosphofructokinase; PK: Phosphokinase; PEPCK: Phosphoenolpyruvate carboxykinase; G6Pase: Glucose-6 phosphatase.




Figure S1. Chia hydrolyzed phenolics up to 80 ppm did not exert HepG2 cell toxicity. Cell viability (% of control). Cells were treated with chia phenolics (10 – 320 ppm) for 48 h and cell viability was determined with resazurin test as detailed in materials and methods. Data are mean \pm standard error of the mean (SEM). * represent significant difference ($p < 0.05$) by Dunnett's test.

6. GENERAL CONCLUSIONS

This work brought some new information about chia seed effects on health, regarding molecular pathways. We first demonstrated by systematic review the hypothesis formulated after analyzing animal studies results, which received chia (seed or oil) accompanied of unbalanced diet, throughout a systematic review. The data extracted allowed us to conclude that AMPK is the central protein affected by chia seed. The consumption of chia seed and chia oil by animals, increased the expression of AMPK, which increased the expression of biomarkers related to mitochondrial activity and fatty acid oxidation. In addition, activated AMPK stimulates insulin receptor phosphorylation, that together, translocate GLUT4 to cellular membrane, increasing glucose uptake and oxidation, and lowering blood glucose. Moreover than results about chia's effect, the review demonstrated the lack of information about the methods used to carry the experiment. The absence of certain data, such as blinding protocols, information about randomization, sample size, dose of chia consumed, and number of animals evaluated on statistical analysis. The quality of data extracted from experimental studies is important for confident results and to plan future experiments, including clinical trials.

Second, we demonstrated throughout original data, for the first time, that chia's fractions (whole seed, oil and phenolics) have different effects on health, especially, on glucose metabolism. Our data provided information claiming that the oil from chia presents superior activity on glucose metabolism, improving glucose tolerance and positively affecting insulin resistance conditions. Chia oil improved blood glucose and insulin tolerance, increased AKT gene expression and AKT[pS473] protein. Besides that, the gene expression of AMPK, FOXO1, INSR and enzymes involved on glycolysis (glucokinase, phosphofructo kinase, and pyruvate kinase). The whole seed increased AKT gene expression, AKT[pS473] protein, and AMPK gene expression, but blood glucose and insulin tolerance was not affected, as well as, gene expression of FOXO1, INSR and glycolysis enzymes. The phenolics from chia modulated the expression of gluconeogenesis enzymes, but this event was not sufficient to improve central biomarkers related to glucose control. The phenolics however, may have other properties, such as antioxidant activity, cited in published literature, but not investigated in this work.

From the three fractions investigated in this research (whole seed, oil and phenolics), the oil from chia demonstrated superior results regarding glucose metabolism in insulin resistance conditions.

7. FINAL CONSIDERATIONS

These results from these studies are promising and allow understanding about the mechanisms related to the beneficial effects of chia seed consumption related to unbalanced diets, especially on insulin resistance conditions. Until the present moment, other studies have investigated only two fractions of chia, whole seed and oil, but this is the first time that the effects of phenolics from chia were investigated.

Phenolics did not improve glucose metabolism on insulin resistance conditions, but they might demonstrate positive effects on other conditions, such as, inflammation. We strongly suggest an investigation about chia's phenolics compounds on inflammatory biomarkers, since, previous studies demonstrated improvement on inflammation status after chia intake. However, since these studies were performed using the oil or the whole seed, and phenolics can be found on both fractions, the isolation of these compounds and treatment with it is recommended.

Then, the results obtained in this work can allow future studies, including clinical trials, in attempt to establish adequate doses of chia oil or seed that could prevent and attenuate biomarkers related to diseases, such as type 2 diabetes or its previous status, glucose and insulin resistance.

We suggest for our research group, the investigation of the intestinal microbiota of these animals, since recent data showed that chia seed soluble extract positively modulated intestinal health and functionality. We also suggest that lipogenesis pathway on liver should be investigated, since, chia seed and oil increased AMPK expression, which can indicate enhance on energy fuel utilization, that usually is disrupted by unbalanced diets, such as HFHF, used in this research.

The results obtained from this work will contribute to knowledge for Nutrition Science, regarding functional foods. These data are able to explain the mechanisms related to chia seed consumption on insulin resistance conditions.


APPENDIX 1

CERTIFICADO

A Comissão de Ética no Uso de Animais - CEUA/UFV certifica que o processo nº 31/2018, intitulado **“Propriedades funcionais da fração oleosa da semente de chia (*Salvia hispanica* L.), na inflamação, estresse oxidativo, adipogênese e modulação da microbiota intestinal em modelos de obesidade”**, coordenado pela professora Hércia Stampini Duarte Martino do Departamento de Nutrição e Saúde, está de acordo com a Legislação vigente (Lei Nº 11.794, de 08 de outubro de 2008), as Resoluções Normativas editadas pelo CONCEA/MCTI, a DBCA (Diretriz Brasileira de Prática para o Cuidado e a Utilização de Animais para Fins Científicos e Didáticos) e as Diretrizes da Prática de Eutanásia preconizadas pelo CONCEA/MCTI, portanto sendo aprovado por esta Comissão em 26/04/2018, com validade de 12 meses.

CERTIFICATE

The Ethic Committee in Animal Use/UFV certify that the process number 31/2018, named **“Functional properties of the oil fraction of chia seed (*Salvia hispanica* L.), inflammation, oxidative stress, adipogenesis and modulation of the intestinal microbiota in models in obesity”**, is in agreement with the actual Brazilian legislation (Lei Nº 11.794, 2008), Normative Resolutions edited by CONCEA/MCTI, the DBCA (Brazilian Practice Guideline for the Care and Use of Animals for Scientific Purposes and Teaching) and the Guidelines of Practice the Euthanasia recommended by CONCEA/MCTI therefore being approved by the Committee on April 26, 2018 valid for 12 months.


Prof. Atima Clemente Alves Zuanon

Presidente

Comissão de Ética no Uso de Animais – CEUA/UFV